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Chapter 1
Introduction
Synthesis of optically active β-amino alcohols has been a constant challenge for syn-
thetic organic chemists.1 Chiral β-amino alcohol fragment is a common structural sub-
unit in natural products and plays a key role in the treatment of various human disor-
ders. From a synthetic point of view, enantiopure vicinal amino alcohols are recognized
as useful tools, being used as ligands and chiral auxiliaries in organic synthesis.
A variety of natural compounds contain the β-amino alcohol moiety. Isolated from
Hapalosin welwitschii,2 the hydroxyamino acid Hapalosin has drawn considerable at-
tention from the synthetic community (Figure 1.1).3 Hapalosin shows ability to inhibit
multidrug resistance; therefore, it has potential use in cancer treatment. Swainsonine
is a member of indolizidine alkoloids.4 It is an inhibitor of glycoprotein processing and
a potential anticancer agent.5,6 Aminoglycoside antibiotics are another class of natural
compounds that contain β-amino alcohol moiety. Aminoglycosides are widely used
against infections.7 Hygromycin B is produced by streptomyces hygroscopicus (Figure
1.1). It is an aminoglycoside derivative that kills fungi and bacteria by means of in-
hibiting protein synthesis. It was reported that Hygromycin B has also the ability to
inhibit infections of mouse hepatitis virus both in vitro8 and in vivo.9
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Figure 1.1: Natural products having β-amino alcohol moiety.
The vicinal amino alcohol moiety is an essential substructure in asymmetric synthe-
sis. It has been widely recognized that enantiopure β-amino alcohols are valuable lig-
ands and chiral auxiliaries in a number of asymmetric organic transformations. Chiral
oxazolidinones 1 have been employed in numerous asymmetric reactions like aldol
condensations, asymmetric alkylations, Diels–Alder reactions, etc. (Figure 1.2).10 Ox-
azaborolidines 2 are 1,2-amino alcohol derivatives, which have been explored exten-
sively for several transformations.11 One of the most successful transformation of this
type of compounds is reduction of ketones.
O NH
O
R1R2
N
O
RR
B
Me
1 2
Figure 1.2: Vicinal amino alcohols as chiral auxiliaries and ligands.
The β-amino alcohol moiety frequently appears in a diverse number of synthetic mole-
cules used as drugs or pharmacological agents. The human immunodeficiency virus
(HIV) protease is an essential enzyme for the life cycle of the virus. With this vital role
in HIV replication, the protease enzyme has been a prime target of drug discovery ef-
forts. Invirase® (3) is the first protease inhibitor approved for treatment by the Food
and Drug Administration (FDA) (Figure 1.3).∗ This peptidomimetic protease inhibitor
contains a syn-vicinal amino alcohol functionality. In 1996, Merck introduced an HIV
∗http://www.fda.gov/oashi/aids/virals.html
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protease inhibitor under the trade name Crixivan® (4).12 The inhibitor bears a cyclic
β-amino alcohol moiety, which plays a crucial role in biding to the protease enzyme.
The 1,2-amino alcohol functionality also serves as a chiral auxiliary to direct the stere-
ochemistry of two subsequent reactions in the synthesis of the protease inhibitor.13
N N
H
N
N
H
HN
O
O
OOH
H
H
N
N
Ot-BuHN
OH PhH
N
O
OH
H2SO4
O
NH2
N
3 4
Figure 1.3: HIV protease inhibitors having β-amino alcohol functionality.
1.1 Synthesis of cyclic β-amino alcohols
Most of the synthetic pathways to chiral β-amino alcohols utilize the transformation of
readily available α-amino acids. This approach, nevertheless, constrains the diversity
of accessible vicinal amino alcohols. Synthetic methodologies for acquiring enantiop-
ure 1,2-amino alcohols can be divided into two groups. The first group covers the
reactions in which a new C–C bond is created, i.e. coupling reactions. The second
group contains the reactions delivering chiral β-amino alcohols without changing the
carbon skeleton of the molecule undergoing transformation.
1.1.1 β-Amino alcohols via C–C bond formation
A common method for the synthesis of cyclic β-amino alcohols is the coupling of two
fragments, one containing an oxygen and the other having a nitrogen functionality.
The transformation involves formation of a new C–C bond between carbons bearing
nitrogen and oxygen functionalities. The creation of two new stereocenters must be
controlled enantio- and diastereoselectively.
4 CHAPTER 1. INTRODUCTION
Fu et al. reported azobisisobutyronitrile (AIBN) mediated cyclization of oxime ethers
tethered to a ketone or an aldehyde (Scheme 1.1).14 The stannyl radical addition–
cyclization of aldehyde-aldoximes, aldehyde-ketoximes and ketone-aldoximes (5) gives
corresponding cis- and trans-cyclic vicinal amino alcohols (6) of which the trans-isomer
is the major product. The reaction takes place entirely in an exo-trig fashion and forms
no endo-trig products.
SnBu3H
AIBN
NO
OMe
R1 R2
n
n = 1, 2
R2
NHOMeR1
HO
5 6
Scheme 1.1: Radical cyclization affording cyclic 1,2-amino alcohols.
Awell studied example of C–C bond forming process is the Henry reaction, which is an
aldol type condensation of nitroalkanes with carbonyl compounds.15 A report by Chiu
describes reductive intramolecular Henry reactions of nitroalkenones using Stryker’s
reagent ([Ph3PCuH]6) (Scheme 1.2).
16 Themethod affords cyclic β-nitro alcohols 8a and
8b, which can be further derivatized into cyclic vicinal amino alcohols by a sequential
reduction step.
[Ph3PCuH]6
+
O
NO2
HO NO2 HO NO2
HH
7 8a, 54% 8b, 8%
Scheme 1.2: Cyclic 1,2-amino alcohols via intramolecular Henry reaction.
1.1.2 β-Amino alcohol synthesis without changing carbon skeleton
Cyclic vicinal amino alcohols can also be constructed without altering the carbon skele-
ton of the substrate. The most common substrates for the purpose are alkenes and
their derivatives. Even though these transformations often proceed stereospecifically,
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regioselectivity stays as the main drawback of the method. The problem can only be
overcome by varying the substitution pattern of the substrate by functionalities having
steric and/or electronic influence.
Functionalities of molecules having two heteroatoms on adjacent carbons can be ma-
nipulated to furnish cyclic vicinal amino alcohols. One approach is to modify an imine
or carbonyl group bymeans of nucleophilic addition or reduction. Another variant uti-
lizes ring opening of epoxides or aziridines with a nitrogen or an oxygen nucleophile
to give β-amino alcohols.
Reduction of cyclic alpha-amino ketones affords 1,2-amino alcohols diastereoselectively
depending on the choice of hydride source. Reduction of chiral α-amino naphtalenone
9 with Red-Al (sodium bis(2-methoxyethoxy)-aluminum hydride) provides the cyclic
vicinal amino alcohols trans- and cis-10 with high diastereoselectivity (Scheme 1.3).17
O
NHCO2Me NHCO2Me
OH
NHCO2Me
OH
+
92%, dr: 95:5
Red-Al
Red-Al: (CH2O(CH2)2O)2H2Al Na
9 trans-10 cis-10
Scheme 1.3: Diastereoselective reduction of α-amino ketone 9.
Asymmetric reduction of keto oxime ethers using oxazaborolidine reagents is amethod
for the enantioselective synthesis of cyclic β-amino alcohols. Tillyer reported the asym-
metric reduction of keto oxime ether 11 catalyzed by the oxazaborolidine-borane com-
plex 12 to afford the cis-1,2-amino alcohol 13 with high diastereo- and enantioselectiv-
ities (Scheme 1.4).18
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O
TBDPSON
OH
H2N
N B
CH3
Ph Ph
BH3
11
12
13
13-cis 96% ee, 13-trans 90% ee
cis:trans 10:1, 95% yield
Scheme 1.4: Enantiooselective synthesis of the β-amino alcohol 13.
Ring opening reactions of epoxides or aziridines with heteronucleophiles (nitrogen or
oxygen) are well studied methods for the preparation of β-amino alcohols. Due to the
fact that heteronucleophile can attack either carbon of the heteroatom containing ring,
regioselectivity is a common issue of this approach.
In 1997, Jacobsen published synthesis of cyclic 1,2-amino alcohols via catalytic asym-
metric ring opening of meso-epoxides.19 The (salen)Cr(III)N3 complex 14
20 catalyzes
the asymmetric ring opening of the meso-epoxide 15 with TMSN3 to afford the cyclic
β-amino alcohol 16 (Scheme 1.5).
N
Cr
N
O ON3t-Bu
t-Bu t-Bu
t-Bu
H H
O N3 OTMS
2  mol%
TMSN3
88% yield, 99% ee
14
14
15 16
Scheme 1.5: Asymmetric ring opening of the meso-epoxide 15 catalyzed by
(salen)Cr(III)N3 complex 14.
Hadgson et al. reported the enantioselective alkylative double ring opening of aza-
bicycloalkene-derived epoxides which lead to enantioenriched cyclic amino alcohols.21
The reaction of Boc-protected azabicyclo[2.2.1]hept-2-ene-derived epoxide 17 with iso-
propyl lithium in the presence of (–)-sparteine (18) delivers the corresponding cyclic
amino alcohol 19 in 78% yield and 87% ee (Scheme 1.6).
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Boc
N
O
i-Pr
OH
NHBoc
N
N
H
H
i-PrLi
17
18
19
Scheme 1.6: Enantioselective alkylative double ring opening of azabicyclo-
alkene-derived epoxides.
Research group at Sepracor outlined the synthesis of cyclic 1,2-amino alcohol 22 (Scheme
1.7).22 Upon treatment with ammonia, the enantiomerically pure epoxide 20 provided
the trans-aminoindanol, which was converted without isolation into benzamide 21 by
application of Schotten-Baumann conditions. The patented method further outlines
the transformation of the optically pure trans-benzamidoindane 21 into cis-1-amino-2-
indanol (22) upon exposure to sulfuric acid, followed by addition of water.
O
NH2
OH
HN
OH
Ph
O
I) NH3 / MeOH
II) PhC(O)Cl
I) 80% H2SO4
II) H2O
20 21 22
Scheme 1.7: Epoxide opening with nitrogen nucleophile.
Aminohydroxylation reaction enables the synthesis of β-amino alcohols from alkene
starting materials. The method utilizes an osmium salt and a Cinchona alkoloid de-
rived ligand together with a nitrogen source. Aminohydroxylation of cyclohexene (23)
affords the corresponding vicinal amino alcohol 24with 63% enantiomeric excess (Fig-
ure 1.8).23
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Scheme 1.8: Aminohydroxylation reaction of cyclohexene (23).
The most suitable substrates for this reaction are reported to be α,β-unsaturated esters
and phosphonates.24 Although high enantioselectivities can be obtained with these
substrates, low yields, due to poor regioselectivity, is the main drawback of this ap-
proach.
An enantioselective synthesis of cis-1-amino-2-indanol (22) was published by Ko re-
search group.25 (E)-Cinnamate ester 25 is converted to the syn-diol 26 by Sharpless
asymmetric dihydroxylation protocol (Scheme 1.9).26 Diol 26 is then treated with HN3
under the Mitsunobu conditions employing DIPAD (diisopropyl azadicarboxylate).27
Obtained anti-azido alcohol 27 is converted to oxazolidinone 29 by a sequence of re-
actions shown in the Scheme 1.9. The reduction of keto function of 29 followed by
unmasking the amino alcohol function produces the amino indanol 22.
CO2Et CO2Et
OH
OH
CO2Et
N3
OH
CO2Et
O
HN
O
O
H
N
O
O
OH
NH2
(DHQD)2PHAL PPh3 
DIPAD
97%, >99% ee
1. H2, Pd-C
2. Triphosgene
3. 1N NaOH, Et2O
63%
1. SOCl2
2. AlCl3
76%83%56%
1. Et3SiH, BF3 OEt2
2. 2N NaOH
25 26 27
282922
Scheme 1.9: Enantioselective synthesis of cis-1-amino-2-indanol (22) by Ko.
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1.2 Aggrecanase Inhibitors
Cartilage is an elastic, flexible yet tough connective tissue, which serves many func-
tions in the human body. It covers the surface of joints to supply smooth surfaces for
the articulating bones, thus reducing friction and preventing damages. Cartilage is also
found in the external ear, the voice box, nose and in the rib. The skeleton is formed by
cartilage which is progressively substituted by bone as the embryo grows. Cartilage is
composed primarily of collagen, which grants strength and support, and proteoglycan,
which supplies compressibility and elasticity functions. The major type of proteogly-
can present in cartilage is aggrecan. Aggrecan is very sensitive toward proteolysis.∗
Aggrecanases, which are the members of the ADAM (a disintegrin and metallopro-
tease) protein family, and matrix metalloproteinases (MMP-1, 2, 3, 7, 8, 9, and 13) have
been reported to degrade aggrecan.28,29 The proteolysis of aggrecane causes damages
in cartilage matrix. Such damage in cartilage results in the development of arthri-
tis.† Unlike other connective tissues in the body, cartilage does not contain nerves or
blood vessels. Thus, once it is damaged, it does not heal readily. Protecting cartilage
from such damages has major potential therapeutically and economically.30 If carti-
lage degradation can be avoided or significantly reduced, joint functionality could be
protected and severe disability could be prevented. To hinder the progression of joint
demolition, there has been an increasing effort in discovering a selective aggrecanase
inhibitor.31
Most of the reported aggrecanase and MMP inhibitors possess a hydroxamic acid moi-
ety that functions as a zinc-chelating group. Furthermore, it has been reported that
hydroxamic acid-based pseudopeptide MMP inhibitors exhibit activity against tumor
necrosis factor (TNFα) processing enzyme.32 TNFα is a cytokine that has been associ-
ated with several diseases including arthritis.33 Noe et al. has reported the synthesis
and in vivo efficacy of 3-hydroxy-3-methylpipecolic hydroxamate 31 (Figure 1.4).34 The
hydroxamic acid 31was reported to be an orally available inhibitor of aggrecanase and
MMP-13. The potency of the inhibitor was optimized by modification of the benzy-
loxyarylsulfonamide group. In 1997, MacPherson et al. from Novartis Pharmaceuticals
∗degradation (digestion) of proteins by enzymes called proteases
†(Greek arthro-, joint + -itis, inflammation) is a group of conditions involving damage to the joints of
the body.
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described the sulfonamide-based hydroxamic acid 32, which is a potent inhibitor that
blocks cartilage degradation in rabbits (Figure 1.4).35 The sulfonamide moiety of the
potent inhibitor 32 plays a vital role for its efficiency. In the report it was shown that
replacement of sulfonamide by an amide group results in total loss of inhibitor activity.
HO H
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N
H
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N
HO
HN
O OH
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S
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Cl
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NS
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O
MeO
N
31 32 33
Figure 1.4: Potent inhibitors against cartilage degradation.
Yao et al. reported structure-activity relationship (SAR) investigations on aggrecanase
with peptide mimetics.36 The results obtained and the successful utilization of the β-
amino alcohol 22 in the development of Crixivan® (4)12,13 led Yao group to examine cis-
1(S)2(R)-amino-2-indanol (22) as a phenylglycine mimetic. As a result of this research
they discovered the indanol 22 based hydroxamic acid 33 (Figure 1.4), which shows
excellent inhibitor activity against aggrecanase.36,37
1.3 Sulfoximines in biologically active compounds
Since the discovery of methionine sulfoximine 34 (Figure 1.5) in 1950,38 sulfoximines
have become a popular research subject among chemists and biologists. The sulfox-
imine substituted amino acid 34 exhibits inhibitor activity against glutamine synthe-
tase.39 Extensive research on this compound gave rise to the discovery of buthionine
sulfoximine 35 (Figure 1.5).40 The sulfoximine-substituted α-amino acid derivative 35
has drawn considerable attention from the medical community as a result of its selec-
tive inhibitory action on γ-glutamylcysteine.41
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Figure 1.5: Methionine- and buthionine sulfoximine (34, 35).
Several studies have shown novel biological aspects of sulfoximines. Phosphorus con-
taining substrate 36was reported as an enzyme inhibitor for carboxypeptidase A (Fig-
ure 1.6).42 Mock reported the synthesis of the analogue inhibitor 37, which was ob-
tained by replacing the phosphonyl moiety in the carboxylic acid 36with a sulfoximine
(Figure 1.6). The obtained transition state analogue 37 showed significant diastereose-
lection in carboxypeptidase A inhibition.43,44
S
OHN
CO2H
Ph
P N
H
OHO
CO2H
Ph
36 37
Figure 1.6: Carboxypeptidase A inhibitors.
Recently, Posner reported an example of isosteric replacement using sulfoximines.45
The natural hormone Calcitriol (1α,25-dihydroxyvitamin D3, 38) together with keto-
conazole (40) is a promising combination for chemotherapy of diverse human diseases
(Figure 1.7).46 Posner group showed that the vitamin D analogue 39, even though lack-
ing terminal OH group, is a potent and selective inhibitor of the human cytochrome
P45024 hydroxylase enzyme, which is known to be responsible for the main catabolism
of Calcitriol (38, Figure 1.7).45 Sulfoximine 39 was found to be forty times more potent
than ketoconazole (40) against P45024 inhibition. Therefore, the sulfoximine analogue
39 can potentially be used for a more effective treatment of human illnesses in conjunc-
tion with the natural hormone Calcitriol (38).
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Figure 1.7: Sulfoximine analogue of the natural hormone Calcitriol (38).
The first application of sulfoximine in HIV protease inhibitor design was published by
Vince et al..47 The research group incorporated sulfoximine functionality into the com-
pound L700,417 (41, Figure 1.8),12 which is a potent pseudosymmetric HIV protease
inhibitor. After analyzing several possible stereoisomers, the group found that the sul-
foximine β-amino alcohol 42 is the most potent stereoisomer with activity comparable
to that of Crixivan® (4)12 against the enzyme (Figure 1.8).
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41 42
Figure 1.8: HIV protease inhibitor incorporating sulfoximine functionality.
Chapter 2
Carbometalation-Cyclization
Carbometallation-cyclization is a widely used strategy in organic chemistry for the
synthesis of cyclic compounds. The basic idea behind these type of cyclizations is to
generate a carbon–metal bond that further reacts intramolecularly with an electrophlic
functionality like an ester, aldehyde, alkly halide etc.
Michael addition to an enoate leads to generation of a carbon–lithium bond that can
cyclize via intramolecular substitution of a halide. Enders et al. reported the highly
diastereo- and enantioselective conjugate addition of TMS-SAMP∗ to halide-substituted
enolates leading carbocyclic β-amino acids by an intramolecular Michael–initiated ring
closure of the hydrazinomoiety.48 The aza-Michael addition of lithiated TMS-SAMP 43
to the α,β-unsaturated ester 44 leads to the formation of the intermediate 45, which un-
dergoes an intramolecular cyclization to deliver the trimethylsilyl protected hydrazine
46 (Scheme 2.1).
∗(S)-(–)-1-(trimethylsilylamino)-2-(methoxymethyl)pyrrolidine.
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Scheme 2.1: Synthesis of the heterocyclic β-amino acid 47 by tandem aza-
Michael addition/intramolecular cyclization.
Organocopper reagents are widely used in organic synthesis due to their practical
properties. Organocopper reagents do not react rapidly with ketones, ester or amides,
but will react with aldehydes, α,β-unsaturated ketones and esters, as well as alkyl,
aryl halides at a faster rate. Alexakis reported a novel method for the construction of
cyclic compounds with multiple chiral centers.49 The copper-catalyzed intramolecu-
lar conjugate addition-cyclization of 48 in the presence of the chiral phosphoramidite
49 delivers the substituted cyclohexane 50 in high diastereo- and enantioselectivities
(Scheme 2.2).
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CO2Me
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dr: 90:10, 92% ee
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Scheme 2.2: Copper-catalyzed conjugate addition-cyclization on 48.
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Several other transitionmetals can be utilized in carbometalation reactions. The Krische
group reported a Rh-catalyzed enantioselective carbometallative aldol cycloreduction
of aromatic and aliphatic mono-enone mono-ketones.50 Using the Rh-BINAP catalyst
system, mono-enone mono-ketone 51 is converted to the corresponding cyclized prod-
uct 52 in 88% yield with >99% de and 88% ee values (Scheme 2.3).
O
Ph Me
O
Rh(C2H4)2(acac)
R-BINAP, PhB(OH)2
Me OH
Ph
O
Ph
88%, >99% de, 88% ee
51 52
Scheme 2.3: Rh-catalyzed enantioselective carbometallative aldol cyclore-
duction of 51.
Sulfones are valuable auxiliaries for the activation of hydrocarbons and have proved
to be of great importance in synthesis.51,52 Sulfone moiety enhances the affinity of
adjacent unsaturated carbon–carbon bonds to undergo carbometalation reaction. The
adduct 54, which formed via the carbometalation of vinyl sulfone 53 has negative
charge density next to the sulfone moiety, which stabilizes the intermediate (Figure
2.1. This therefore increases the electrophilicity of the carbon–carbon unsaturation.51
This feature makes the vinyl sulfones efficient Michael acceptors. The role of vinyl
sulfones in organic chemistry has been reviewed by Simpkins.53
RO2S R' M RO2S
M
R'
+
53 54
Figure 2.1: Stabilization of negative charge density by sulfone moiety.
IntramolecularMichael additions of vinyl sulfones have found use in synthesis of natu-
ral products, biologically active compounds. Craig et. al showed that 2,6-disubstituted
tetrahydropyrans can be achieved efficiently with high stereoselectivities.54 The base
catalyzed conjugate addition reaction of vinyl sulfone 55 leads to cis-2,6-disubstituted
56 and trans-2,6-disubstituted heterocycle 57 in 78% and 2% yield, respectively (Scheme
2.4).
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Scheme 2.4: Stereoselctive conjugate addition of vinyl sulfone 55.
Fuchs et al. developed amethod to obtain the intramolecular conjugate addition of ary-
loxy anions to β-functionalized vinyl sulfones.55 The treatment of the β-bromoethyl-
substituted vinyl sulfone 58with tert-butyllithium affords a yield of 73% of bis-cyclized
product 59 (Scheme 2.5).
Br
Br
O
t-BuO2S
O
SO2t-Bu
t-BuLi
THF, -78oC
73%
58 59
Scheme 2.5: Intramolecular conjugate addition/intramolecular alkylation re-
action of the vinyl sulfone 58.
Like vinyl sulfones as shown in Scheme 2.4 and 2.5, vinyl sulfoxides are well-known
chiral Michael acceptors.56 Sulfones and sulfoxides tend to increase the acidity of
the adjacent C–H bonds due to the high electronegativities of the sulfone and sul-
foxide groups. This implies that vinylic sulfones and sulfoxides can also be used as
Michael donors. In 2004, Tanaka reported an example of asymmetric intramolecular
Michael addition reaction, inwhich the vinylic sulfoxidemoiety employed as aMichael
donor.57 Upon treatment of enoate 60 with LDA, deprotonation α-sulfinyl proton and
intramolecular Michael addition of the resulting carbanion to the enoate delivers γ,δ-
unsaturated ester 61 in 71% yield and excellent diastereoselectivity (Scheme 2.6).
17
CO2Me
SO Tol SO Tol
CO2Me
LDA
THF, -78oC
71%, 100% de60
61
Scheme 2.6: Employing vinyl sulfoxide 60 as a Michael donor.
Aluminium is another metal that can be utilized in carbometalation reactions. Alu-
minium is the most abundant metal of the earth’s crust and it is widely used in daily
life. This asset makes aluminium an ideal metal for carbometalation reactions. Ziegler
et al. showed that the reactions of DIBAL-H with hexa-1,5-dienes afford α-alumino-
methylcyclopentanes.58 In 1971, Zweifel published the synthesis of substituted cyclo-
pentyl derivatives via the hydroalumintaion of hex-1-en-5-yne (Figure 2.2).59
DIBAL-H
79%
Figure 2.2: Cyclization of hex-1-en-5-yne via hydroalumintaion.
The first reductive cyclization employing lithium aluminum hydride (LiAlH4) was
published by Sung.60 Treatment of imidazolidinone 62with LiAlH4 in anhydrous ether
delivers the bicyclic octane derivative 63 as a single diastereomer in 86% yield (Scheme
2.7).
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CO2Me
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N
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Ar: p-tolyl 86%, >98% de
62 63
Scheme 2.7: Reductive cyclization of 62with LiAlH4.
During an investigation of stereoselective routes to damsinic acid (64), Jones and his
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co-workers developed a method in which the anionic specie formed by treatment of
vinyl sulfone 65 with diisobutyllithium hydride–isobutyllithium (DIBAL-H–i-BuLi)
reacts intramolecularly with the ester functionality to form the six-membered cyclic
α-sulfonyl ketone 66 in 95% yield (Scheme 2.8).61,62
O O
CO2RR
SO2Ar
H
DIBAL-H, i-BuLi
Hexane, THF
R: Me, Ar: p-tolyl
O OR O
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95%
O Me
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64
65 66
Scheme 2.8: Reductive cyclization of sulfone 65with DIBAL-H–i-BuLi.
Chapter 3
Aim of the study
Due to the fact that cyclic amino alcohols found wide application in organic chemistry,
their synthesis is a well studied topic. Whereas significant effort has been devoted
for the synthesis of monocyclic β-amino alcohols, the synthesis of bicyclic β-amino
alcohols is not much investigated except the research dedicated to the synthesis of
amino indanol derivatives.22,36, 37, 63, 64 The target of this work was to obtain bicyclic
1,2-amino alcohol derivatives and to apply them in the synthesis of the sulfoximine-
substituted potential aggrecanase inhibitor.
Gais research group developed a highly regio- and diastereoselective synthesis of β,γ-
unsaturated α-amino acid derivatives E-70 (Scheme 3.1).65–67 The reaction of bis(allyl-
sulfoximine)titanium complexes 68 with α-iminoester 69 deliver the syn-E-configured
sulfoximine-substituted homoallylic amines E-70 in high yields (Scheme 3.1).
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Scheme 3.1: Aminoalkylation of cyclic allysulfoximines 67.
In the first part of this work, the conversion of the sulfoximine-substituted α-amino
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esters E-70 into the corresponding bicyclic β-amino alcohols 71 was studied. The tar-
geted transformation encompasses formation of a new carbocycle and construction of
three new contiguous stereocenters (Figure 3.1).
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71 E-70
Figure 3.1: Planned bicyclic 1,2-amino alcohol 71 synthesis.
Recently, the synthesis of sulfoximine-substituted biologically active compounds has
drawn much attention. The results mentioned in Section 1.3 show the recent advances
reported in the field. In the second part of this study, the bicyclic 1,2-amino alcohol
74 is employed for the synthesis of sulfoximine-substituted potential aggrecanase in-
hibitor 72 (Figure 3.2). The potential inhibitor 72 can be obtained via coupling of acid
73with sulfoximine-substituted β-amino alcohol 74. The two approaches that were in-
vestigated for the synthesis of the oxabutanoic acid derivative 73 were discussed vide
infra.
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Figure 3.2: Retrosynthetic analysis of sulfoximine-substituted N1-hydroxy-
N4-(2-hydroxyoctahydro-1H-inden-1-yl)succinamide (72).
Chapter 4
Results and Discussion
The enantiomerically pure allylic sulfoximines 76–80 required for the synthesis of α,β-
unsaturated sulfoximine-substituted α-amino esters 81–85 (Figure 4.2) are readily avail-
able starting from (S)-N,S-dimethyl-S-phenyl sulfoximine (75)68,69 and the correspond-
ing ketones or aldehyde by the addition-elimination-isomerization (AEI) route shown
in Figure 4.1.70–72
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Figure 4.1: Addition-Elimination-Isomerization Route for the synthesis of al-
lylic sulfoximines 76–80.
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Upon reaction with n-BuLi, followed by addition of ClTi(Oi-Pr)3 β,γ-unsaturated sul-
foximines 76–78, 80 form bis(allyl)titanium complexes,65,66 which are subsequently
treated with the N-Bus protected iminoester 6967 to afford the E- and Z- configured
α,β-unsaturated sulfoximine-substituted α-amino esters E-81–83, E-85 and Z-81–83, Z-
85 (Figure 4.2).65,66 Similarly, successive treatment of the sulfoximine-substituted cyclic
ketal 79 with n-BuLi, ClTi(Oi-Pr)3 and iminoester 69 gives the required α-amino ester
derivative E-84 as a single compound (Figure 4.2).72 The starting materials, 76–80,
E-81–85 and Z-81–83, Z-85 were prepared according to over mentioned literature pro-
cedures, and same and/or similar yield, enantio- and diastereoselectivities were ob-
tained.
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Figure 4.2: γ-Aminoalkylation of allylic sulfoximines 76–80.
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4.1 Synthesis of β-Amino Alcohols
A challenging part of the project was to acquire cyclic β-amino alcohols 90 starting from
α,β-unsaturated sulfoximine-substituted α-amino esters 86 (Figure 4.3). Our approach
to achieve this formidable task was to find a suitable nucleophile that attacks directly
at the quaternary carbon of the double bond (87, Figure 4.3). The regioselectivity of
the chosen nucleophile was crucial for this purpose, because of the fact that substrates
bear a reactive ester carbonyl functionality. Supposedly, the formed intermediate 87
would undergo a cyclization reaction by attacking at the carbonyl carbon. Then the
hemiacetal intermediate 88 should provide the cyclic ketone 89, which could possibly
be reduced by a suitable hydride source stereoselectively utilizing sulfoximine moiety
for 1,3 asymmetric induction. Such methodology, however, would require isolation of
the intermediate ketone 89.
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Figure 4.3: Planning synthesis of cyclic 1,2-amino alcohols.
Instead of making a two step transformation, it was intended to make one pot reaction,
in which both cyclization and reduction steps occur. The issue of this approach was to
activate the double bond in such a way that upon treatment with hydride the double
bond would be selectively attacked first in the presence of the ester group. There are
few examples where sulfone vinyl esters are transformed into cyclic ketosulfones upon
treatment with aluminium reagents.61,62 However, to our best knowledge, there is no
methodology reported, in which α,β-unsaturated sulfoximines undergo hydroalumi-
nation reaction to perform cyclization (87 to 88, Figure 4.3).
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4.1.1 DIBAL-H Reduction Reaction
Preliminary investigations of hydroalumination reaction of sulfoximine-substituted un-
saturated α-amino esters were performed with the substrates (S)-(S-(cyclohexylidene-
methyl)sulfonimidoyl)benzene (91) and α-amino ester E-82. Sulfoximine 91was treated
with 1.2 equiv of DIBAL-H in THF at 0 ◦C to test the reactivity of the double bond. The
reaction afforded the saturated derivative 92 proving the fact that sulfoximine sub-
stitution increased the electrophilicity of the quarternery carbon of the double bond.
(Scheme 4.1). Although analysis of the reaction mixture by 1H NMR showed full con-
sumption of the α,β-unsaturated sulfoximine 91, the saturated sulfoximine 92 was iso-
lated in 81% yield by column chromatography.
81%
S
N OMe
DIBAL-H (1.2 eq.)
THF, 0 oC
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91 92
Scheme 4.1: Reaction of sulfoximine 91with DIBAL-H.
For the above conversion it was sufficient to utilize an almost equimolar amount of
DIBAL-H. However, due to the fact that α,β-unsaturated sulfoximine E-82 bears an
acidic proton on sulphonamide nitrogen, at least two equiv of the hyride should be
used for a successful transformation. The reaction of the cyclic sulfoximine E-82 with
two equiv DIBAL-H afforded the saturated derivative 93 as single compound with ≥
98 de (Scheme 4.2).
35%, de ≥ 98%
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Scheme 4.2: DIBAL-H reduction of α,β-unsaturated sulfoximine E-82.
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The obtained result showed clearly that the sulfoximine-substituted double bond is
more reactive than ester carbonyl toward hydride nucleophile. The configuration of
the α-amino ester 93 was determined to be as shown by 2D NMR NOE analysis. The
strong NOE effect between H-1 and H-2 indicates that these protons are cis to each
other. Moreover, the absence of NOE effect betweenH-1 andH-7 supports the depicted
structure of 93 in Scheme 4.2.∗
The stereoselective formation of sulfoximine 93 can be explained by the following plau-
sible mechanism depicted in the Figure 4.5. The equatorial arrangement of the α-amino
ester moiety in the α,β-unsaturated sulfoximine E-82would result in an increase in the
energy. Hence, the α-amino ester group should lie in an axial orientation. Moreover,
Gais et al. reported the X-ray crystal structure analysis of ent-E-82, wherein the axial
orientation of α-amino ester functionality was observed (Figure 4.4).65 For sulfoximine
ent-E-82 strong NOE effect was observed between S-CH and N-CH-CH protons.
Figure 4.4: Structure of ent-E-82 in the crystal.
In light of the foregoing, it can be concluded that there are three possible conformers
94, 95 and 96, related to the hydroalumination of the double bond of the substrate E-82.
The conformer 96 should be energetically the highest one, owing to the steric interac-
tion between phenyl group and themethylene of the six membered ring. The staggered
alignment 95 is more stable than 96. However, once the coordination of DIBAL-H to the
∗for details of the analysis please see the table on page 79
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nitrogen of the sulfoximine occurs to form the intermediate 98, there occurs an increase
in the steric hindrance arising from aluminium rest and the α-amino ester functional-
ity. In other terms, α-amino ester group blocks an attack at the double bond carbon
from the si-face. Most probably the least energetic, therefore most stable conformer
of the unsaturated sulfoximine E-82 should be the conformer 94 (Figure 4.5), in which
the phenyl group of the sulfoximine is aligned in an anti-periplanar fashion to the ex-
ocyclic double bond. In this case, the NMe function of the sulfoximine directs to the
re-face of the double bond. Coordination of aluminium reagent followed by attack of
hydride from re-face of the double bond yields in the formation of hydroaluminated in-
termediate 99. Working up the reaction with water delivered the saturated sulfoximine
93 with ≥ 98% diastereomeric excess.
An insufficient amount of DIBAL-H for the transformation depicted in Scheme 4.2 re-
sulted in partial saturation of the double bond. Therefore, it was essential to increase
the equiv of the hydride used for the reaction. Treatment of E-82 with three equiv
of DIBAL-H resulted in formation of the desired cyclic β-amino alcohols 100 and 101
in 50% and 4% yield, respectively (Scheme 4.3, entry 1). This initial result was very
promising due to that fact that the obtained diastereomers, 100 and 101, are only al-
tering at the carbon bearing the alcohol functionality. In other terms, the hydroalumi-
nation of the sulfoximine-substituted double bond occurs exclusively from the re-face
(97, Figure 4.5). This highly diastereoselective reaction was repeated with five equiv of
DIBAL-H and the formation of the sulfoximine-substituted cyclic 1,2-amino alcohols
100 and 101 was observed with 86% and 7% yield, respectively (Scheme 4.3, entry 2).
A X-ray crystal structure analysis of 100 showed it to have the absolute configuration
depicted in Figure 4.6.∗
∗for details of the analysis please see page 134
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For the N-Bus protected amino alcohol 101 the stereochemistry of the carbons C-1 and
C-7a were known from the α-amino ester E-82 (Scheme 4.3) to be as shown in the Figure
4.7. Assignment of the remaining carbons of 1,2-amino alcohol 101 was inferred by a
NOE experiment, which revealed strong NOE effect between the protons H-1 and H-2,
H-1 and H-3, H-2 and H-3. Moreover, the absence of NOE effect between H-2 and ring
conjunction protons, H-3a and H-7a, supported the assigned structure for 101 (Figure
4.7).∗
∗for details of the analysis please see the table on page 81
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A reasonable mechanism for the formation of cyclic 1,2-amino alcohols 100 and 101
is outlined in Figure 4.8. The first step employs the formation of 97, which arise from
treatment of sulfoximine E-82with DIBAL-H. Next, attack of hydride at the quaternary
carbon of the double bond from the re-face leads to the hydroaluminated intermediate
99 (prefered re-face attack of the hydride is discussed on page 27). Later, cyclization
via attack at the carbonyl carbon affords the hemiacetal 102, which delivers the cyclic
ketone 103. As seen in Figure 4.8 for ketone 103 the sulfoximine and sulfonamide moi-
eties are on the same plane. The reduction of ketone can occur both from re- and si-face
of the carbonyl. However, coordination of the aluminium reagent to the sulfoximine
nitrogen and possibly also to the sulfonamide nitrogen (intermediate 104) increases
the si-face attack probability of the hydride at the carbonyl, therefore delivering 100
as the major product of the reaction. Obviously, hydride attack from the re-face of the
carbonyl is less probable because of the fact that aluminium specie has no chance to co-
ordinate in the concave site of the bicyclic system to afford the intermediate 107 (Figure
4.8).
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Having developed a highly diastereoselective synthesis of the cyclic β-amino alco-
hols 100 from the amino acid derivative E-82, reaction of α,β-unsaturated sulfoximine-
substituted α-amino esters with DIBAL-H was also studied. Treatment of the homoal-
lylic amine E-81 with DIBAL-H afforded 1-aminooctahydropentalen-2-ols 108 and 109
in 50% and 21% yields, respectively (dr 76:24) (Scheme 4.4). A X-ray crystal structure
analysis of 108 showed it to have the absolute configuration depicted in Figure 4.9.∗
The absolute configuration of the bicyclic 1,2-amino alcohol 109 was determined to be
as shown by 2D NMR NOE analysis.†
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Scheme 4.4: Synthesis of sulfoximine-substituted cyclic β-amino alcohols 108
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The reaction of the sulfoximine-substituted amino acid derivative E-83 with DIBAL-H
led to the formation of bicyclic 1,2-amino alcohols 110 and 111 in a ratio of 1:1 with
33% yield and the monocyclic α-hydroxy amine 112 with 50% yield (Scheme 4.5). The
stereochemistry of the carbons C-1 and C-8a in 110 and 111 and the carbons C-1 and
C-9 in 112 were known from the ester derivative E-83. Assignments of the remaining
∗for details of the analysis please see page 123
†for details of the analysis please see the table on page 76
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chiral carbons were inferred by NOE experiments. For 110, the medium NOE effect
between H-8a and H-2 and the strong NOE effect between H-8a and H-3a indicate that
these protons are on the same plane of five-membered ring. The absence of NOE corre-
lation between H-8a and H-3 and the strong NOE effect between H-1 and H-3 suggest
the shown absolute configuration for 110 (Scheme 4.5).∗ In case of the β-amino alcohol
111, strong NOE effect between the protons H-1 and H-2, H-1 and H-3 and H-2 and
H-3 were observed. Although a weak NOE effect between the H-8a and H-1 was de-
tected, the strong NOE effect between H-3a and H-8a was decisive for assigning the
absolute stereochemistry of 111.† For 112, NOE experiments revealed strong correla-
tion between H-1 and H-2. No NOE effect between the H-1 and H-8 was observed.
These results indicated the assigned structure for 112 (Scheme 4.5).‡
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Scheme 4.5: Reaction of DIBAL-H with vinylic sulfoximine E-83.
The low yield observed for the bicyclic β-amino alcohols 110 and 111 and the favored
formation of alcohol 112 can be rationalized on the basis of comparative conforma-
tional analysis of cycloheptane. The most stable conformation of cyclohexane is the
chair conformation illustrated in Table 4.1. Chair conformation of cyclohexane (C) can
interconvert to another chair conformation by a ring-flip, which requires 10.1kcal/mol
∗for details of the analysis please see the table on page 88
†for details of the analysis please see the table on page 89
‡for details of the analysis please see the table on page 90
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activation energy to access the first transition state conformation half-chair (HC). In
2003, Wiberg reported the twist-chair (TC) conformer as the global minimum energy
structure for cycloheptane.73 Relative energies∗ of cycloheptane conformers show only
slight differences (Table 4.1), which leads to levelling the conformational population of
possible conformers (Table 4.2). The exponential relation between free-energy differ-
ence (∆G◦) and percent population of conformers at equilibriummeans loss of rigidity
for cycloheptane due to low energy barriers between its conformers.
Table 4.1: Calculated relative energies of cyclohexane and cycloheptane con-
formers.
Relative Energy (kcal.mol−1)
cyclohexane
C, 0.0 B, 6.9TB, 5.3HC, 10.1
cycloheptane
TC, 0.0 C, 1.0 TB, 4.0 B, 4.1
Table 4.2: Relationship between free-energy difference and conformer per-
centage at equilibrium at 0 ◦C (∆G◦ = −RT[lnKeq])
.
Free-energy difference, More stable conformer Less stable conformer
∆G◦ (kcal.mol−1) (%) (%)
0 50 50
1.0 (cycloheptane, TC to C) 86 14
10.1 (cyclohexane, C to HC) > 99.999 < 0.001
Despite the conformational instability of the ring, hydroalumination step for E-83with
DIBAL-H occurs with ≥ 98% diastereoselectivity (all products 110, 111 and 112 have
the same absolute configuration at the ring-carbon, which is β to sulfoximine sub-
stituent) to afford the intermediate 113 (Figure 4.10). Due to lack of rigidity in the
seven-membered intermediate 113, the subsequent cyclization step, barely takes place
to deliver the hemiacetal intermediate 114. Accordingly, the rate of the competing re-
action (reduction of ester functionality to alcohol) increases (k1 << k2) in such a way
∗calculated at B3LYP/6-311+G∗ theoretical level
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that the cycloheptanol homolog 112 was formed as the major product of the reaction.
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Figure 4.10: Possible reaction pathways of the sulfoximine-substituted
hydroaluminated intermediate 113.
In order to test the rigidity requirement of the cyclic β-amino alcohol formation reac-
tion, the acyclic sulfoximine E-85 was treated with DIBAL-H under the same condi-
tions (Scheme 4.6). Formation of a 4:1 mixture of vicinal-amino alcohols 116 and 117
with only 25% yield supported the idea that a rigid structure is essential for a success-
ful cyclization reaction. The formation of non-reduced ester 118 can be grounded on
moisture in reaction medium. The result was not corrected. The absolute configura-
tions of the 1,2-amino alcohols 116 and 117were determined by NOE experiments. For
116, weak NOE effect between the adjacent protons (H-1 and H-2, H-2 and H-3, H-5
and H-1) were observed. The strong NOE effects between H-1 and H-3, H-2 and H-5
indicated the absolute configuration for 116 (Scheme 4.6).∗ For 117, the strong NOE
∗for details of the analysis please see the table on page 94
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effect between H-1 and H-2, H-2 and H-3, H-1 and H-3, additionally the absence of
NOE effect between H-5 and H-2, H-5 and H-3 indicate that the absolute configuration
of the β-amino alcohol 117 is as depicted in Scheme 4.6.∗
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Scheme 4.6: Reaction of DIBAL-H with vinylic sulfoximine E-85.
For the preparation of more functionalized bicyclic 1,2-amino alcohols, reaction of
sulfoximine-substituted cyclic ketal E-84with DIBAL-Hwas investigated (Scheme 4.7).
The highly diastereoselective transformation afforded the ketal-functionalized cyclic
β-amino alcohols 119 and 120 in 72% and 15% yields, respectively. For the amino alco-
hols 119 and 120, the absolute configurations of the carbons C-3 and C-3a were know
from the α-amino ester E-84 (Scheme 4.7). Assignment of the remaining carbons of
1,2-amino alcohols 119 and 120 were inferred by NOE experiments. For the bicyclic
amino alcohol 119, the mediumNOE effect between H-7a and H-2 and the strong NOE
effect between H-3a and H-7a indicate that these protons are on the same plane of
five-membered ring. The absence of NOE correlation between H-3a and H-3 and the
strong NOE effect between H-1 and H-3 suggest the shown absolute configuration for
119 (Scheme 4.7).† For 120, strong NOE effect between protons H-1 and H-2, H-1 and
H-3, H-2 and H-3 were observed. Furthermore, the absence of NOE effect between H-2
and ring conjunction protons H-3a and H-7a supported the assigned structure for 120
∗for details of the analysis please see the table on page 95
†for details of the analysis please see the table on page 86
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(Scheme 4.7).∗
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Scheme 4.7: Synthesis of ketal-functionalized bicyclic β-amino alcohols 119
and 120.
4.1.2 Influence of Double Bond Configuration
In the previous sections, the synthesis of cyclic β-amino alcohols from α,β-unsaturated
sulfoximine-substituted α-amino esters bearing E-configured double bond was dis-
cussed. Reaction of DIBAL-H with unsaturated sulfoximines Z-82 and Z-83was inves-
tigated ad hoc to examine the influence of double bond configuration on the transfor-
mation. When reacted with five equiv of DIBAL-H, vinylic sulfoximine Z-82 furnished
the tetrahydrofuranyl sulfonamide 121 in 48% yield (Scheme 4.8, entry 1). Although
the 1H NMR of the crude mixture indicated high conversion, only moderate yields
were obtained for this transformation. Yield can be improved by alternative work up
methods. Similarly, treatment of Z-83 with DIBAL-H delivered the furan homolog 122
in good yield (Scheme 4.8, entry 2). In both reactions high diastereoselectivities were
obtained.
∗for details of the analysis please see the table on page 85
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*Determined by 1H NMR spectroscopy of the crude reaction mixture.
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Scheme 4.8: Reactions of DIBAL-H with Z-82 and Z-83.
The structural elucidation of tetrahydrofurans 121 and 122 was made based on the
NOE experimental results. Absolute configurations were assigned relative to the car-
bons C-4 and C-3 (Figure 4.11), stereochemistry of which are known from the start-
ing materials Z-82 and Z-83. Strong NOE effect between protons H-1 and H-4, and
also between H-3 and H-2 were observed. Therefore it was concluded that C-5 is (S)-
configured.
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Figure 4.11: NOE’s of the cyclic tetrahydrofuran derivatives 121 and 122.
The synthesis of similar sulfoximine-substituted tetrahydrofuran derivatives 124 and
126was reported by Gais74 and Reggelin,75 respectively (Figure 4.12). In bothmethods,
removal of silyl protecting group led to a diastereoselective cyclization, which afforded
the tetrahydrofurans 124 and 126.
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Mechanism of furan formation
Even though having the opposite configuration at the exocyclic double bond, the α-
amino ester functionality of Z-82 aligns in an axial orientation as in the unsaturated
sulfoximine E-82 (Figure 4.13). Eclipsed conformation of the double bond and Cα–
Cβ bond in conformer 127 results in torsional strain. To increase the torsion angle,
the molecule undergoes a ring-flip to adopt the chair conformation 128, in which the
α-amino ester is in an axial position.
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Figure 4.13: Comparison of chair conformations of Z-82.
As the sulfonamido acetate group of Z-82 prefers an axial orientation (Figure 4.13),
there are three possible conformers 129, 130 and 131, arising from the bond rotation
around the sulfur carbon bond axis (Figure 4.14). Among these conformers, 129 should
be the least stable one due to the steric interaction between the phenyl and the α-amino
ester groups. The conformer 130 is relatively more stable. However, once the alu-
minium reagent coordinates to the nitrogen of the sulfoximine group (intermediate
132 in Figure 4.14), hydroalumination of double bond cannot take place due to fact
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that aluminium reagent is anticlinal to the p-orbitals of the double bond. Possibly, the
most stable conformer is 131. The axial oriented α-amino ester moiety blocks the si-face
of the double bond. Hence, a hydride attack at the vinylic carbon is not possible.
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Figure 4.14: Conformational hinderance of double bond hydroalumination
of Z-82.
Since the hydroalumination of the double bond can not occur (vide supra), DIBAL-H
reduces the ester group of Z-82 (Figure 4.15). Attack of hydride at carbonyl leads to the
hemiacetal intermediate 134, which later delivers the aldehyde 135. Subsequent reac-
tion of DIBAL-H with aldehyde 135 forms the intermediate 136. Nucleophilic attack of
oxygen at the terminal carbon of the exocyclic double bond from the si-face leads to the
formation of 137, which furnishes the sulfoximine-substituted bicyclic furan 121 upon
work-up with water.
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4.2 Further Transformations of Cyclic β-Amino Alcohol
100
Sulfoximines provide high asymmetric induction in chiral synthesis. After being used
in asymmetric synthesis, they can easily be removed, substituted or transformed into
different functionalities, i.e. sulfones. With these exclusive collection of possible trans-
formations, sulfoximines fulfill a major requirement for being a powerful chiral auxil-
iary.
4.2.1 Chlorine-Substitution
The substitutionmechanism of sulfoximine by chloroformates is not known. In chlorine-
substitution of secondary sulfoximes, both retention and inversion of configuration
have been reported.76–78 Treatment of sulfoximine 100 with ClCO2CH(Cl)CH3 deliv-
ered chloride 138 and also the α-amino ketone 139 in 41% and 27% yield, respectively
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(Scheme 4.9). NOE experiments revealed strong correlation between H-2 and H-3, H-
3 and H-3a, H-3a and H-7a. No NOE effect between the H-1 and H-3 was observed.
These results indicated the assigned structure for 138 (Scheme 4.9).∗ Purification of the
reaction mixture with column chromatography delivered a non-UV-visible compound.
This observation gave clue that the compound does not contain a sulfoximine group,
which shows exhibits strong UV-absorption. The 13C NMR of this compound showed
a quaternary carbon at 215.3 ppm. Evaluation of 1H and 2D NMR experiment results
revealed the diastereotopic proton pair (Ha: 2.08–2.15 ppm and Hb: 2.39 ppm) with a
geminal coupling constant (2J) of 19.3 Hz. IR spectrum showed a strong absorption at
1752 cm−1. Hence, it was concluded that the compound should be ketone 139 (Scheme
4.9). The HRMS analysis also supported the assigned structure.
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Scheme 4.9: Substitution of sulfoximine by chloride.
As earlier studies76–78 showed, treatment of sulfoximine leads to acylation of sulfox-
imine group at the nitrogen atom. The amino sulfoxonium salt 140 undergoes an
SN2 type substitution by chloride to furnish the chlorine-substituted amino alcohol
138 (Figure 4.16). The formation of the observed ketone 139 can be explained by the
formation of the carbenium ion 142. Upon removal of sulfinamide 141, the interme-
diate salt 140 generates the carbenium ion 142, which undergoes a semi-pinacol type
rearrangement79 to deliver the sulfoximine-substituted ketone 139.
∗for details of the analysis please see the table on page 97
42 CHAPTER 4. RESULTS AND DISCUSSION
NHSO2t-Bu
O
O
OCl
Cl S
Ph
OMeN
NHSO2t-Bu
OH
O
O
Cl
Cl
NHSO2t-Bu
OH
Cl O
S
Ph N
Me
O
O
Cl
_
NHSO2t-Bu1,2 [H]-shift
HO H
NHSO2t-Bu
OH
SN2
OH
NS
S
HN OMe
O
O
100
140
141
142143139
138
Figure 4.16: Mechanism of formation of chloride 138 and ketone 139.
4.2.2 Iodine Substitution
Substitution of the sulfoximine group by iodine was also investigated. Gratifyingly,
treatment of the cyclic 1,2-amino alcohol 100 with in situ prepared ICO2Ph
80 in ace-
tonitrile gave the iodide derivative 144 in 77% with ≥ 98% de (Scheme 4.10). NOE ex-
periments revealed strong correlation between H-2 and H-3, H-3 and H-3a, H-3a and
H-7a. No NOE effect between the H-1 and H-3 was observed. These results indicated
the assigned structure for 144 (Scheme 4.10).∗
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HN OMe
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O 7a3a
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123 NHSO2t-Bu
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77%, ≥98% de
CH3CN
O
OI Ph
100 144
Scheme 4.10: Substitution of sulfoximine by iodide.
The substitution of the sulfoximine group by iodine proceeded with inversion of con-
∗for details of the analysis please see the table on page 99
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figuration as in the case of chlorine-substitution reaction (Scheme 4.9). However, for-
mation of ketone 139 was not observed for the iodine-substitution reaction. The halo-
formates (ClCO2CH(Cl)CH3 and ICO2Ph) used in the substitution reactions vary, hence,
different sulfoxonium salts 140 (Figure 4.16) and 145 (Figure 4.17) are formed as inter-
mediates of the reactions. The leaving group abilities of sulfoxonium salts 140 and
145 are such different that 145 forms no carbenium. Moreover, due to its higher polar-
izability of iodine compared to chlorine, rate of iodine-substitution should be higher
than that of chlorine-substitution. Therefore ketone formation was not observed for
the iodide substitution of sulfoximine depicted on Scheme 4.10.
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Figure 4.17: Sulfoxonium salt 145.
4.2.3 Oxidation of Sulfoximine
Sulfones are valuable components of the natural and biologically active compounds.81,82
Conversion of N-alkyl, N-aryl and N-H sulfoximines into the corresponding sulfones
has been investigated by Gais et al..83,84 The reported high yielding protocol em-
ploys m-chloroperbenzoic acid (m-CPBA) as oxidizing reagent. Treatment of the vicinal
amino alcohol 100with m-chloroperbenzoic acid in the presence of catalytic amount of
hydrochloric acid led to the formation of the corresponding sulfone 147 in 83% yield
(Scheme 4.11) Neither isomerization nor elimination of the alcohol functionality was
observed in this reaction.
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Scheme 4.11: Synthesis of sulfone 147.
4.2.4 Mitsunobu conditions
Mitsunobu reaction is a frequently usedmethod for substitution of alcohols with acidic
nucleophiles (NuH). The substitution reaction proceeds primarily with inversion of
configuration. In the absence of an acidic nucleophile and β-amino alcohols as sub-
strates reaction may afford aziridines via a ring closure. In 2005, Smith reported em-
ployment of the Mitsunobu ring closure method for the synthesis of aziridine 149,
which is one of the key component for the total synthesis of the alkaloid (–)-205B (150)
(Scheme 4.12).85
NHTsMeO2C
OH NTs
MeO2C
N
H
HH
Ph3P, DEAD
THF
92%
148 149 150
Scheme 4.12: An example of Mitsunobu ring closure method.
The attemptedMitsunobu reaction of the cyclic β-amino alcohol 100with triphenylphos-
phine and diethyl azodicarboxylate (DEAD) delivered the vinylic sulfoximine 151 in
90% yield (Scheme 4.13).
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Scheme 4.13: Synthesis of the γ-amino vinylic sulfoximine 151.
The result obtained for this reaction was not surprising since it is known that treatment
of secondary alcohols may afford the corresponding unsaturated derivatives upon
treatment with Ph3P/DEAD.
86 A putative reaction mechanism is depicted on Figure
4.18. Triphenyl phosphine reacts with DEAD to form the reagent-derived base 152 to
promote the regioselective elimination of intermediary oxyphosphonium salt 153.
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Figure 4.18: Putative mechanism of dehydration of 100.
Mitsunobu activation of a vicinal amino alcohol for elimination may also proceed via
an intermediate aziridinium cation. The intramolecular attack of sulfonamide nitrogen
at the carbon bearing the alcohol moiety delivers the aziridinium cation 155 (Figure
4.19). Abstraction of α-H of sulfoximine by the base 154 and subsequent ring opening
forms the α,β-unsaturated γ-amino sulfoximine 151.
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Figure 4.19: Alternative mechanism of the allyl amine 151 formation.
4.2.5 Removal of sulfoximine group
After employment in an asymmetric transformation the sulfoximine chiral auxiliary
can be removed from the molecule via reductive methods. Low redox potential of
the sulfoximine group makes such transformations possible. There are two frequently
used reagents for reductive removal of sulfoximines: Raney-Nickel and aluminium
amalgam.
Aluminium amalgam
Employment of aluminium amalgam in reductive substitution of sulfoximine group
is a well studied topic. Johnson has published the foremost examples of such desul-
furization. In his reports he described the transformation of β-hydroxy sulfoximines
into alcohols87 or alkenes.88 When treated with aluminium amalgam in a mixture of
water and THF, β-hydroxy sulfoximines 156 produce alcohols 157 (Scheme 4.14). The
reduction proceeds predominantly with retention of configuration. When acetic acid
is also added to the Al/Hg in water/THF mixture, the isolated products are alkene
derivatives 158.
HO
R'
R S NO Ph
Me Al/Hg, THF
H2O, AcOH
Al/Hg, THF
H2O
HO
R'
R R'
R
156157 158
Scheme 4.14: Removal of sulfoximines by aluminium amalgam method.
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β-Hydroxy γ-amino sulfoximine 100 was treated with freshly prepared aluminium
amalgam in a mixture of THF, water and acetic acid (Scheme 4.15). The reaction deliv-
ered the expected cyclic unsaturated sulfonamide 159 in 80% yield.
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80%
159100
Scheme 4.15: Aluminium amalgam reduction of sulfoximine 100.
Raney-Nickel
Another useful method for desulfurization is utilizing Raney-Nickel as the reductive
reagent. The attempted subtraction of sulfoximine moiety from 1,2-amino alcohol 100
with Raney-Nickel in tetrahydrofuran, according to the method developed by Johnson
et al.89 for the sulfoximine-mediated syntheses of optically active alcohols, lead to the
corresponding cyclic β-amino alcohol 160 in 92% yield.
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160100
Scheme 4.16: Removal of sulfoximine by Raney-Nickel.
4.2.6 Deprotection of N-tert-buty sulfonyl group
As mentioned in Chapter 3 (page 19), our approach to obtain sulfoximine substituted
potential aggrecanase inhibitor requires the synthesis of the sulfoximine-substituted
cyclic β-amino alcohol 161. For the deprotection of the N-tert-buty sulfonyl group,
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the sulfoximine derivative 100 was treated with trifluoromethanesulfonic acid (TfOH)
and an equimolar amount of anisole in CH2Cl2 for 2 h, to furnish the sulfoximine-
substituted cyclic 1,2-amino alcohol 161 as TfOH salt in 94% yield (Scheme 4.17). The
structure of the amine salt 161 was confirmed by elemental analysis, 1H and 19F NMR
experiments. Work up with sat. NaHCO3 did not help to obtain 161 as an acid com-
pound. Therefore 161 · 1/2(CF3SO3H) was used as it is in the further synthesis.
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94%
161100
Scheme 4.17: Synthesis of the β-amino alcohol 161 · 1/2(CF3SO3H) via acidic
deprotection of 100.
4.3 Synthesis of Sulfoximine-Substituted Potential Ag-
grecanase Inhibitor 72
As mentioned earlier in the introduction part, Yao group discovered that the hydrox-
amic acid 33 (Figure 1.4, page 10) exhibits excellent inhibitor activity against aggre-
canase.36,37 Given the advances obtained in the field of biologically active sulfoximine
derivatives (see Section 1.3), it was our interest to obtain the sulfoximine-substituted
potential aggrecanase inhibitor 72 (Figure 4.20), which not only bears the core struc-
ture of inhibitor 33 but also contains a sulfoximine functionality. Introduction of sul-
foximine group may lead profound inhibitor activity against aggrecanase.
Our retrosynthetic analysis split the target molecule 72 into two parts: the sulfoximine-
substituted bicyclic β-amino alcohol salt 161 and the oxabutanoic acid 73 shown in
Figure 4.20.
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4.3.1 Racemic Approach
Our initial attempt was to obtain the acid 73 starting either from methy or tert-butly
alkyl 3-(3-(benzyloxy)phenyl)propanoate (R = Me 162; R = tert-Bu 163) (Figure 4.20).
Alkylation employing a benzyl 2-haloacetate could afford benzyl succinate (R = Me
164; R = tert-Bu 165). After racemate separation, the correct enantiomer could selec-
tively be hydrolyzed under acidic conditions to give the corresponding oxabutanoic
acid 73.
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Figure 4.20: Retrosynthetic analysis of sulfoximine-substituted N1-hydroxy-
N4-(2-hydroxyoctahydro-1H-inden-1-yl)succinamide (72).
Synthesis of Methyl 3-(3-(benzyloxy)phenyl)propanoate (162)
Methyl propanoate 162 could be obtained from dimethyl malonate (166) via two step
synthesis. 1-(Benzyloxy)-3-(chloromethyl)benzene was prepared starting from thionyl
chloride and (3-(benzyloxy)phenyl)methanol according to the literature.90 Alkylation
of malonate 166 with 1-(benzyloxy)-3-(chloromethyl)benzene delivered dimethyl 2-(3-
(benzyloxy)benzyl)malonate (167) with 82% yield (Scheme 4.18). Krapcho dealkoxy-
carbonylation using catalytic amount of water afforded the desired methyl propanoate
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162 only in 37% yield. Use of equimolar amount of salt, NaCl or KCN, in the dealkoxy-
carbonylation reaction of 162 gave complex mixtures. Due to the low yield obtained
from the reaction, this approach was left out.
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Scheme 4.18: Synthesis of methyl 3-(3-(benzyloxy)phenyl)propanoate (162).
Synthesis of tert-Butyl 3-(3-(benzyloxy)phenyl)propanoate (163)
The retrosynthetic approach requires either the methly ester 162 or the tert-butl ester
163 (Figure 4.20). Due to the fact that the attempts to obtain ester 162 was not success-
ful, the tert-butyl ester 163 was prepared starting from tert-butyl acetate. LDA alky-
lation of tert-butyl acetate with 1-(benzyloxy)-3-(chloromethyl)benzene did not give
ester 163 (Scheme 4.19).
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t-BuO
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2.
Cl
OBn
163
Scheme 4.19: Attempted alkylation of tert-butyl acetate with 1-(benzyloxy)-
3-(chloromethyl)benzene.
The problem facedwas overcome by changing the alkylhalide. 1-(Benzyloxy)-3-(bromo-
methyl)benzene was prepared from (3-(benzyloxy)phenyl)methanol and hexamethyl-
disilane (HMDS)/pyridinium bromide perbromide according to the literature91 and
utilized in the LDA alkylation of tert-butyl acetate. The reaction afforded tert-butyl
3-(3-(benzyloxy)phenyl)propanoate (163) in 88% yield (Scheme 4.20).
t-BuO
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OBn
O
t-BuO
1. LDA, THF
2.
Br
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HO
OBn
NHBr3 , HMDS
82%
88%
163
Scheme 4.20: Synthesis of tert-butyl 3-(3-(benzyloxy)phenyl)propanoate
(163).
Alkylation attempts to obtain benzyl tert-butyl succinate 165
After accomplishing the synthesis of ester 163, the next step in the retrosynthetic anal-
ysis (depicted in Figure 4.20, page 49) is the alkylation of tert-butyl ester 163 to deliver
succinate 165. Treatment of 163 with freshly prepared LDA and addition of benzyl
2-bromoacetate did not deliver the desired diester 165 (Scheme 4.21).
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Scheme 4.21: Attempted alkylation of tert-butyl 3-(3-(benzyloxy)phenyl)pro-
panoate (163) with benzyl 2-bromoacetate.
With the purpose of verifying the enolate formation, the following two reactions were
designed. Freshly prepared LDA was reacted with the model compound tert-butyl
3-phenylpropanoate and in situ formed enolate was allowed to react with benzyl bro-
mide to deliver tert-butyl 2-benzyl-3-phenylpropanoate in 82% yield (Scheme 4.22).
Likewise, the enolate was also treated with deuterated acetic acid (CD3COOD). In the
1H NMR spectrum of crude mixture, it was observed that only 50% deuteration took
place.
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Scheme 4.22: Enolate formation verification.
As Seebach et al. reported in 1985,92 upon work up with CD3COOD, the free diiso-
propyl amine present in the reaction mixture forms a salt with the acid and then is
either protonated or deuterated (Scheme 4.23). Therefore, the degree of deuteration
can only be up to 50%.
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Scheme 4.23: Degree of deuteration of enolate.
The results obtained from deuteration and sample alkylation experiments (Scheme
4.22), showed that the LDA prepared prior to application is not the reason of failure
in the alkylation reaction depicted in Scheme 4.21. Hence it was concluded that pos-
sibly the electrophile used was not the right choice for this purpose. To increase the
electrophilicty, benzyl 2-bromoacetate was transformed into the corresponding iodo
derivative by treating with sodium iodide in refluxing acetone (Scheme 4.24). The ob-
tained derivative was used in a test LDA alkylation of tert-butyl 3-phenylpropanoate.
Enolate formation with LDA, followed by benzyl 2-iodoacetate treatment surprisingly
delivered the tert-butyl 2-iodo propanoate 168 in 22% yield. As this test reaction was
not promising, the retrosynthesis of sulfoximine-substituted potential aggrecanase in-
hibitor 72was modified.
1. LDA, THF
2. O
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∆
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Scheme 4.24: Testing LDA alkylation with benzyl 2-iodoacetate as elec-
trophile.
54 CHAPTER 4. RESULTS AND DISCUSSION
4.3.2 Asymmetric Approach
The racemic approach was based on the synthesis of diester 165, which was consid-
ered as the precursor of the acid 73. In our second, asymmetric approach, (S)-4-benzyl-
oxazolidin-2-one was employed to perform the introduction of tert-butyloxy-2-acetyl
group (asymmetric approach, Figure 4.21). The asymmetric approach brings to ad-
vantages to the method: 1. a racemate separation as in the case of first retrosynthesis
(racemic approach, Figure 4.20) is not required, 2. simplicity of chiral auxiliary de-
tachment in asymmetric synthesis with optically active oxazolidinone eliminates the
potential problems that could arise from selective hydrolysis of ester 73.
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Figure 4.21: Alternative retrosynthetic analysis of sulfoximine-substituted
N1-hydroxy-N4-(2-hydroxyoctahydro-1H-inden-1-yl)succinam-
ide (72).
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The precursor oxazolidinone 171 was obtained in a two step synthesis as depicted
in Scheme 4.25. tert-Butyl propanoate 163 was hydrolyzed under acidic conditions
in CH2Cl2 to give propanoic acid 172 in 83% yield. In situ generation of mixed an-
hydride by treating acid 172 with pivaloyl chloride, followed by addition of (S)-4-
benzyloxazolidin-2-one93 in the presence of LiCl/NEt3 afforded the key oxazolidin-
2-one derivative 171 in 82% yield.
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Scheme 4.25: Synthesis of 4-tert-butoxy-4-oxobutanoic acid 169 starting from
tert-butyl propanoate 163.
The oxazolidinone derivative 171 was then reacted with LDA and tert-butyl bromo-
acetate was added to the mixture. The reaction delivered the alkylated oxazolidinone
170 with 71% yield and over 98% diastereomeric excess.∗ The absolute configuration
of 170 was assigned based on the literature results.94,95 Moreover, a similar analog of
170was reported by Heitsch in 1993 (Scheme 4.26).96 Deprotonation of 173 followed by
alkylation with tert-butyl bromoacetate generates R configuration at the newly formed
chiral centere in the compound 174.
∗diastereomeric excess was determined based on the 1H NMR spectra of the crude reaction mixture
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Scheme 4.26: A literature example of Evans’ chiral enolate methodology.
After employment of Evans’ oxazolidinone in the alkylation step, the auxiliary was
cleaved of with lithium peroxide hydrolysis.97 Treatment of 170 with LiOH/H2O2
afforded tert-butyl oxabutanoic acid 169 in 97% yield (Scheme 4.25). The auxiliary,
(S)-4-benzyloxazolidin -2-one, was recovered from the reaction in 89% yield.
The tert-butyl oxabutanoic 169was then coupled with sulfoximine-substituted bicyclic
β-amino alcohol 161 using BOP (benzotriazole-1-yl-oxy-tris-(dimethylamino)-phospho-
nium hexafluorophosphate) as the coupling reagent (Scheme 4.27). The coupling reac-
tion gave the sulfoximine amide 175 in 95% yield. The IR spectra of the obtained com-
pound showed strong absorption at 1727 cm−1, which corresponds to the existance of
carbonyl group in the structure. The strong signal of tert-butyl group at 1.40 ppm and
the diastereotopic proton pair (Ha: 2.36 ppm and Hb: 2.61 ppm) with a geminal cou-
pling constant (2J) of 17.1 Hz. These results proved that the coupling reaction delivered
the aimed product 175. Moreover, the CHN analysis revealed the molecular formula
C38H48N2O6S as anticipated.
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Scheme 4.27: Coupling of acid 169 with sulfoximine-substituted β-amino al-
cohol 161.
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The next step towards the synthesis of the sulfoximine-substituted potential aggre-
canase inhibitor 72 involved the hydrolysis of tert-butyl ester followed by O-benzyl-
hydroxylamine coupling. The ester functionality of 175 was hydrolyzed with TFA to
corresponding acid, which was subsequently treated with TBTU (O-(benzotriazol-1-
yl)-N,N,N′,N′-tetramethyluronium tetrafluoroborate) andiO-benzylhydroxylamine ·HCl
toi afford O,O-dibenzyl protected hydroxy hydroxamic acid 177 in 85% yield (Scheme
4.28).
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Scheme 4.28: Synthesis of O,O-dibenzyl protected hydroxy hydroxamic acid
177.
The 1HNMR spectrum of 177 (B, recorded at 25 ◦C, Figure 4.22) showed two signals for
N–O–CH2–Ph at σ = 4.72 and 4.75 ppm and for O–NH at σ = 9.01 and 9.20 ppm with
different intensities. When the 1H NMR spectrum was recorded at 55 ◦C (A, Figure
4.22), a coalescence phenomenon was observed and only one signal each for N–O–
CH2–Ph at σ = 4.74 ppm and for O–NH at σ = 8.84 ppmwere detected. The same effect
was also observed in 13C NMR spectra. When the 13C NMR was recorded at room
temperature (B, recorded at 25 ◦C, Figure 4.23) two signals for N–CO–CH2 at σ = 33.6
and 35.2 ppm, for N–CO–CH at σ = 43.5 and 45.0 ppm, for N–O–CH2–Ph at σ = 78.2
and 79.3 ppm and for hydroxamic acid carbonyl at at σ = 175.2 and 175.9 ppm were
observered. When the 13C NMR spectrum was recorded at a higher temperature (B,
recorded at 25 ◦C, Figure 4.23) following signals were recorded; for N–CO–CH2 at σ =
35.0 ppm, for N–CO–CH at σ = 44.9 ppm, for N–O–CH2–Ph at σ = 78.4 ppm and for
hydroxamic acid carbonyl at at σ = 175.2 ppm. These observations indicate that 177
exists as a mixture of syn- and anti-NOBn rotamers.98–100
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Figure 4.22: 1HNMR spectrum of 177 recorded at A: at 55 ◦C and B: at 25 ◦C.
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Figure 4.23: 13C NMR spectrum of 177 recorded at A: at 55 ◦C and B: at 25
◦C.
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The last step of our route to sulfoximine-substituted potential aggrecanase inhibitor 72
consisted of the benzyl deprotection. As known, benzyl group incline to cleave upon
exposure to H2 in the presence of a metal catalyst. The mostly used metal catalyst is
palladium supported on carbon (Pd/C). A common problem in the deprotection of
O-benzyl hydroxamates is the amide formation, which is arising from cleavage of N–
O σ-bond. In 1995, Nikam published that Pd/BaSO4 is a milder, efficient catalyst in
hydrogenolysis of O-benzyl hydroxamates to deliver the corresponding hydroxamic
acids without reduction to amides.101 Therefore, for the deprotection of benzyl groups
of 177, Pd/BaSO4 was employed. O,O-Dibenzyl protected hydroxy hydroxamic acid
177 was treated with 0.2 equiv of 5% Pd/BaSO4 under 4 bar H2 atmosphere in an
autoclave for 4 h, however, reaction didn’t lead the aimed hydroxamic acid 72 (entry
a, Scheme 4.29). Increasing the time of hydrolysis (entry b, Scheme 4.29) or the applied
pressure of H2 (entry c, Scheme 4.29) did not effect the outcome and 177was recovered
from the reactions.
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Scheme 4.29: Attempted deprotection of 177 using an autoclave and
Pd/BaSO4 catalyst.
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Yao group applied similar conditions for the synthesis of the potential aggrecanase
inhibitor 33.36 Starting from the dibenzyl protected compound 178 the hydrogenolysis
reaction gives 33 in 67% yield (Scheme 4.30).
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Scheme 4.30: Hydroxamic acid 33 synthesis via hydrogenolysis.
Using an autoclave with a magnetic or mechanic stirrer may damage the surface of
the catalyst and catalyst may not function. Moreover, the activity of the commercial
catalyst is another crucial factor for the deprotection reaction. Therefore, it was desir-
able to test both shaking apparatus condition and catalyst quality. In a test reaction,
a solution of O-benzylhydroxylamine and 5% Pd/BaSO4 in methanol was placed in
an Erlenmayer flask (Scheme 4.31). The flask was placed on a shaker apparatus and
then connected to a balloon of H2. The mixture was shaken for 4 h and the
1H NMR
spectra of mixture indicated full conversion. Hence, it was concluded that the shaker
apparatus is suitable to perform benzyl deprotection reaction. The result of the test
also suggests that the quality of the catalyst used, Pd/BaSO4, is high enough to carry
out deprotection reaction.
OClH3N
Pd/BaSO4, MeOH,
H2 (balloon)
> 98%
Ph OHClH3N
Scheme 4.31: Testing the shaker apparatus and catalyst quality.
Deprotection of bezyl groups in 177 via hydrogenolysis reaction was, therefore, also
made in shaker apparatus. A solution of amide 177 and 5% Pd/BaSO4 in MeOH (20
mL) was placed in an Erlenmeyer flask. The flask was placed on a shaker apparatus
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and then connected to a balloon of H2 (entry a, Scheme 4.32). After 4 h, no conversion
was observed, and 177was recovered. Increasing the catalyst load by five times (entry
b, Scheme 4.32) did not deliver the desired potential aggrecanase inhibitor 72.
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Scheme 4.32: Attempted deprotection of 177 using shaker apparatus and
Pd/BaSO4 catalyst.
Using Pd/C as the metal catalyst in the hydrogenolysis of O-benzyl hydroxamates
increases the probability of amide formation whereas Pd/BaSO4 is reported to be de-
livering no amide product.101 This means the order of catalyst activity is: Pd/C >
Pd/BaSO4. The Pd/C (wet support, Degussa type E 101 NO/W) is claimed to be
designed especially for benzyl deprotection hydrogenolysis reactions. A solution of
amide 177 and 5% Pd/C (E 101 NO/W) in MeOH was placed in an Erlenmeyer flask
(Scheme 4.33). The flask was placed on a shaker apparatus and then connected to a
balloon of H2. After 4 h, neither TLC nor reversed phase TLC of the reaction mixture
showed any conversion. More Pd/C (1.6 equiv, E 101 NO/W) was added and the mix-
ture was shaken at room temperature for further 6 h under H2 atmosphere. Both TLC
and reversed phase TLC analysis of the mixture showed no conversion.
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Scheme 4.33: Attempted deprotection of 177 employing Pd/C (wet support,
Degussa type E 101 NO/W) catalyst.
Catalytic transfer hydrogenolysis with Pd/C as catalyst and ammonium formate as hy-
drogen source has foundwidespread application in the deprotection of benzyl groups.102
The attempted deprotection of the O,O-dibenzyl protected hydroxy hydroxamic acid
177 by catalytic hydrogenolysis with ammonium formate and 5% Pd/C did not yield
the desired hydroxamic acid 72 (entry a, Scheme 4.34). Another type of catalytic trans-
fer hydrogenolysis involves employment of formic acid together with palladium-car-
bon.103,104 When formic acid was used instead of ammonium formate (entry b, Scheme
4.34), the result of the reaction was again the recovery of the starting material. After
testing several variables of the deprotection reaction e.g. stirring, metal catalyst used,
catalyst load, reaction time, hydrogen source, it was concluded that catalyst poisoning
could be the reason of failure in the deprotection reaction. Most common palladium
catalyst poisons are lead, sulfur and nitrogen. Sulfoximine group in the structure of
amide 177 bears two potential catalyst poison atoms: sulfur and nitrogen. The sulfur
atom of the sulfoximine has no electron pair available to interact with the metal cata-
lyst. Therefore, the suspect is the nitrogen atom. Amines and nitrogen containing bases
have long been known to be catalyst poisons of palladium(0) for hydrogenolysis. Few
reports were published concerning utilization of amines to suppress hydrogenolysis of
benzyl protection groups. However, to our best knowledge there is no study where in
the presence of amines, deprotection of benzyl group via hydrogenolysis with palla-
dium(0) is enhanced.
4.3 SYNTHESIS OF SULFOXIMINE-SUBSTITUTED POTENTIAL AGGRECANASE
INHIBITOR 72 63
O
O
N
H
OBn
H
N
OH
S
N OMe
OBn
O
O
N
H
OH
H
N
OH
S
N OMe
OH
5% Pd/C, MeOH, 
additive, ∆
entry
a
b
additive
NH4COOH
HCOOH
177 72
Scheme 4.34: Attempted deprotections of benzyl groups via transfer hy-
drogenolysis.
In order to test the possible catalyst poisoning effect of sulfoximine, the following test
reaction was performed. One equiv of sulfoximine 75, O-benzylhydroxylamine and 5%
Pd/BaSO4 in methanol was placed in an Erlenmayer flask (Scheme 4.35). The flask was
placed on a shaker apparatus and then connected to a balloon of H2. The mixture was
shaken for 4 h. The 1H NMR spectra of the mixture indicated no conversion. Refering
to the result obtained from the reaction depicted in Scheme 4.31, sulfoximine acts as a
catalyst poison in the deprotection of benzyl group via hydrogenolysis.
OClH3N Ph OHClH3N
Pd/BaSO4, MeOH,
H2 (balloon)
+
Me
S
N OMe
X
75
Scheme 4.35: Testing the catalyst poisoning potential of sulfoximine func-
tionality.
Sulfoximine nitrogen is known to be a good Lewis base. Gais et al. published sev-
eral report where this feature is made use of.66,77, 105, 106 If nitrogen of the sulfoximine
is the catalyst poison for palladium(0) in hydrogenolysis of benzyl groups, protona-
tion of sulfoximine nitrogen with a proper acid prior to deprotection reaction should
solve the catalyst poisoning. Amide 177was treated with trifluoroacetic acid in MeOH
(Scheme 4.36). Then 5% Pd/C (E 101 NO/W) was added to the mixture. After shak-
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ing the mixture at room temperature under H2 atmosphere, TLC analysis showed no
conversion.
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Scheme 4.36: Protonation prior to deprotection of benzyl groups via hy-
drogenolysis.
The purity of the starting amide 177 could be a reason of the failure in benzyl deprotec-
tion. However, our HPLC and FTMS analysis showed high purity. A solution of O,O-
dibenzyl protected hydroxy hydroxamic acid 177 in CDCl3 was analyzed on HPLC
(Kromasil Si 100, 4.6 mm, EtOAc/MeOH, 99:1, 254 nm + RI, 1 mL/min), and the chro-
matogram B depicted in Figure 4.24 was obtained. Amide 177 appears at RT = 8.73min.
The peaks seen before 177 belongs to the solvent system used (EtOAc/MeOH) and im-
purities arising from CDCl3. A sample of CDCl3 was injected on analytical HPLC un-
der same condition as above. The result is depicted on chromtogram A (Figure 4.24).
Hence, it was concluded that the O,O-dibenzyl protected hydroxy hydroxamic acid 177
was pure enough to perform the deprotection reaction.
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Figure 4.24: HPLC chromatograms: A. CDCl3 sample, B. 177 in CDCl3.
Chapter 5
Summary and Outlook
In the first part of the study, the synthesis of cyclic β-amino alcohols 71 via hydroalu-
mination of the sulfoximine-substituted unsaturated α-amino esters E-70was achieved
(Scheme 5.1). To the best of our knowledge this is the first asymmetric cyclic β-amino
alcohol synthesis, in which a new cycle and three new stereocenters were built in a
single step. The cyclic vicinal-amino alcohols 71 were obtained in poor to good yields
and low to high diastereomeric ratios. E configuration of the double bond is essential
for the cyclic 1,2-amino alcohol synthesis. The Z-configured sulfoximine-substituted
α,β-unsaturated α-amino esters Z-82, Z-83 afforded bicyclic furan derivatives 121, 122
in good yield and high diastereoselectivities.
Benefiting from the versatility of the sulfoximine group, several transformations were
accomplished starting from the obtained β -amino alcohols. Sulfoximine moiety of the
cyclic vic-amino alcohol 100 was substituted with chloride and iodide. Furthermore,
it was oxidized to sulfone in high yield. Reductive removal of the sulfoximine group
was also studied and successful results were attained.
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Scheme 5.1: Hydroalumination of E- and Z-configured α,β-unsaturated
sulfoximine-substituted α-amino esters.
In the second part of the study, the sulfoximine-substituted bicyclic β-amino alcohol
100was utilized in the synthesis of the potential aggrecanase inhibitor 72 (Scheme 5.2).
The asymmetric synthesis of acid 169 was achieved in good yield and high enantios-
electivity starting from tert-butyl acetate. The enantiopure acid 169 was converted via
a coupling reaction into the sulfoximine-substituted 175 in high yield. Subsequent hy-
drolysis, followed by couplingwithO-benzylhydroxylamine afforded theO,O-dibenzyl
protected hydroxy hydroxamic acid 177. Although great deal of effort was put forth
to perform the deprotection of benzyl groups of 177, sulfoximine-substituted potential
aggrecanase inhibitor 72 could not be obtained.
Hydroalumination of the sulfoximine-substituted α,β-unsaturated compounds can be
further investigated for the synthesis of bicyclic 1,2-diols 179 (Scheme 5.3). The re-
quired α-hydroxy esters 180 should be readily available via the reaction of sulfoximine-
substituted allyltitanium complexes with ethyl glyoxylate (181). DIBAL-H treatment
of 180 should afford sulfoximine-substituted bicyclic 1,2-diols 179.
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Scheme 5.2: Planned synthesis of sulfoximine-substituted potential aggre-
canase inhibitor 72.
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Scheme 5.3: Possible bicyclic β-amino alcohol synthesis via hydroalumina-
tion of sulfoximine-substituted α-hydroxy esters 180.
In this work, although the synthesis of potential aggrecanase inhibitor 72 could not be
accomplished, asymmetric synthesis of tert-butyl oxabutanoic acid 169 was outlined.
Because of the fact that several benzyl deprotection methods and conditions did not
afford the desired product, the protecting group scheme of the retrosynthesis should
be reassessed.
Chapter 6
Experimental
6.1 General methods and chemicals
6.1.1 Inert atmosphere conditions and solvents
All reactions involving air- or moisture-sensitive compounds were carried out under
argon using standard Schlenk and vacuum line techniques.107 Glassware were heated
under vacuum with a heat gun and flushed with argon. Addition of all reagents as
well as solvents was carried out with glass or polypropylene syringes equipped with
V2A steel needles under an argon stream. Labile chemicals were stored under argon
and kept in a refrigerator. Diethyl ether and THF were distilled from sodium ben-
zophenone ketyl under argon. Dichloromethane was distilled from CaH2 under argon.
Toluene was distilled from sodium benzophenone ketyl under argon and stored over 4
A˚ molecular sieve. Unless otherwise specified, all reagents were purchased from com-
mercial suppliers (Acros, Aldrich, Fisher-Scientific, Fluka, Lancaster, Merck) and used
without further purification. The vinylic sulfoximines (2S)-ethyl 2-(1,1-dimethylethyl-
sulfonamido)-2-((1R,E)-2-(((S)-N-methylphenylsulfonimidoyl)methylene)cyclopentyl)-
acetate (E-81),66 (2S)-ethyl 2-(1,1-dimethylethylsulfonamido)-2-((1R,E)-2-(((S)-N-methyl-
phenylsulfonimidoyl)methylene)cyclohexyl)acetate (E-82),66 (2S)-ethyl 2-(1,1-di-methyl-
ethylsulfonamido)-2-((1R,Z)-2-(((S)-N-methylphenylsulfonimidoyl)methylene)cyclohexyl)-
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acetate (Z-82),66 (2S)-ethyl 2-(1,1-dimethylethylsulfonamido)-2-((1R,E)-2-(((S)-N-methyl-
phenylsulfonimidoyl)methylene)cycloheptyl)acetate (E-83),66 (2S)-ethyl 2-(1,1-dimethy-
lethylsulfonamido)-2-((1R,Z)-2-(((S)-N-methylphenylsulfonimidoyl)methylene)cycloheptyl)-
acetate (Z-83),66 (2S)-ethyl 2-((8R,E)-3,3-dimethyl-9-(((S)-N-methylphenylsulfonimidoyl)-
methylene)-1,5-dioxaspiro[5.5]undecan-8-yl)-2-(1,1-dimethylethylsulfonamido)-acetate
(E-84),72 (2S,3R,E)-ethyl 2-(1,1-dimethylethylsulfonamido)-3-isopropyl-5-((S)-N-methyl-
phenylsulfonimidoyl)pent-4-enoate (E-85)65 were prepared starting from enantiomer-
ically pure (S)-N,S-dimethyl-S-phenylsulfoximine (75)68,69 according to the literature.
1-(Benzyloxy)-3-(chloromethyl)benzene,90 1-(benzyloxy)-3-(bromomethyl)benzene91 and
benzyl 2-iodoacetate108 were prepared according to literature procedures. THF solu-
tions of DIBAL-H were prepared from neat DIBAL-H and anhydrous THF (vide supra).
The concentration of commercial solutions of n-BuLi in THF (Merck) was determined
immediately prior to use by titration with diphenylacetic acid109 in THF.
6.1.2 Determination of the physical data
1H NMR
Unless otherwise stated, 1H NMR spectra were recorded at room temperature on a
Varian VXR 300 (300 MHz), Varian Gemini 300 (300 MHz), Inova 400 (400 MHz) or
Unity 500 (500 MHz) spectrometer. The chemical shifts are given in ppm using tetram-
ethylsilane (δ = 0.00 ppm) as internal standard, and in the absence of tetramethylsilane,
they are based on the deuterated solvent peak (acetone δ = 2.09 ppm, chloroform δ =
7.25 ppm, DMSO δ = 2.50 ppm, methanol δ = 3.34 ppm). The coupling constants J are
given in Hertz. The following abbreviations are used in order to describe the signals
observed in the 1H NMR spectra: s (singlet), d (doublet), t (triplet), q (quartet), quin
(quintet), m (multiplet), br (broad signal). Assignments in 1HNMR spectra were made
by GMQCOSY, GNOE and GTOCSY experiments. The diastereomeric ratio (dr) was
determined by analysis of the 1H NMR spectra of the crude reaction product.
13C NMR
Unless otherwise specified, 13CNMR spectrawere 1H-broad band-decoupled andmea-
sured with a Varian VXR 300 (75 MHz), Varian Gemini 300 (75 MHz), Inova 400 (100
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MHz) or Unity 500 (125 MHz) spectrometer. The chemical shifts are given in ppm
using tetramethylsilane (δ = 0.00 ppm) or the deuterated solvent peak as internal stan-
dard. Peaks in the 13C NMR spectra are assigned as u (up, for carbons with zero or
two attached protons) and d (down, for carbons with one or three attached protons)
as determined from APT experiment. Assignments in 13C NMR spectra were made by
DEPT, HETCOR, or GHMQC experiments.
Mass spectrometry
Mass spectra were recorded on a Finnigan MAT 95 spectrometer using either electron
ionization (EI 70 eV) or chemical ionization (CI, 100 eV, methane or isobutane as reac-
tant gas) method. All values are given in atomic units of mass per elemental charge
(m/z). The intensity is given as a percentage of the base peak. High resolution mass
spectra were recorded on Varian MAT 95 using electron ionization (EI, 70 eV). FTMS
analysis was recorded on an LTQ Orbitrap XL™ instrument (Thermo Scientific, Bre-
men, Germany).
Elemental analysis
All microanalyses were conducted on a Heraeus CHN RAPID instrument.
IR-spectroscopy
Infrared spectra were recorded on a Perkin-Elmer FTIR 1760 S apparatus. All bands are
given in cm−1. Bands with intensities ≥10 % were taken into account and following
abbreviations were used; w = weak (intesities 10–40 %), m = middle (40–75 %), s =
strong (75–95 %), vs = very strong (75–95 %), and br (broad signal).
Optical rotation
Optical rotations were determined on a Perkin Elmer PE-241 instrument at room tem-
perature (ca. 20 ◦C). The measurements were carried out using a light frequency of 589
nm (D-line of a sodium vapour lamp) in a cuvette (length d = 10 cm; concentration c is
given in g/100 mL).
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Melting point
Melting Points were measured with a Bu¨chi B-540 apparatus and are uncorrected.
6.1.3 Chromatography
Thin layer chromatography (TLC)
TLC was performed using precoated aluminium backed sheets (Merck silica gel 60
F254). Detection was performed by using UV radiation (254 nm) or by developing the
TLC plate with either with ninhydrin or phosphomolybdic acid solution in ethanol.
Column chromatography
All column chromatography were conducted using silica gel 60 (Merck, mesh 40-63
µm) as stationary phase. Flash column chromatographies were performed under slight
pressure (0.1–0.4 bar) All solvents have been distilled prior to use.
Analytic HPLC
For optimization of separation method following instrument and column were used:
Pump: Waters 600 E UV 481 with wavelength detector, Column: Kromasil Si 100 (250
mm · 4.6 mm).
Preparative HPLC
For the HPLC separations a Varian SD-1 Pump with built-in UV detector (Prostar 320)
and RI detector of Knauer company was used. The column used was Kromasil Si 100
(100 mm · 30 mm).
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N-((1S,2R,3R,3aS,6aR)-2-hydroxy-3-((S)-N-methylphenylsulfonimidoyl)octahydropen-
talen-1-yl)-2-methylpropane-2-sulfonamide (108) andN-((1S,2S,3R,3aS,6aR)-2-hydroxy-
3-((S)-N-methylphenylsulfonimidoyl)octahydropentalen-1-yl)-2-methylpropane-2-sul-
fonamide (109)
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To a solution of sulfoximine E-81 (260 mg, 0.57 mmol) in THF (20 mL) was added
DIBAL-H (2.85 mL of 1.0 M solution in THF, 2.85 mmol) dropwise under stirring at 0
◦C. After the reaction mixture was allowed to warm to room temperature within 3 h,
pieces of ice were added until hydrogen gas evolution ceased. Then the mixture was
further stirred for 30 min. The gel-like mixture was suction filtered through a filter-
paper and the residue was washed with hot EtOAc (∼ 50 ◦C, 300 mL). The filtrate was
concentrated in a rotary evaporator. Purification and separation by HPLC (Kromasil Si
100, 30 mm, EtOAc/cyclohexane, 3:7, 254 nm + RI, 20 mL/min) furnished the amino
alcohols 108 (120 mg, 51%) and 109 (52 mg, 20%) as white solids (R f (109) > R f (108)).
Analytical data of 108
1H NMR (300 MHz, CDCl3): δ = 0.42–0.46 (m, 1H), 1.05–1.15 (m, 1H), 1.25–1.35 (m,
1H), 1.40–1.53 (m, 2H), 1.94–1.99 (m, 1H) (S-CH-CH-CH2, CH-CH-CH2-CH2, N-CH-
CH-CH2), 1.47 (s, 9H, C(CH3)3), 2.24–2.32 (m, 1H, N-CH-CH), 2.62 (s, 3H, NCH3), 2.65–
2.73 (m, 1H, S-CH-CH), 2.93 (dd, J = 9.3 Hz, J = 9.3 Hz, 1H, S-CH), 3.32 (ddd, J = 9.8
Hz, J = 9.8 Hz, J = 9.3 Hz, 1H, N-CH), 4.31 (dd, J = 9.8 Hz, J = 9.3 Hz, 1H, O-CH), 4.36
(d, J = 9.8 Hz, 1H, NH), 7.57–7.68 (m, 3H, Ph), 7.82–7.85 (m, 2H, Ph).
13C NMR (75 MHz, CDCl3): δ = 24.3 (d, CH3), 25.1 (u, CH2), 28.9 (d, CH3), 29.9 (u,
CH2), 32.4 (u, CH2), 37.6 (d, CH), 47.6 (d, CH), 60.3 (u, C), 65.0 (d, CH), 71.3 (d, CH),
74.8 (d, CH), 129.6 (d, CH), 129.8 (d, CH), 133.6 (d, CH), 136.5 (u, C).
MS (EI, 70 eV): m/z (%) 414 [M+] (1), 293 (21), 198 (6), 156 (53), 140 (15), 139 (17), 138
(100), 125 (34), 122 (19), 110 (15), 107 (14), 106 (5), 96 (10), 78 (7), 77 (8), 69 (8), 57 (58),
56 (17).
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IR (KBr): ν˜ = 3282 (vs), 3066 (w), 2939 (m), 2871 (m), 2803 (w), 2370 (w), 2344 (w), 1627
(w), 1455 (m), 1384 (w), 1359 (w), 1305 (s), 1229 (s), 1122 (vs), 1026 (w), 1001 (w), 917
(m), 878 (m), 830 (m), 765 (m), 730 (m), 673 (m), 619 (w), 543 (w), 496 (w) cm−1.
Elemental Analysis: Anal. Calcd for C19H30N2O4S2 (414.58): C, 55.04; H, 7.29; N, 6.76.
Found: C, 55.14; H, 7.04; N, 6.62.
Optical Rotation: [α]D = +101.7
◦ (c = 1.0, CH2Cl2).
Melting Point: 221 ◦C.
Analytical data of 109
1H NMR (300 MHz, CDCl3): δ = 1.38 (s, 9H, C(CH3)3), 1.42–1.49 (m, 1H), 1.59–1.82
(m, 5H) (S-CH-CH-CH2, CH-CH-CH2-CH2, N-CH-CH-CH2), 2.63–2.70 (m, 1H, N-CH-
CH), 2.69 (s, 3H, NCH3), 2.71–2.74 (m, 1H, S-CH), 3.17 (ddd, J = 10.2 Hz, J = 9.6 Hz, J
= 2.9 Hz, 1H, N-CH), 3.36–3.44 (m, 1H, S-CH-CH), 4.03 (dd, J = 2.9 Hz, J = 2.9 Hz, 1H,
O-CH), 4.62 (d, J = 10.2 Hz, 1H, NH), 7.58–7.68 (m, 3H, Ph), 7.85–7.88 (m, 2H, Ph).
13C NMR (75 MHz, CDCl3): δ = 24.3 (d, CH3), 25.2 (u, CH2), 28.5 (d, CH3), 30.4 (u,
CH2), 33.1 (u, CH2), 40.5 (d, CH), 49.1 (d, CH), 59.7 (u, C), 64.4 (d, CH), 69.0 (d, CH),
73.2 (d, CH), 129.3 (d, CH), 129.9 (d, CH), 133.6 (d, CH), 137.8 (u, C).
1H{1H}-NOE (400 MHz, CDCl3): selected observations†
irradiated frequency
H-1 H-2 H-3 H-3a H-6a
observed frequency H-1 – s s n.o. n.o.
H-2 s – s n.o. n.o.
H-3 s s – n.o. n.o.
H-3a n.o. n.o. n.o. – s
H-6a n.o. n.o. n.o. s –
†numbering is same as in the figure on page 75
MS (EI, 70 eV): m/z (%) 415 [M+ + 1] (1), 293 (7), 157 (9), 156 (100), 140 (16), 139 (26),
138 (42), 126 (6), 125 (55), 122 (28), 110 (7), 107 (11), 96 (8), 81 (5), 78 (6), 77 (7), 58 (48),
57 (11).
HRMS: Calcd for C19H30N2O4S2: 414.164703. Found: 414.164641.
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IR (KBr): ν˜ = 3056 (w), 2960 (m), 2872 (m), 2810 (w), 1446 (s), 1310 (s), 1247 (s), 1129
(vs), 1018 (w), 984 (w), 915 (m), 850 (m), 819 (w), 788 (w), 760 (w), 733 (w), 693 (m), 662
(m), 604 (m), 545 (m), 518 (m) cm−1.
Optical Rotation: [α]D = +14.3
◦ (c = 1.0, CH2Cl2).
Melting Point: 169 ◦C.
(((S)-N-methylphenylsulfonimidoyl)methyl)cyclohexane (92)
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To a solution of vinyl sulfoximine 91 (487 mg, 1.95 mmol) in THF (20 mL) was added
DIBAL-H (2.01 mL of 1.12 M solution in THF, 2.25 mmol) dropwise under stirring at
0 ◦C. After the reaction mixture was allowed to warm to room temperature within 4
h, pieces of ice were added until hydrogen gas evolution ceased. Then the mixture
was further stirred for 30 min. The gel-like mixture was suction filtered through a
filter-paper and the residue was washed with hot EtOAc (∼ 50 ◦C, 300 mL). The fil-
trate was concentrated in a rotary evaporator. Purification by column chromatography
(pentane/Et2O, 1:4) furnished sulfoximine 92 (395 mg, 81%) as a pale yellow oil.
Analytical data of 92
Rf: 0.27 (pentane/Et2O, 1:4).
1H NMR (300 MHz, CDCl3): δ = 0.85–1.37 (m, 5H), 1.56–1.78 (m, 4H), 1.87–1.92 (m,
1H) (CH-CH2, CH-CH2, CH-CH2-CH2, CH-CH2-CH2, CH-CH2-CH2-CH2), 2.01–2.06
(m, 1H, S-CH2-CH), 2.64 (s, 3H, NCH3), 2.96 (dd, J = 6.5 Hz, J = 14.3 Hz, 1H, S-CHH),
3.12 (dd, J = 5.7 Hz, J = 14.3 Hz, 1H, S-CHH), 7.53–7.64 (m, 3H, Ph), 7.84–7.88 (m, 2H,
Ph).
13C NMR (75 MHz, CDCl3): δ = 25.7 (u, CH2), 25.76 (u, CH2), 25.82 (u, CH2), 29.5 (d,
CH), 32.8 (d, CH3), 33.1 (u, CH2), 33.3 (u, CH2), 63.2 (u, CH2), 129.1 (d, CH), 129.4 (d,
CH), 132.6 (d, CH), 138.8 (u, C).
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MS (EI, 70 eV): m/z (%) 251 [M+] (4), 173 (11), 172 (20), 171 (8), 156 (27), 155 (15), 154
(5), 140 (28), 127 (5), 126 (20), 125 (77), 109 (5), 108 (9), 107 (100), 106 (14), 105 (14), 97
(15), 95 (8), 94 (7), 91 (20), 81 (9), 79 (5), 78 (22), 77 (18), 67 (6), 55 (49), 54 (6), 53 (7).
HRMS: Calcd for C14H21NOS: 251.134387. Found: 251.134370.
IR (capillary): ν˜ = 3061 (w), 2924 (vs), 2855 (s), 2801 (m), 2362 (w), 1448 (m), 1401 (w),
1242 (vs), 1147 (s), 1105 (m), 1080 (m), 915 (w), 863 (w), 779 (m), 740 (s), 691 (m), 584
(m), 509 (m) cm−1.
Optical Rotation: [α]D = +86.7
◦ (c = 1.02, CH2Cl2).
(2S)-ethyl 2-(1,1-dimethylethylsulfonamido)-2-((1R,2S)-2-(((S)-N-methylphenylsulfon-
imidoyl)methyl)cyclohexyl)acetate (93)
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To a solution of ester E-82 (468 mg, 0.99 mmol) in THF (40 mL) was added DIBAL-H
(1.78 mL of 1.12 M solution in THF, 1.99 mmol) dropwise under stirring at 0 ◦C. After
the reactionmixture was allowed to warm to room temperature within 4 h, pieces of ice
were added until hydrogen gas evolution ceased. Then the mixture was further stirred
for 30 min. The gel-like mixture was suction filtered through a filter-paper and the
residue was washed with hot EtOAc (∼ 50 ◦C, 300 mL). The filtrate was concentrated
in a rotary evaporator. Purification by flash chromatography (increasing polarity of
EtOAc/cyclohexane from 1:9 to 4:1) furnished the sulfoximine 93 (165 mg, 35%) as a
white solid.
Analytical data of 93
Rf: 0.48 (EtOAc/cyclohexane, 4:1).
1H NMR (300 MHz, CDCl3): δ = 0.88–0.94 (m, 1H), 1.26–1.60 (m, 4H), 1.71–1.92 (m,
3H) (S-CH2-CH-CH2, CH2-CH-CH2-CH2, N-CH-CH-CH2, N-CH-CH-CH2-CH2), 1.31
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(t, J = 7.1 Hz, 3H, CH2-CH3), 1.40 (s, 9H, C(CH3)3), 1.98–2.08 (m, 1H, N-CH-CH), 2.63
(s, 3H, NCH3), 2.93 (dd, J = 8.4 Hz, J = 14.1 Hz, 1H, S-CHH), 3.04–3.11 (m, 1H, S-CH2-
CH), 3.75–3.80 (m, 1H, S-CHH), 4.12 (dd, J = 9.1 Hz, J = 10.4 Hz, 1H, N-CH), 4.21 (dt, J
= 7.1 Hz, J = 12.6 Hz, 2H, O-CH2), 7.38 (d, J = 10.4 Hz, 1H, NH), 7.55–7.63 (m, 3H, Ph),
7.94–7.98 (m, 2H, Ph).
13C NMR (75 MHz, CDCl3): δ = 14.3 (d, CH3), 20.4 (u, CH2), 24.3 (d, CH3), 25.3 (u,
CH2), 25.9 (u, CH2), 29.0 (d, CH3), 29.2 (d, CH), 31.4 (u, CH2), 44.4 (d, CH), 53.9 (u,
CH2), 59.7 (u, C), 59.8 (d, CH), 61.6 (u, CH2), 129.3 (d, CH), 129.4 (d, CH), 132.8 (d,
CH), 138.6 (u,C), 173.0 (u, C).
1H{1H}-NOE (400 MHz, CDCl3): selected observations†
irradiated frequency
H-1 H-2 H-7 H-7′
observed frequency H-1 – s n.o. n.o.
H-2 s – m n.o.
H-7 n.o. m – s
H-7′ n.o. n.o. s –
†numbering is same as in the figure on page 78
MS (EI, 70 eV): m/z (%) 473 [M+ + 1] (3), 399 (18), 352 (7), 351 (34), 275 (7), 274 (40), 250
(5), 202 (9), 198 (19), 197 (18), 196 (100), 173 (6), 172 (9), 170 (13), 169 (5), 168 (6), 157 (6),
156 (60), 155 (7), 140 (33), 126 (6), 125 (47), 124 (72), 108 (6), 107 (57), 106 (5), 105 (7), 102
(28), 95 (19), 91 (11), 81 (7), 79 (5), 77 (7), 67 (6), 57 (46).
HRMS: Calcd for C22H36N2O5S2–C3H5O2: 399.177613. Found: 399.177727.
IR (capillary): ν˜ = 3986 (w), 3957 (w), 3876 (m), 3841 (w), 3768 (w), 3722 (w), 3697 (w),
3604 (w), 3571 (m), 3520 (m), 3413 (m), 3375 (m), 3331 (w), 3279 (m), 3204 (w), 3113 (w),
3070 (w), 2928 (vs), 2865 (s), 2769 (w), 2694 (w), 2639 (w), 2588 (w), 2508 (w), 2238 (w),
1735 (m), 1580 (w), 1445 (vs), 1314 (m), 1245 (w), 1120 (s), 1025 (m), 912 (w), 874 (w),
750 (w), 693 (m), 644 (m), 528 (s), 474 (m) cm−1.
Optical Rotation: [α]D = +65.4
◦ (c = 1.0, CH2Cl2).
Melting Point: 55–57 ◦C.
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N-((1S,2R,3R,3aS,7aR)-2-hydroxy-3-((S)-N-methylphenylsulfonimidoyl)octahydro-1H-
inden-1-yl)-2-methylpropane-2-sulfonamide (100) andN-((1S,2S,3R,3aS,7aR)-2-hydro-
xy-3-((S)-N-methylphenylsulfonimidoyl)octahydro-1H-inden-1-yl)-2-methylpropane-
2-sulfonamide (101)
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To a solution of sulfoximine E-82 (400 mg, 0.85 mmol) in THF (40 mL) was added
DIBAL-H (3.79 mL of 1.12 M solution in THF, 4.25 mmol) dropwise under stirring at 0
◦C. After the reaction mixture was allowed to warm to room temperature within 3 h,
pieces of ice were added until hydrogen gas evolution ceased. Then the mixture was
further stirred for 30 min. The gel-like mixture was suction filtered through a filter-
paper and the residue was washed with hot EtOAc (∼ 50 ◦C, 300 mL). The filtrate was
concentrated in a rotary evaporator. Purification and separation by flash chromatog-
raphy (increasing polarity of EtOAc/cyclohexane from 1:9 to 1:1) furnished the amino
alcohols 100 (313 mg, 86%) and 101 (26 mg, 7%) as white solids.
Analytical data of 100
Rf: 0.35 (EtOAc/cyclohexane, 1:1).
1H NMR (500 MHz, CDCl3): δ = 1.01–1.11 (m, 3H), 1.34–1.60 (m, 4H), 1.87–1.90 (m,
1H) (S-CH-CH-CH2, S-CH-CH-CH2-CH2, N-CH-CH-CH2, N-CH-CH-CH2-CH2), 1.47
(s, 9H, C(CH3)3), 1.96–1.99 (m, 1H, N-CH-CH-CH2), 2.16–2.21 (m, 1H, S-CH-CH-CH2),
2.62 (s, 3H, NCH3), 3.08 (dd, J = 6.6 Hz, J = 3.8 Hz, 1H, S-CH), 3.74 (ddd, J = 7.7 Hz, J =
10.1 Hz, J = 11.5 Hz, 1H, N-CH), 4.35 (d, J = 10.1 Hz, 1H, NH), 4.59 (dd, J = 6.6 Hz, J =
7.7 Hz, 1H, O-CH), 7.57–7.66 (m, 3H, Ph), 7.85–7.87 (m, 2H, Ph).
13C NMR (125 MHz, CDCl3): δ = 20.9 (u, CH2), 23.5 (u, CH2), 24.3 (d, CH3), 24.4 (u,
CH2), 29.2 (d, CH3), 30.1 (u, CH2), 35.2 (d, CH), 41.7 (d, CH), 60.2 (u, C), 61.7 (d, CH),
73.2 (d, CH), 76.8 (d, CH), 129.6 (d, CH), 133.2 (d, CH), 136.5 (u, C).
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MS (EI, 70 eV): m/z (%) 429 [M+ + 1] (1), 355 (1), 292 (8), 260 (2), 198 (4), 156 (100), 152
(24), 136 (55), 125 (48), 77 (4), 57 (24).
IR (KBr): ν˜ = 3984 (w), 3911 (w), 3856 (w), 3450 (w), 3271 (vs), 3065 (w), 2971 (m), 2930
(s), 2864 (m), 2803 (w), 1453 (s), 1398 (w), 1305 (vs), 1235 (vs), 1178 (w), 1125 (vs), 1082
(s), 1013 (m), 962 (w), 916 (m), 870 (m), 828 (m), 804 (m), 760 (m), 704 (m), 667 (m), 621
(m), 556 (m), 501 (m) cm−1.
Elemental Analysis: Anal. Calcd for C20H32N2O4S2 (428.61): C, 56.05; H, 7.53; N, 6.54.
Found: C, 56.28; H, 7.62; N, 6.56.
Optical Rotation: [α]D = +32.2
◦ (c = 1.0, CH2Cl2).
Melting Point: 213 ◦C.
Analytical data of 101
Rf: 0.19 (EtOAc/cyclohexane, 1:1).
1H NMR (300 MHz, CDCl3): δ = 1.28–1.92 (m, 7H), 1.85–1.92 (m, 1H) (S-CH-CH-CH2,
S-CH-CH-CH2-CH2, N-CH-CH-CH2, N-CH-CH-CH2-CH2), 1.43 (s, 9H, C(CH3)3), 2.23–
2.33 (m, 1H, N-CH-CH-CH2), 2.66 (s, 3H, NCH3), 2.78–2.89 (m, 1H, S-CH-CH-CH2),
2.95 (dd, J = 5.0 Hz, J = 5.3 Hz, 1H, S-CH), 3.50 (ddd, J = 4.0 Hz, J = 10.1 Hz, J = 11.1 Hz,
1H, N-CH), 4.15 (dd, J = 4.0 Hz, J = 5.0 Hz, 1H, O-CH), 4.64 (d, J = 10.1 Hz, 1H, NH),
7.57–7.66 (m, 3H, Ph), 7.91–7.94 (m, 2H, Ph).
13C NMR (75 MHz, CDCl3): δ = 20.7 (u, CH2), 23.6 (u, CH2), 23.7 (u, CH2), 24.3 (d,
CH3), 28.7 (d, CH3), 31.2 (u, CH2), 35.0 (d, CH), 40.4 (d, CH), 59.7 (u, C), 60.4 (d, CH),
69.2 (d, CH), 69.9 (d, CH), 129.3 (d, CH), 129.8 (d, CH), 133.5 (d, CH), 137.7 (u, C).
1H{1H}-NOE (400 MHz, CDCl3): selected observations†
irradiated frequency
H-1 H-2 H-3 H-3a H-7a
observed frequency H-1 – s n.o. n.o. n.o.
H-2 s – s n.o. n.o.
H-3 n.o. s – n.o. n.o.
H-3a n.o. n.o. n.o. – s
H-7a n.o. n.o. n.o. s –
†numbering is same as in the figure on page 80
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MS (EI, 70 eV): m/z (%) 429 [M+ + 1] (1), 307 (8), 292 (17), 198 (9), 156 (36), 152 (100),
136 (20), 125 (25), 107 (13), 78 (4), 57 (23).
IR (KBr): ν˜ = 3602 (w), 3281 (s), 3056 (w), 2932 (s), 2808 (m), 1735 (w), 1446 (s), 1366
(w), 1315 (s), 1246 (s), 1125 (vs), 1082 (m), 1025 (w), 986 (m), 927 (m), 900 (m), 850 (m),
805 (m), 754 (m), 695 (m), 670 (m), 607 (m), 556 (m), 518 (m) cm−1.
Elemental Analysis: Anal. Calcd for C20H32N2O4S2 (428.61): C, 56.05; H, 7.53; N, 6.54.
Found: C, 56.14; H, 7.64; N, 6.45.
Optical Rotation: [α]D = +12.3
◦ (c = 1.0, CH2Cl2).
Melting Point: 148 ◦C.
2-methyl-N-((3S,3aS,7aS)-7a-(((S)-N-methylphenylsulfonimidoyl)methyl)octahydro-
benzofuran-3-yl)propane-2-sulfonamide (121)
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To a solution of ester Z-82 (497 mg, 1.06 mmol) in THF (35 mL) was added DIBAL-H
(5.5 mL of 1.0 M solution in THF, 5.49 mmol) dropwise under stirring at 0 ◦C. The reac-
tion mixture was stirred at 0 ◦C for 2 h and later warmed to room temperature within
3 h. Then pieces of ice were added until hydrogen gas evolution ceased. Then the mix-
ture was further stirred for 30 min. The gel-like mixture was suction filtered through
a filter-paper and the residue was washed with hot EtOAc (∼ 50 ◦C, 400 mL). The fil-
trate was concentrated in a rotary evaporator. Purification by flash chromatography
(increasing polarity of EtOAc/cyclohexane from 1:9 to 1:1) furnished sulfoximine 121
(215 mg, 48%) as a white solid.
Analytical data of 121
Rf: 0.35 (cyclohexane/EtOAc, 1:1).
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1H NMR (500 MHz, CD3OD,H2O): δ = 1.26 (s, 9H, C(CH3)3), 1.30–1.57 (m, 7H), 2.05–
2.11 (m, 1H) (O-C-CH2-CH2, O-C-CH2-CH2, CH-CH2-CH2, CH-CH2-CH2), 2.34–2.38
(m, 1H, N-CH-CH), 2.47 (s, 3H, NCH3), 3.34 (d, J = 15.3 Hz, 1H, S-CHH), 3.37 (dd, J
= 6.7 Hz, J = 9.0 Hz, 1H, O-CHH), 3.64 (d, J = 15.3 Hz, 1H, S-CHH), 3.83–3.87 (m, 1H,
N-CH), 3.96 (dd, J = 8.0 Hz, J = 6.7 Hz, 1H, O-CHH), 4.87 (br s, H2O) 7.51–7.60 (m, 3H,
Ph), 7.77–7.80 (m, 2H, Ph).
13C NMR (125 MHz, CD3OD): δ = 20.6 (u, CH2), 21.7 (u, CH2), 23.3 (d, CH3), 23.7 (u,
CH2), 28.1 (d, CH3), 32.7 (u, CH2), 46.9 (d, CH), 57.1 (d, CH), 59.1 (u, C), 60.7 (u, CH2),
71.5 (u, CH2), 81.4 (u, C), 128.8 (d, CH), 129.2 (d, CH), 132.9 (d, CH), 138.7 (u, C).
1H{1H}-NOE (500 MHz, CD3OD): selected observations†
irradiated frequency
H-1 H-2 H-3 H-3a
observed frequency H-1 – n.o. n.o. s
H-2 n.o. – m n.o.
H-3 n.o. m – w
H-3a s n.o. w –
†numbering is same as in the figure on page 82
MS (EI, 70 eV): m/z (%) 428 [M+] (5), 371 (11), 293 (8), 292 (47), 277 (15), 213 (6), 171
(10), 170 (100), 169 (11), 156 (55), 154 (10), 152 (13), 151 (8), 140 (52), 138 (15), 137 (14),
136 (37), 125 (42), 124 (31), 123 (25), 122 (19), 107 (34), 95 (13), 91 (12), 77 (12), 57 (58), 55
(14).
IR (KBr): ν˜ = 3447 (w), 3076 (m), 2932 (s), 2864 (m), 1636 (w), 1477 (m), 1446 (m), 1404
(w), 1366 (w), 1312 (vs), 1232 (s), 1189 (w), 1155 (s), 1129 (vs), 1104 (s), 1077 (m), 1048
(m), 1020 (w), 991 (m), 947 (w), 909 (w), 888 (w), 856 (w), 835 (w), 802 (w), 784 (w), 757
(m), 725 (w), 692 (m), 667 (s), 627 (w), 589 (m), 556 (m), 515 (m) cm−1.
Elemental Analysis: Anal. Calcd for C20H32N2O4S2 · 1/2(H2O) (428.61): C, 55.31; H,
7.81; N, 6.29. Found: C, 55.42; H, 7.41; N, 6.39.
Optical Rotation: [α]D = +168.7
◦ (c = 1.0, CH2Cl2).
Melting Point: 117 ◦C.
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N-((1′R,2′R,3′S,3a′R,7a′S)-2′-hydroxy-5,5-dimethyl-1′-((S)-N-methylphenylsulfonimi-
doyl)octahydrospiro[[1,3]dioxane-2,5′-indene]-3′-yl)-2-methylpropane-2-sulfonamide
(119) andN-((1′R,2′S,3′S,3a′R,7a′S)-2′-hydroxy-5,5-dimethyl-1′-((S)-N-methylphenyl-
sulfonimidoyl)octahydrospiro[[1,3]dioxane-2,5′-indene]-3′-yl)-2-methylpropane-2-sul-
fonamide (120)
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To a solution of sulfoximine E-84 (260 mg, 0.46 mmol) in THF (20 mL) was added
DIBAL-H (2.03 mL of 1.12 M solution in THF, 2.28 mmol) dropwise under stirring at 0
◦C. After the reaction mixture was allowed to warm to room temperature within 3 h,
pieces of ice were added until hydrogen gas evolution ceased. Then the mixture was
further stirred for 30 min. The gel-like mixture was suction filtered through a filter-
paper and the residue was washed with hot EtOAc (∼ 50 ◦C, 300 mL). The filtrate was
concentrated in a rotary evaporator. Purification and separation by flash chromatog-
raphy (increasing polarity of EtOAc/cyclohexane from 1:9 to 1:1) furnished the amino
alcohols 120 (36 mg, 15%) and 119 (174 mg, 72%) as white solids.
Analytical data of 120
Rf: 0.37 (EtOAc/cyclohexane, 1:1).
1H NMR (300 MHz, CD3OD): δ = 0.86 (s, 3H, CH2-C-CH3), 0.98 (s, 3H, CH2-C-CH3),
1.36–1.47 (m, 2H, S-CH-CH-CHH, S-CH-CH-CH2-CHH), 1.39 (s, 9H, C(CH3)3), 1.55–
1.59 (m, 1H, S-CH-CH-CHH), 1.81 (dd, J = 6.6 Hz, J = 14.0 Hz, 1H, N-CH-CH-CHH),
2.05 (dd, J = 6.6 Hz, J = 14.0 Hz, 1H, N-CH-CH-CHH), 2.11–2.15 (m, 1H, S-CH-CH-
CH2-CHH), 2.40–2.46 (m, 1H, N-CH-CH-CH2), 2.64 (s, 3H, NCH3), 2.67–2.71 (m, 1H,
S-CH-CH-CH2), 3.36 (dd, J = 4.5 Hz, J = 6.3 Hz, 1H, S-CH), 3.40–3.47 (m, 3H), 3.55–3.58
(m, 1H) (O-CH2, O-CH2), 3.54–3.57 (m, 1H, N-CH), 4.22-4.23 (m, 1H, O-CH), 7.64–7.74
(m, 3H, Ph), 7.88–7.92 (m, 2H, Ph).
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13C NMR (75 MHz, CD3OD): δ = 21.2 (d, CH3), 21.7 (d, CH3), 23.3 (d, CH3), 26.3 (u,
CH2), 27.6 (u, CH2), 29.44 (d, CH3), 29.44 (u, C), 31.6 (u, CH2), 34.1 (d, CH), 38.7 (d,
CH), 59.3 (u, C), 61.8 (d, CH), 69.1 (d, CH), 69.60 (u, CH2), 69.60 (u, CH2), 71.3 (d, CH),
98.0 (u, C), 129.2 (d, CH), 129.5 (d, CH), 133.4 (d, CH), 137.3 (u, C).
1H{1H}-NOE (400 MHz, CD3OD): selected observations†
irradiated frequency
H-1 H-2 H-3 H-3a H-7a
observed frequency H-1 – s s n.o. w
H-2 s – s n.o n.o.
H-3 s s – n.o. n.o.
H-3a n.o. n.o. n.o. – s
H-7a w n.o. n.o. s –
†numbering is same as in the figure on page 84
MS (EI, 70 eV): m/z (%) 529 [M+ + 1] (2), 392 (20), 373 (7), 254 (5), 253 (18), 252 (100),
237 (6), 236 (14), 235 (6), 234 (22), 198 (10), 196 (28), 168 (8), 166 (29), 156 (18), 148 (6),
141 (6), 125 (12), 57 (15).
HRMS: Calcd for C25H40N2O6S2–C4H10NO2S: 392.189556. Found: 392.189601.
IR (CH2Cl2): ν˜ = 3482 (w), 3364 (w), 3272 (w), 3061 (m), 2956 (s), 2871 (m), 2806 (w),
1472 (m), 1449 (m), 1397 (w), 1366 (w), 1308 (s), 1278 (m), 1242 (s), 1126 (vs), 1015 (w),
968 (w), 900 (w), 811 (w), 778 (w), 707 (m), 664 (m), 615 (w), 562 (w), 517 (w) cm−1.
Optical Rotation: [α]D = +20.7
◦ (c = 1.0, CH2Cl2).
Melting Point: 104 ◦C.
Analytical data of 119
Rf: 0.21 (EtOAc/cyclohexane, 1:1).
1H NMR (400 MHz, CDCl3): δ = 0.82 (s, 3H, CH2-C-CH3), 0.99 (s, 3H, CH2-C-CH3),
1.21–1.33 (m, 3H), 1.95–2.08 (m, 2H) (N-CH-CH-CHH, S-CH-CH-CH2, S-CH-CH-CH2-
CH2), 1.47 (s, 9H, C(CH3)3), 1.80 (dd, J = 14.3 Hz, J = 5.0 Hz, 1H, N-CH-CH-CHH), 2.18–
2.27 (m, 1H, N-CH-CH-CH2), 2.40–2.48 (m, 1H, S-CH-CH-CH2), 2.63 (s, 3H, NCH3),
3.16 (dd, J = 5.8 Hz, J = 5.8 Hz, 1H, S-CH), 3.36–3.41 (m, 3H, O-CH2, O-CHH), 3.50 (d,
J = 11.5 Hz, 1H, O-CHH), 3.79–3.86 (m, 1H, N-CH), 4.48 (s, 1H, OH), 4.55–4.58 (m, 1H,
O-CH), 4.63 (d, J = 9.6 Hz, 1H, NH), 7.55–7.65 (m, 3H, Ph), 7.85–7.89 (m, 2H, Ph).
86 CHAPTER 6. EXPERIMENTAL
13C NMR (100 MHz, CDCl3): δ = 22.4 (d, CH3), 22.7 (d, CH3), 24.3 (d, CH3), 25.2 (u,
CH2), 28.2 (u, CH2), 29.2 (d, CH3), 29.9 (u, C), 32.5 (u, CH2), 35.4 (d, CH), 41.4 (d, CH),
60.2 (u, C), 65.0 (d, CH), 69.7 (u, CH2), 69.9 (u, CH2), 72.1 (d, CH), 78.6 (d, CH), 97.0 (u,
C), 129.4 (d, CH), 129.5 (d, CH), 133.0 (d, CH), 136.7 (u, C).
1H{1H}-NOE (400 MHz, CDCl3): selected observations†
irradiated frequency
H-1 H-2 H-3 H-3a H-7a
observed frequency H-1 – n.o. s n.o. w
H-2 n.o. – n.o. s m
H-3 s n.o. – n.o. n.o.
H-3a n.o. s n.o. – s
H-7a w m n.o. s –
†numbering is same as in the figure on page 84
MS (EI, 70 eV): m/z (%) 529 [M+ + 1] (1), 392 (8), 373 (7), 253 (18), 252 (100), 237 (6), 236
(32), 197 (8), 167 (19), 166 (29), 156 (27), 150 (12), 141 (7), 125 (19), 107 (6), 69 (11).
HRMS: Calcd for C25H40N2O6S2: 528.232782. Found: 528.232902.
IR (KBr): ν˜ = 3248 (m), 3062 (w), 2952 (s), 2871 (m), 2810 (w), 1738 (w), 1638 (w), 1450
(m), 1396 (w), 1364 (m), 1309 (s), 1241 (s), 1189 (w), 1125 (vs), 1015 (w), 972 (w), 901 (m),
834 (w), 794 (m), 753 (m), 693 (m), 669 (m), 619 (m), 569 (w), 545 (w), 510 (w) cm−1.
Optical Rotation: [α]D = –12.8
◦ (c = 1.0, CH2Cl2).
Melting Point: 121 ◦C.
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N-((1S,2R,3R,3aS,8aR)-2-hydroxy-3-((S)-N-methylphenylsulfonimidoyl)decahydroazu-
len-1-yl)-2-methylpropane-2-sulfonamide (110) andN-((1S,2S,3R,3aS,8aR)-2-hydroxy-
3-((S)-N-methylphenylsulfonimidoyl)decahydroazulen-1-yl)-2-methylpropane-2-sul-
fonamide (111) andN-((1S)-2-hydroxy-1-((1R,2S)-2-(((S)-N-methylphenylsulfonimidoyl)-
methyl)cycloheptyl)ethyl)-2-methylpropane-2-sulfonamide (112)
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To a solution of sulfoximine E-83 (320mg, 0.66 mmol) in THF (10 mL) was added
DIBAL-H (2.95 mL of 1.12 M solution in THF, 3.30 mmol) dropwise under stirring at 0
◦C. After the reaction mixture was allowed to warm to room temperature within 4 h,
pieces of ice were added until hydrogen gas evolution ceased. Then the mixture was
further stirred for 30 min. The gel-like mixture was suction filtered through a filter-
paper and the residue was washed with hot EtOAc (∼ 50 ◦C, 400 mL). The filtrate was
concentrated in a rotary evaporator. Column chromatography (EtOAc/cyclohexane,
1:1) afforded alcohol 112 (144 mg, 50%) as a white solid and a mixture of 110 and 111
(R f : 0.54, EtOAc/cyclohexane, 1:1). The mixture was separated by HPLC (Kromasil Si
100, 30 mm, Et2O/cyclohexane, 1:2, 254 nm + RI, 30 mL/min) to furnish amino alco-
hols 110 (49 mg, 17%) and 111 (46 mg, 16%) as white solids (R f (110) > R f (111)).
Analytical data of 110
1H NMR (400 MHz, CDCl3): δ = 0.39–0.44 (m, 1H), 0.83–0.89 (m, 1H), 1.01–1.43 (m,
4H), 1.61–1.67 (m, 2H), 1.81–1.87 (m, 1H), 2.11–2.19 (m, 1H) (S-CH-CH-CH2, S-CH-
CH-CH2-CH2, CH-CH2-CH2-CH2, N-CH-CH-CH2, N-CH-CH-CH2-CH2), 1.47 (s, 9H,
C(CH3)3), 1.88–1.97 (m, 1H, N-CH-CH-CH2), 2.35–2.43 (m, 1H, S-CH-CH-CH2), 2.61 (s,
3H, NCH3), 3.00 (dd, J = 8.0 Hz, J = 9.1 Hz, 1H, S-CH), 3.37–3.45 (m, 1H, N-CH), 4.04
(d, J = 9.9 Hz, 1H, NH), 4.32–4.36 (m, 1H, O-CH), 5.20 (s, 1H, OH), 7.56–7.66 (m, 3H,
Ph), 7.82–7.85 (m, 2H, Ph).
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13C NMR (100 MHz, CDCl3): δ = 24.3 (d, CH3), 27.1 (u, CH2), 28.7 (u, CH2), 28.9 (d,
CH3), 29.8 (u, CH2), 30.8 (u, CH2), 31.8 (u, CH2), 38.6 (d, CH), 46.4 (d, CH), 60.2 (u,
C), 64.3 (d, CH), 72.1 (d, CH), 74.1 (d, CH), 129.4 (d, CH), 129.5 (d, CH), 133.3 (d, CH),
136.4 (u, C).
1H{1H}-NOE (400 MHz, CDCl3): selected observations†
irradiated frequency
H-1 H-2 H-3 H-3a H-8a
observed frequency H-1 – n.o. s n.o. n.o.
H-2 n.o. – n.o. w m
H-3 s n.o. – w n.o.
H-3a n.o. w w – s
H-8a n.o. m n.o. s –
†numbering is same as in the figure on page 87
MS (EI, 70 eV): m/z (%) 662∗ (1), 443 [M+ + 1] (2), 306 (10), 168 (12), 167 (25), 166 (65),
157 (9), 156 (100), 150 (59), 149 (16), 148 (10), 126 (5), 125 (53), 124 (6), 107 (16), 106 (7),
81 (5), 78 (7), 77 (8), 67 (6), 58 (57), 57 (24), 56 (10).
MS (CI, methane): m/z (%) 471 [M+ + C2H5] (6), 445 (11), 444 (25), 443 (100), 441 (13),
168 (5), 166 (9), 156 (19), 150 (8), 125 (10).
HRMS: Calcd for C21H34N2O4S2+H: 443.203828. Found: 443.204662.
IR (CHCl3): ν˜ = 3957 (w), 3872 (w), 3831 (w), 3789 (w), 3727 (w), 3698 (w), 3578 (w),
3512 (w), 3458 (w), 3283 (s), 3063 (w), 3017 (m), 2925 (s), 2857 (m), 2809 (w), 1452 (s),
1365 (m), 1308 (s), 1234 (s), 1124 (vs), 1081 (s), 1026 (m), 918 (m), 865 (m), 812 (w), 757
(vs), 666 (m), 621 (m), 574 (w), 500 (m), 476 (m) cm−1.
Optical Rotation: [α]D = +51.4
◦ (c = 1.0, CH2Cl2).
Melting Point: 228 ◦C.
Analytical data of 111
1H NMR (400 MHz, CDCl3): δ = 0.84–0.90 (m, 1H), 1.19–1.49 (m,4H), 1.81–1.92 (m,
∗analysis of the evaporation curve of the EI spectrum indicated that due to over heating during the
volatilization process the molecule underwent a bimolecular reaction resulting in this fragment. The CI
spectrum showed (vide supra) only the expected fragment proving the purity of the sample.
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3H), 2.02–2.08 (m, 1H), 2.15–2.20 (m, 1H) (S-CH-CH-CH2, S-CH-CH-CH2-CH2, CH-
CH2-CH2-CH2, N-CH-CH-CH2, N-CH-CH-CH2-CH2), 1.37 (s, 9H, C(CH3)3), 2.39–2.48
(m, 1H, N-CH-CH-CH2), 2.70 (s, 3H, NCH3), 2.80 (dd, J = 3.3 Hz, J = 9.3 Hz, 1H, S-CH),
3.03–3.12 (m, 1H, S-CH-CH-CH2), 3.16 (dt, J = 10.2 Hz, J = 3.3 Hz, 1H, N-CH), 3.94 (t, J
= 3.3 Hz, 1H, O-CH), 4.45 (d, J = 10.2 Hz, 1H, NH), 7.42 (s, 1H, OH), 7.57–7.65 (m, 3H,
Ph), 7.86–7.89 (m, 2H, Ph).
13C NMR (100 MHz, CDCl3): δ = 24.3 (d, CH3), 28.0 (u, CH2), 28.5 (d, CH3), 29.5 (u,
CH2), 29.7 (u, CH2), 31.2 (u, CH2), 32.4 (u, CH2), 40.3 (d, CH), 47.1 (d, CH), 59.6 (u,
C), 64.1 (d, CH), 68.5 (d, CH), 70.8 (d, CH), 129.0 (d, CH), 129.6 (d, CH), 133.3 (d, CH),
137.7 (u, C).
1H{1H}-NOE (400 MHz, CDCl3): selected observations†
irradiated frequency
H-1 H-2 H-3 H-3a H-8a
observed frequency H-1 – s s n.o. w
H-2 s – s n.o. n.o.
H-3 s s – n.o. n.o.
H-3a n.o. n.o. n.o. – s
H-8a w n.o. n.o. s –
†numbering is same as in the figure on page 87
MS (EI, 70 eV): m/z (%) 662∗ (5), 443 [M+ + 1] (11), 321 (8), 306 (18), 303 (6), 198 (13),
168 (17), 167 (32), 166 (100), 157 (8), 156 (73), 151 (7), 150 (32), 149 (19), 148 (31), 138 (14),
137 (8), 136 (8), 132 (5), 126 (6), 125 (54), 124 (11), 123 (6), 109 (7), 108 (5), 107 (28), 106
(13), 105 (7), 97 (8), 96 (5), 95 (6), 94 (5), 91 (6), 82 (5), 81 (9), 80 (5), 79 (5), 78 (10), 77 (11),
72 (6), 71 (5), 69 (5), 67 (9), 58 (64), 57 (53), 56 (16).
MS (CI, methane): m/z (%) 471 [M+ + C2H5] (1), 443 (12), 125 (5), 101 (7), 87 (12), 85
(65), 83 (100).
HRMS: Calcd for C21H34N2O4S2+H: 443.203828. Found: 443.204473.
∗analysis of the evaporation curve of the EI spectrum indicated that due to over heating during the
volatilization process the molecule underwent a bimolecular reaction resulting in this fragment. The CI
spectrum showed (vide supra) only the expected fragment proving the purity of the sample.
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IR (CHCl3): ν˜ = 3521 (w), 3271 (m), 3020 (m), 2924 (s), 2855 (m), 1448 (m), 1311 (m),
1237 (m), 1128 (s), 1082 (m), 1023 (w), 921 (w), 864 (w), 820 (w), 756 (vs), 689 (w), 667
(w), 612 (w), 557 (w), 509 (w), 463 (w) cm−1.
Optical Rotation: [α]D = –7.8
◦ (c = 1.0, CH2Cl2).
Melting Point: 119 ◦C.
Analytical data of 112
Rf: 0.20 (EtOAc/cyclohexane, 1:1).
1H NMR (400 MHz, CDCl3): δ = 1.42–1.61 (m, 9H), 1.86–1.94 (m, 1H) (CH2-CH-CH2,
CH2-CH-CH2-CH2, CH-CH2-CH2-CH2, N-CH-CH-CH2, N-CH-CH-CH2-CH2), 1.45 (s,
9H, C(CH3)3), 2.15–2.22 (m, 1H, N-CH-CH), 2.61 (s, 3H, NCH3), 2.96 (dd, J = 14.0 Hz, J
= 7.7 Hz, 1H, S-CHH), 3.05–3.09 (m, 1H, S-CH2-CH), 3.51–3.55 (m, 2H, S-CHH, N-CH),
3.85 (dd, J = 11.8 Hz, J = 3.0 Hz, 1H, O-CHH), 3.93 (dd, J = 11.8 Hz, J = 3.0 Hz, 1H,
O-CHH), 5.74 (d, J = 9.6 Hz, 1H, NH), 7.57–7.67 (m, 3H, Ph), 7.84–7.89 (m, 2H, Ph).
13C NMR (100 MHz, CDCl3): δ = 24.5 (d, CH3), 24.7 (u, CH2), 26.4 (u, CH2), 26.6 (u,
CH2), 28.5 (u, CH2), 29.1 (d, CH3), 31.3 (d, CH), 34.0 (u, CH2), 46.3 (d, CH), 56.2 (u,
CH2), 59.6 (d, CH), 59.8 (u,C), 63.3 (u, CH2), 129.0 (d, CH), 129.6 (d, CH), 133.2 (d, CH),
138.1 (u, C).
1H{1H}-NOE (400 MHz, CDCl3): selected observations†
irradiated frequency
H-1 H-2 H-8 H-8′
observed frequency H-1 – s n.o. n.o.
H-2 s – w n.o.
H-8 n.o. w – s
H-8′ n.o. n.o. s –
†numbering is same as in the figure on page 87
MS (EI, 70 eV): m/z (%) 445 [M+ + 1] (7), 413 (19), 323 (6), 308 (6), 293 (10), 258 (10.0),
246 (12), 216 (7), 180 (7), 170 (12), 169 (11), 168 (56), 157 (5), 156 (49), 152 (8), 140 (13),
139 (12), 138 (100), 126 (6), 125 (41), 124 (10), 108 (6), 107 (42), 105 (9), 97 (5), 95 (6), 81
(6), 78 (10), 77 (8), 69 (5), 67 (11), 60 (30), 59 (15), 57 (52), 56 (8), 55 (8).
HRMS: Calcd for C21H36N2O4S2–CH3O: 413.193263. Found: 413.193663.
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IR (KBr): ν˜ = 3965 (w), 3896 (w), 38.42 (w), 3749 (w), 3469 (s), 2928 (vs), 2807 (m), 2370
(w), 2344 (w), 2323 (w), 2250 (w), 1629 (m), 1520 (m), 1455 (s), 1303 (s), 1235 (s), 1123
(vs), 912 (m), 865 (m), 737 (s), 689 (m), 512 (m) cm−1.
Optical Rotation: [α]D = +48.5
◦ (c = 1.0, CH2Cl2).
Melting Point: 109 ◦C.
2-methyl-N-((3S,3aS,8aS)-8a-(((S)-N-methylphenylsulfonimidoyl)methyl)octahydro-
2H-cyclohepta[b]furan-3-yl)propane-2-sulfonamide (122)
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To a solution of ester Z-83 (200 mg, 0.41 mmol) in THF (20 mL) was added DIBAL-H
(1.8 mL of 1.12 M solution in THF, 2.05 mmol) dropwise under stirring at 0 ◦C. The
reaction mixtured was allowed to stir at 0 ◦C for 1 h and later warmed to room tem-
perature within 6 h. Afterwards pieces of ice were added until hydrogen gas evolution
ceased. Then the mixture was further stirred for 30 min. The gel-like mixture was suc-
tion filtered through a filter-paper and the residue was washed with hot EtOAc (∼ 50
◦C, 300 mL). The filtrate was concentrated in a rotary evaporator. Purification by flash
chromatography (EtOAc/Et2O, 6:4) furnished furan 122 (140 mg, 77%) as a white solid.
Analytical data of 122
Rf: 0.53 (EtOAc/Et2O, 6:4).
1H NMR (400 MHz, CDCl3): δ = 1.43 (s, 9H, C(CH3)3), 1.36–1.47 (m, 1H), 1.56 (br s,
H2O) 1.57–1.70 (m, 2H), 1.76–1.86 (m,4H), 1.96–2.03 (m, 1H) (O-C-CH2-CH2, O-C-CH2-
CH2, CH-CH2-CH2, CH-CH2-CH2, CH-CH2-CH2-CH2), 2.67 (s, 3H, NCH3), 2.98–3.03
(m, 1H, N-CH-CH), 3.48 (d, J = 14.6 Hz, 1H, S-CHH), 3.64 (d, J = 14.6 Hz, 1H, S-CHH),
3.66–3.71 (m, 1H, N-CH), 3.72 (dd, J = 9.1 Hz, J = 3.9 Hz, 1H, O-CHH), 3.97 (dd, J =
9.1 Hz, J = 5.0 Hz, 1H, O-CHH), 7.01 (d, J = 8.5 Hz, 1H, NH), 7.56–7.61 (m, 3H, Ph),
7.88–7.91 (m, 2H, Ph).
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13C NMR (100 MHz, CDCl3): δ = 23.2 (u, CH2), 24.5 (d, CH3), 27.0 (u, CH2), 29.6 (d,
CH3), 30.4 (u, CH2), 30.6 (u, CH2), 38.1 (u, CH2), 53.1 (d, CH), 59.6 (u, C), 62.9 (d, CH),
66.0 (u, CH2), 72.5 (u, CH2), 86.3 (u, C), 129.1 (d, CH), 129.3 (d, CH), 133.0 (d, CH),
139.3 (u, C).
1H{1H}-NOE (500 MHz, CD3OD): selected observations†
irradiated frequency
H-1 H-2 H-3 H-3a
observed frequency H-1 – n.o. n.o. s
H-2 n.o. – s n.o.
H-3 n.o. s – w
H-3a s n.o. w –
†numbering is same as in the figure on page 91
MS (EI, 70 eV): m/z (%) 443 [M+ + 1] (1), 385 (7), 321 (9), 307 (8), 306 (32), 287 (5), 227
(7), 180 (10), 171 (15), 170 (100), 169 (10), 166 (25), 165 (13), 156 (59), 152 (47), 151 (24),
150 (62), 141 (12), 140 (84), 138 (23), 137 (30), 136 (18), 135 (6), 125 (57), 109 (13), 108 (10),
107 (33), 106 (18), 105 (8), 97 (6), 96 (7), 95 (9), 94 (11), 93 (8), 91 (21), 82 (6), 85 (11), 80
(8), 79 (9), 78 (11), 77 (17 ), 67 (19), 60 (14), 59 (7), 57.4 (99), 56.6 (11), 56 (22), 55 (6).
Elemental Analysis: Anal. Calcd for C21H34N2O4S2 · 1/2(H2O) (442.64): C, 55.85; H,
7.81; N, 6.20. Found: C, 55.90; H, 7.54; N, 6.25.
IR (CHCl3): ν˜ = 3281 (w), 3057 (w), 2927 (s), 2685 (m), 2806 (w), 1398 (w), 1367 (w),
1306 (s), 1127 (vs), 1086 (s), 1052 (s), 996 (w), 962 (w), 921 (w), 862 (w), 803 (w), 738 (vs),
699 (m), 662 (m), 595 (m), 544 (w), 509 (m) cm−1.
Optical Rotation: [α]D = +63.6
◦ (c = 1.0, CH2Cl2).
Melting Point: 51 ◦C.
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N-((1S,2R,3R,5S)-2-hydroxy-5-isopropyl-3-((S)-N-methylphenylsulfonimidoyl)cyclo-
pentyl)-2-methylpropane-2-sulfonamide (116), N-((1S,2S,3R,5S)-2-hydroxy-5-isopropyl-
3-((S)-N-methylphenylsulfonimidoyl)cyclopentyl)-2-methylpropane-2-sulfonamide (117)
and (2S,3S)-ethyl 2-(1,1-dimethylethylsulfonamido)-3-isopropyl-5-((S)-N-methylphenyl-
sulfonimidoyl)pentanoate (118)
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To a solution of the α-amino ester E-85 (300 mg, 0.65 mmol) in THF (20 mL) was added
DIBAL-H (3.27 mL of 1.0 M solution in THF, 3.27 mmol) dropwise under stirring at 0
◦C. After the reaction mixture was allowed to warm to room temperature within 4 h,
pieces of ice were added until hydrogen gas evolution ceased. Then the mixture was
further stirred for 30 min. The gel-like mixture was suction filtered through a filter-
paper and the residue was washed with hot EtOAc (∼ 50 ◦C, 300 mL). The filtrate was
concentrated in a rotary evaporator. Column chromatography (EtOAc/cyclohexane,
1:1) afforded 118 (39 mg, 13%) as a white solid and a mixture of 116 and 117 (R f : 0.43,
EtOAc/cyclohexane, 1:1). Separation of the mixture by HPLC (Kromasil Si 100, 30 mm,
EtOAc/cyclohexane, 35:65, 254 nm + RI, 25 mL/min) gave the amino alcohols 116 (51
mg, 19%) and 117 (16 mg, 6%) as white solids (R f (116) > R f (117)).
Analytical data of 116
1H NMR (400 MHz, CDCl3): δ = 0.80 (d, J = 7.1 Hz, 3H, CH-CH3), 0.86 (d, J = 7.1
Hz, 3H, CH-CH3), 1.39–1.44 (m, 1H, CH-CHH), 1.47 (s, 9H, C(CH3)3), 1.79–1.87 (m, 1H,
CH3-CH-CH), 1.95 (ddd, J = 7.4 Hz, J = 10.4 Hz, J = 14.0 Hz, 1H, CH-CHH), 2.08–2.15
(m, 1H, CH3-CH), 2.62 (s, 3H, NCH3), 3.30 (dt, J = 10.4 Hz, J = 8.6 Hz, 1H, S-CH), 3.52–
3.57 (m, 1H, N-CH), 4.20 (d, J = 9.9 Hz, 1H, NH), 4.40–4.44 (t, J = 8.6 Hz, 1H, O-CH),
7.57–7.68 (m, 3H, Ph), 7.81–7.85 (m, 2H, Ph).
13C NMR (100 MHz, CDCl3): δ = 15.8 (d, CH3), 20.1 (u, CH2), 21.7 (d, CH3), 24.4 (d,
CH3), 26.3 (d, CH3), 29.2 (d, CH), 47.9 (d, CH), 60.3 (u, C), 62.8 (d, CH), 65.6 (d, CH),
75.8 (d, CH), 129.5 (d, CH), 129.7 (d, CH), 133.4 (d, CH), 136.4 (u, C).
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1H{1H}-NOE (400 MHz, CDCl3): selected observations†
irradiated frequency
H-1 H-2 H-3 H-5
observed frequency H-1 – w s w
H-2 w – w s
H-3 s w – n.o.
H-5 w s n.o. –
†numbering is same as in the figure on page 93
MS (CI, methane): m/z (%) 445 [M+ + C2H5] (6), 419 (11), 418 (22), 417 (100), 415 (7),
206 (6), 156 (21), 125 (10).
HRMS: Calcd for C19H32N2O4S2–C4H9O: 343.115013. Found: 343.114980.
IR (capillary): ν˜ = 3062 (w), 3028 (w), 2955 (vs), 2802 (m), 1463 (s), 1370 (m), 1250 (vs),
1198 (w), 1145 (s), 1090 (s), 979 (m), 922 (w), 864 (s), 838 (s), 777 (m), 731 (m), 695 (s),
629 (w), 591 (m), 547 (m) cm−1.
Optical Rotation: [α]D = +15.7
◦ (c = 1.0, CH2Cl2).
Melting Point: 76 ◦C.
Analytical data of 117
1H NMR (400 MHz, CDCl3): δ = 0.83 (d, J = 6.6 Hz, 3H, CH-CH3), 0.97 (d, J = 6.6 Hz,
3H, CH-CH3) 1.38 (s, 9H, C(CH3)3), 1.85–2.01 (m, 2H, CH3-CH, CH-CHH), 2.17–2.25
(m, 1H, CH3-CH-CH), 2.53 (ddd, J = 9.9 Hz, J = 11.3 Hz, J = 13.7 Hz, 1H, CH-CHH),
2.68 (s, 3H, NCH3), 3.08 (dt, J = 3.3 Hz, J = 9.9 Hz, 1H, S-CH), 3.37 (dt, J = 3.3 Hz, J =
10.2 Hz, 1H, N-CH), 4.04 (t, J = 3.3 Hz, 1H, O-CH), 4.54 (d, J = 10.2 Hz, 1H, NH), 7.21
(s, 1H, OH) 7.57–7.7-65 (m, 3H, Ph), 7.85–7.88 (m, 2H, Ph).
13C NMR (100 MHz, CDCl3): δ = 16.2 (d, CH3), 21.2 (u, CH2), 22.0 (d, CH3), 24.2 (d,
CH3), 27.1 (d, CH), 28.5 (d, CH3), 47.6 (d, CH), 59.5 (u, C), 61.2 (d, CH), 62.5 (d, CH),
71.1 (d, CH), 129.1 (d, CH), 129.7 (d, CH), 133.5 (d, CH), 137.2 (u, C).
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1H{1H}-NOE (400 MHz, CDCl3): selected observations†
irradiated frequency
H-1 H-2 H-3 H-5
observed frequency H-1 – s s n.o.
H-2 s – s n.o.
H-3 s s – n.o.
H-5 n.o. n.o. n.o. –
†numbering is same as in the figure on page 93
MS (EI, 70 eV): m/z (%) 416 [M+] (1), 295 (14), 280 (13), 210 (33), 156 (50), 154 (5), 142
(12), 141 (14), 140 (100), 126 (8), 125 (39), 124 (7), 123 (7), 122 (35), 107 (14), 98 (10), 86
(11), 85 (17), 77 (8), 70 (17), 69 (8), 57 (69), 55 (12).
HRMS: Calcd for C19H32N2O4S2–C4H9SO2: 295.148026. Found: 295.147926.
IR (KBr): ν˜ = 3238 (m), 3058 (w), 2955 (m), 2875 (m), 2810 (w), 1451 (s), 1385 (m), 1308
(s), 1239 (s), 1126 (vs), 1081 (s), 1014 (m), 997 (w), 905 (s), 847 (m), 789 (w), 758 (m), 724
(m), 691 (m), 665 (m), 599 (m), 554 (m), 514 (w), 470 (w) cm−1.
Optical Rotation: [α]D = –12.8
◦ (c = 1.0, CH2Cl2).
Melting Point: 89–90 ◦C.
Analytical data of 118
Rf: 0.15 (EtOAc/cyclohexane, 1:1).
1H NMR (400 MHz, CDCl3): δ = 0.84 (d, J = 6.9 Hz, 3H, CH-CH3), 0.91 (d, J = 6.9 Hz,
3H, CH-CH3), 1.20 (t, J = 7.1 Hz, 3H, CH2-CH3), 1.30 (s, 9H, C(CH3)3), 1.56–1.68 (m,
2H, CH-CH2), 1.86–1.96 (m, 2H, CH3-CH, CH2-CH), 2.58 (s, 3H, NCH3), 3.13–3.19 (m,
1H, S-CHH), 3.34–3.41 (m, 1H, S-CHH), 4.09–4.15 (m, 3H, N-CH, CH3-CH2), 5.91 (d, J
= 8.2 Hz, 1H, NH), 7.48–7.57 (m, 3H, Ph), 7.78–7.81 (m, 2H, Ph).
13C NMR (100 MHz, CDCl3): δ = 14.3 (d, CH3), 19.7 (d, CH3), 21.0 (u, CH2), 21.9 (d,
CH3), 24.4 (d, CH3), 29.5 (d, CH3), 29.7 (d, CH), 47.4 (d, CH), 54.9 (u, CH2), 58.6 (d,
CH), 60.2 (u, C), 61.8 (u, CH2), 129.3 (d, CH), 129.5 (d, CH), 132.9 (d, CH), 137.5 (u, C),
172.2 (u, C).
MS (EI, 70 eV): m/z (%) 460 [M+] (5), 387 (12), 339 (7), 325 (8), 324 (44), 238 (14), 232
(5), 186 (28), 185 (5), 184 (35), 182 (6), 170 (6), 169 (27), 157 (6), 156 (38), 155 (18), 141 (6),
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140 (21), 126 (7), 125 (43), 113 (8), 112 (76), 111 (8), 110 (6), 108 (8), 107 (93), 106 (8), 105
(8), 102 (15), 97 (7), 96 (9), 95 (9), 91 (6), 83 (18), 78 (13), 77 (12), 70 (11), 69 (8), 68 (6), 57
(100), 57 (12), 56 (23), 46 (7).
HRMS: Calcd for C21H36N2O5S2: 460.206567. Found: 460.206441.
IR (CHCl3): ν˜ = 3685 (w), 3622 (w), 3021 (vs), 2976 (m), 2934 (w), 2900 (w), 2736 (w),
2582 (w), 2402 (m), 2268 (w), 2115 (w), 1733 (m), 1524 (w), 1477 (w), 1426 (w), 1322 (w),
1230 (s), 1203 (m), 1131 (w), 1041 (m), 929 (w), 793 (vs), 726 (vs), 671 (s), 622 (w), 533
(m), 511 (m) cm−1.
Optical Rotation: [α]D = +23.8
◦ (c = 1.0, CH2Cl2).
Melting Point: 137 ◦C.
N-((1S,2R,3S,3aS,7aR)-3-chloro-2-hydroxyoctahydro-1H-inden-1-yl)-2-methylpropane-
2-sulfonamide (138) and 2-methyl-N-((1S,3aR,7aR)-2-oxooctahydro-1H-inden-1-yl)pro-
pane-2-sulfonamide (139)
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To a solution of sulfoximine 100 (300 mg, 0.70 mmol) in CH2Cl2 (10 mL) was added
1-chloroethyl chloroformate (97 µL, 0.91 mmol) and the mixture was stirred at room
temperature for 3 h. After the mixture was concentrated in vacuo, purification and sep-
aration by column chromatography (pentane/Et2O, 2:3) gave the diastereomerically
pure chloride 138 (90 mg, 41%) and ketone 139 (51 mg, 27%) as white solids.
Analytical data of 138
Rf: 0.51 (pentane/Et2O, 2:3, dyed with phosphomolybdic acid).
1H NMR (400 MHz, CDCl3): δ = 1.12–1.23 (m, 1H), 1.33–1.48 (m, 2H), 1.55–1.64 (m,
2H), 1.73–1.83 (m, 3H), 1.85–1.90 (m, 1H) (Cl-CH-CH-CH2, Cl-CH-CH-CH2-CH2, N-
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CH-CH-CH2, N-CH-CH-CH2-CH2), 1.44 (s, 9H, C(CH3)3), 2.17–2.25 (m, 1H, Cl-CH-
CH), 2.81 (d, J = 2.5 Hz, 1H, OH), 3.76 (dt, J = 9.6 Hz, J = 4.1 Hz, 1H, N-CH), 4.07–4.10
(m, 1H, O-CH), 4.19 (d, J = 9.6 Hz, 1H, NH), 4.35 (t, J = 6.5 Hz, 1H, Cl-CH).
13C NMR (100 MHz, CDCl3): δ = 20.7 (u, CH2), 23.8 (u, CH2), 24.0 (u, CH2), 24.2 (u,
CH2), 24.3 (d, CH3) 42.3 (d, CH), 42.7 (d, CH) 60.0 (u, C), 63.9 (d, CH), 64.1 (d, CH),
78.2 (d, CH).
1H{1H}-NOE (400 MHz, CDCl3): selected observations†
irradiated frequency
H-1 H-2 H-3 H-3a H-7a
observed frequency H-1 – w n.o. n.o. w
H-2 w – s n.o. n.o.
H-3 n.o. s – s s
H-3a n.o. n.o. s – s
H-7a w n.o. s s –
†numbering is same as in the figure on page 96
MS (CI, methane): m/z (%) 310.0 [M+ + 1] (15), 238 (36), 236 (100), 190 (31), 154 (47),
136 (12), 119 (15), 82 (10).
IR (KBr): ν˜ = 3504 (s), 3293 (s), 2930 (s), 2863 (m), 1453 (m), 1371 (w), 1295 (s), 1241 (m),
1212 (w), 1120 (s), 1063 (m), 989 (m), 923 (m), 886 (m), 758 (m), 662 (w), 559 (m), 519 (w)
cm−1.
Elemental Analysis: Anal. Calcd for C13H24ClNO3S (309.85): C, 50.39; H, 7.81; N, 4.52.
Found: C, 50.48; H, 7.88; N, 4.40.
Optical Rotation: [α]D = –12.9
◦ (c = 1.0, CH2Cl2).
Melting Point: 144 ◦C.
Analytical data of 139
Rf: 0.35 (pentane/Et2O, 2:3, dyed with ninhydrin).
1H NMR (400 MHz, CDCl3): δ = 1.11–1.21 (m, 2H), 1.24–1.32 (m, 1H), 1.48–1.67 (m,
2H), 1.73–1.77 (m, 2H) (N-CH-CH-CH2, N-CH-CH-CH2-CH2, CH2-CH-CH2, CH2-CH-
CH2-CH2), 1.47 (s, 9H, C(CH3)3), 1.96–2.00 (m, 1H, N-CH-CH), 2.08–2.15 (m, 1H, CO-
CHH), 2.19–2.25 (m, 1H, CH2-CH-CH2), 2.39 (dd, J = 8.4 Hz, J = 19.3 Hz, 1H, CO-CHH),
3.99 (d, J = 8.8 Hz, 1H, NH), 4.13 (dd, J = 8.8 Hz, J = 12.9 Hz, 1H, N-CH).
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13C NMR (100 MHz, CDCl3): δ = 19.6 (u, CH2), 24.1 (u, CH2), 24.2 (d, CH3), 25.0 (u,
CH2), 29.5 (u, CH2), 31.2 (d, CH), 42.7 (d, CH), 43.1 (u, CH2), 60.57 (u, C), 60.63 (d, CH),
215.3 (u, C).
MS (EI, 70 eV): m/z (%) 273.1 [M+] (5), 189 (4), 164 (14), 163 (33), 153 (15), 152 (38), 125
(21), 124 (18), 82 (17), 57 (100), 56 (41).
HRMS: Calcd for C13H23NO3S: 273.139866. Found: 273.139783.
IR (KBr): ν˜ = 3889 (w), 3314 (s), 2925 (vs), 1752 (s), 1450 (m), 1304 (vs), 1234 (w), 1126
(vs), 1071 (m), 983 (w), 899 (m), 870 (m), 669 (m), 546 (m), 509 (m) cm−1.
Optical Rotation: [α]D = +40.5
◦ (c = 1.0, CH2Cl2).
Melting Point: 142 ◦C.
N-((1S,2R,3S,3aS,7aR)-2-hydroxy-3-iodooctahydro-1H-inden-1-yl)-2-methylpropane-
2-sulfonamide (144)
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To a solution of sodium iodide (669 mg, 4.5 mmol) in CH3CN (7mL) was added phenyl
chloroformate (0.2497 mL, 1.9 mmol) and the resulting mixture was stirred at 70 ◦C
for 1.5 h. Formation of colourless precipitate was observed. After cooling the mix-
ture to room temperature, the β-amino alcohol 100 (200 mg, 0.47 mmol) was added to
the solution. After stirring the reaction mixture for 2 h, volatiles were removed in a
rotary evaporator. Purification by column chromatography (pentane/Et2O, 9:1) gave
(S)-phenyl methyl(phenylsulfinyl)carbamate74,110 (95 mg, 75%) as a viscous oil and io-
dide 144 (145 mg, 77%) as a white solid.
Analytical data of 144
Rf: 0.32 (pentane/Et2O, 9:1, dyed with phosphomolybdic acid).
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1H NMR (400 MHz, CDCl3): δ = 1.11–1.36 (m, 3H), 1.50–1.60 (m, 2H), 1.69–1.85 (m,
3H) (I-CH-CH-CH2, I-CH-CH-CH2-CH2, N-CH-CH-CH2, N-CH-Ch-CH2-CH2), 1.43 (s,
9H, C(CH3)3), 1.90–1.94 (m, 1H, N-CH-CH), 2.01–2.08 (m, 1H, I-CH-CH), 2.91 (d, J = 2.2
Hz, 1H, OH), 3.78 (dt, J = 3.3 Hz, J = 9.6 Hz, 1H, N-CH), 3.92–3.96 (m, 1H, O-CH), 4.26
(d, J = 9.6 Hz, 1H, NH), 4.53 (t, J = 7.1 Hz, 1H, I-CH).
13C NMR (100 MHz, CDCl3): δ = 21.0 (u, CH2), 24.1 (u, CH2), 24.3 (d, CH3), 25.3 (u,
CH2), 28.9 (u, CH2), 38.7 (d, CH), 43.4 (d, CH), 44.9 (d, CH), 60.1 (u, C), 62.8 (d, CH),
78.7 (d, CH).
1H{1H}-NOE (400 MHz, CDCl3): selected observations†
irradiated frequency
H-1 H-2 H-3 H-3a H-7a
observed frequency H-1 – w n.o. n.o. w
H-2 w – s n.o. n.o.
H-3 n.o. s – s s
H-3a n.o. n.o. s – m
H-7a w n.o. s m –
†numbering is same as in the figure on page 98
MS (CI, methane): m/z (%) 402 [M+ + 1] (10), 328 (81), 282 (60), 264 (45), 247 (27), 202
(16), 154 (100).
IR (KBr): ν˜ = 3731 (w), 3676 (w), 3505 (s), 3285 (s), 3070 (w), 2936 (s), 2861 (s), 2373 (w),
2345 (w), 1606 (m), 1448 (m), 1372 (m), 1311 (s), 1266 (s), 1181 (m), 1120 (s), 1052 (w),
981 (m), 917 (m), 728 (m), 665 (s), 565 (m), 522 (m), 470 (w) cm−1.
Elemental Analysis: Anal. Calcd for C13H24INO3S (401.30): C, 38.91; H, 6.03; N, 3.49.
Found: C, 39.21; H, 6.24; N, 3.45.
Optical Rotation: [α]D = –20.8
◦ (c = 1.0, CH2Cl2).
Melting Point: 163 ◦C.
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N-((1R,3aR,7aR)-3a,4,5,6,7,7a-hexahydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide
(159)
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HgCl2 (1.0 g) was dissolved in H2O (50 mL) and small pieces of aluminium (1.5 g) were
added. After stirring the mixture for 2 min, it was filtered and the residue was sus-
pended in THF/H2O/AcOH (2:1:1, 40 mL). The resulting mixture was added to a solu-
tion of the amino alcohol 100 (200 mg, 0.47 mmol) in THF (10mL). The reactionmixture
was stirred for 3 h at room temperature. After filtration, the filtrate was concentrated
in a rotary evaporator. Purification by column chromatography (pentane/Et2O, 4:1)
gave the unsaturated sulfonamide 159 (97 mg, 80%) as a viscous colourless oil.
Analytical data of 159
Rf: 0.26 (pentane/Et2O, 4:1).
1H NMR (400 MHz, CDCl3): δ = 1.03–1.12 (m, 1H), 1.16–1.45 (m, 2H), 1.47–1.63 (m,
3H), 1.67–1.85 (m, 2H) (N-CH-CH-CH2, N-CH-CH-CH2-CH2, CH=CH-CH-CH2, CH=CH-
CH-CH2-CH2), 1.41 (s, 9H, C(CH3)3), 1.93–1.99 (m, 1H, N-CH-CH-CH2), 2.58–2.65 (m,
1H, CH=CH-CH-CH2), 4.06 (d, J = 9.9 Hz, 1H, NH), 4.17–4.23 (m, 1H, N-CH), 5.75
(dt, J = 5.8 Hz, J = 1.6 Hz, 1H, N-CH-CH=CH), 5.94 (dt, J = 5.8 Hz, J = 2.2 Hz, 1H,
N-CH-CH=CH).
13C NMR (100 MHz, CDCl3): δ = 22.5 (u, CH2), 23.7 (u, CH2), 24.5 (d, CH3), 24.9 (u,
CH2), 29.5 (u, CH2), 42.2 (d, CH), 46.6 (d, CH), 59.7 (u, C), 63.4 (d, CH), 131.7 (d, CH),
139.9 (d, CH).
MS (EI, 70 eV): m/z (%) 257 [M+] (3), 200 (7), 137 (93), 136 (100), 120 (44), 108 (16), 94
(19), 82 (15), 57 (92).
HRMS: Calcd for C13H23NO2S: 257.144952. Found: 257.144917.
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IR (KBr): ν˜ = 3273 (s), 3052 (w), 2926 (s), 2857 (s), 2256 (w), 1447 (m), 1212 (w), 1126 (s),
1076 (m), 1018 (w), 977 (w), 914 (s), 732 (s), 661 (m), 558 (m), 514 (m) cm−1.
Optical Rotation: [α]D = –90.9
◦ (c = 1.02, CH2Cl2).
2-methyl-N-((1S,3aS,7aR)-3-(N-methylphenylsulfonimidoyl)-3a,4,5,6,7,7a-hexahydro-
1H-inden-1-yl)propane-2-sulfonamide (151)
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To a solution of sulfoximine 100 (203 mg, 0.47 mmol) and PPh3 (128 mg, 0.49 mmol) in
THF (10 mL) was added diethyl azodicarboxylate (DEAD) (85 µl, 0.54 mmol) at room
temperature. The mixture was stirred for 16 h and the volatiles were removed under
reduced pressure. Purification by chromatography (EtOAc/cyclohexane, 4:1) gave the
unsaturated sulfoximine 151 (172 mg, 90%) as a white solid.
Analytical data of 151
Rf: 0.39 (EtOAc/cyclohexane, 4:1).
1H NMR (300 MHz, CDCl3): δ = 0.78–0.89 (m, 1H), 1.02–1.12 (m, 1H), 1.17–1.28 (m,
1H), 1-37–1.49 (m, 1H), 1.53–1.62 (m, 2H), 1.77–1.84 (m, 1H), 1.93–2.00 (m, 1H) (S-C-CH-
CH2, S-C-CH-CH2-CH2, N-CH-CH-CH2, N-CH-CH-CH2-CH2), 1.41 (s, 9H, C(CH3)3),
2.11–2.17 (m, 1H, N-CH-CH), 2.68–2.72 (m, 1H, S-C-CH), 2.70 (s, 3H, NCH3), 4.48 (t, J =
10.2 Hz, 1H, N-CH), 4.83 (d, J = 10.2 Hz, 1H, NH), 6.69 (d, J = 1.1 Hz, 1H, N-CH-CH-C),
7.52–7.67 (m, 3H, Ph), 7.88–7.92 (m, 2H, Ph).
13C NMR (100 MHz, CDCl3): δ = 21.5 (u, CH2), 24.0 (u, CH2), 24.0 (u, CH2), 24.4 (d,
CH3), 29.5 (d, CH3), 29.6 (u, CH2), 42.3 (d, CH), 48.7 (d, CH), 60.0 (u. C), 60.8 (d, CH),
129.0 (d, CH), 129.3 (d, CH), 132.9 (d, CH), 138.0 (u, C), 142.1 (d, CH), 151.0 (u, C).
MS (EI, 70 eV): m/z (%) 410 [M+] (3), 291 (8), 290 (32), 289 (74), 276 (6), 275 (13), 274
(72), 260 (6), 244 (6), 226 (17), 165 (13), 156 (21), 152 (5), 148 (6), 139 (5), 136 (19), 135
102 CHAPTER 6. EXPERIMENTAL
(37), 134 (100), 125 (39), 119 (7), 117 (11), 110 (7), 109 (10), 107 (15), 106 (19), 97 (7), 94
(6), 91 (15), 83 (10), 79 (11), 77 (12), 57.4 (82), 56.6 (14), 56 (11).
MS (CI, methane): m/z (%) 439 [M+ + C2H5] (13), 429 (8), 413 (11), 412 (23), 411 (100),
410 (6), 409 (12), 289 (7), 274 (5).
HRMS: Calcd for C20H30N2O3S2–C4H9SO2: 289.137461. Found: 289.137707.
IR (KBr): ν˜ = 3458 (w), 3263 (w), 3076 (m), 2927 (s), 2807 (m), 2745 (w), 2253 (w), 1611
(w), 1454 (s), 1384 (w), 1309 (vs), 1236 (s), 1123 (vs), 1022 (m), 999 (m), 893 (s), 756 (w),
731 (m), 702 (m), 655 (m), 601 (w), 554 (w), 515 (m) 472 (w) cm−1.
Optical Rotation: [α]D = –62.2
◦ (c = 0.01, CH2Cl2).
Melting Point: 109 ◦C.
N-((1S,2R,3R,3aS,7aR)-2-Hydroxy-3-(phenylsulfonyl)octahydro-1H-inden-1-yl)-2-meth-
ylpropane-2-sulfonamide (147)
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Sulfoximine 100 (107 mg, 0.25 mmol), 3-chlorobenzoperoxoic acid (60 mg, 0.35 mmol)
and hydrochloric acid (0.1 M, 18 µL) were placed in a round bottom flask equipped
with a reflux condenser and THF (2 mL) was added. The resulting mixture was re-
fluxed for 7 h. After cooling the mixture to room temperature, NaOH (1 M, 1.2 mL)
was added. The mixture was extracted with ether (3 × 15 mL). The combined organic
layers were dried with MgSO4 and concentrated in a rotary evaporator. Purification by
column chromatography (Et2O) afforded sulfone 147 (86 mg, 83%) as a white solid.
Analytical data of 147
Rf: 0.59 (Et2O).
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1H NMR (300 MHz, CDCl3): δ = 1.21–1.68 (m, 7H), 1.83–1.87 (m, 1H) (S-CH-CH-CH2,
S-CH-CH-CH2-CH2, N-CH-CH-CH2, N-CH-CH-CH2-CH2), 1.43 (s, 9H, C(CH3)3), 2.19–
2.27 (m, 1H, N-CH-CH-CH2), 2.45–2.52 (m, 1H, S-CH-CH-CH2), 3.08 (dd, J = 1.7 Hz, J
= 4.7 Hz, 1H, S-CH), 3.61 (d, J = 2.2 Hz, 1H, OH), 3.67–3.76 (m, 1H, N-CH), 4.38–4.44
(m, 1H, O-CH), 4.47 (d, J = 9.4 Hz, 1H, NH), 7.56–7.71 (m, 3H, Ph), 7.92–7.95 (m, 2H,
Ph).
13C NMR (75 MHz, CDCl3): δ = 20.5 (u, CH2), 23.5 (u, CH2), 24.3 (d, CH3), 25.1 (u,
CH2), 30.0 (u, CH2), 36.8 (d, CH), 41.5 (d, CH), 60.3 (u, C), 64.0 (d, CH), 74.3 (d, CH),
78.7 (d, CH), 128.5 (d, CH), 129.4 (d, CH), 134.0 (d, CH), 137.8 (u, C).
MS (CI, methane): m/z (%) 444 [M+ + C2H5] (4), 416 (11), 342 (6), 298 (6), 297 (15), 296
(100), 274 (70), 154 (16), 74 (7).
IR (KBr): ν˜ = 3955 (w), 3482 (s), 3284 (s), 2930 (s), 2863 (m), 1627 (w), 1454 (s), 1298 (vs),
1130 (vs) 1005 (m), 911 (m), 826 (w), 730 (m), 667 (m), 600 (m), 560 (m), 514 (m) cm−1.
Elemental Analysis: Anal. Calcd for C19H29NO5S2 (415.57): C, 54.91; H, 7.03; N, 3.37.
Found: C, 54.73; H, 7.32; N, 3.17.
Optical Rotation: [α]D = –54.5
◦ (c = 1.0, CH2Cl2).
Melting Point: 87 ◦C.
(1S,2R,3R,3aS,7aR)-1-Amino-3-((S)-N-methylphenylsulfonimidoyl)octahydro-1H-inden-
2-ol (161)
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To a solution of sulfoximine 100 (300 mg, 0.70 mmol) and anisole (0.1 mL, 0.70 mmol)
in CH2Cl2 (30 mL) was added trifluoromethanesulfonic acid (60 mL of 0.12 M solution
in CH2Cl2) at 0
◦C. After the reaction mixture was allowed to warm to room temper-
ature within 2 h, the pH of the reaction mixture was adjusted to 8 by the addition of
sat. NaHCO3. The aqueous phase was extracted with CH2Cl2 (3 × 100 mL) and the
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combined organic layers were dried with MgSO4. Purification by flash chromatogra-
phy (Et2O/MeOH, 9:1) gave the β-amino alcohol 161 · 1/2(CF3SO3H) (202 mg, 94%) as
a white solid.
Analytical data of 161
Rf: 0.33 (Et2O/MeOH, 1:4).
1H NMR (300 MHz, CDCl3): δ = 0.93–1.08 (m, 3H), 1.16–1.30 (m, 1H), 1.35–1.54 (m,
3H), 1.71–1.80 (m, 2H) (S-CH-CH-CH2, S-CH-CH-CH2-CH2, N-CH-CH-CH2, N-CH-
CH-CH2-CH2, N-CH-CH-CH2), 2.11–2.18 (m, 1H, S-CH-CH-CH2), 2.63 (s, 3H, NCH3),
2.86 (br s, 2H, NH2), 3.04–3.08 (m, 1H, S-CH), 3.11–3.15 (m, 1H, N-CH), 4.31 (t, J = 7.7
Hz, 1H, O-CH), 7.55–7.65 (m, 3H, Ph), 7.85–7.89 (m, 2H, Ph).
13C NMR (75 MHz, CDCl3): δ = 21.0 (u, CH2), 23.6 (u, CH2),24.6 (u, CH2), 29.2 (d,
CH3), 30.6 (u, CH2), 35.6 (d, CH), 41.3 (d, CH), 57.9 (d, CH), 73.7 (d, CH), 78.8 (d, CH),
129.5 (d, CH), 129.6 (d, CH), 133.0 (d, CH), 136.8 (u, C).
19F NMR (376 MHz, CDCl3): δ = –78.3 (s, CF3).
MS (EI, 70 eV): m/z (%) 309 [M+ + 1] (17), 156 (12), 155 (11), 154 (83), 153 (55), 137 (16),
13 (80), 125 (89), 110 (39), 110 (17), 109 (18), 108 (15), 107 (25), 106 (22), 97 (40), 95 (14),
94 (13), 93 (16), 91 (17), 82 (13), 81 (15), 80 (11), 79 (15), 78 (18), 77 (55), 67 (24), 56 (100),
55 (13), 53 (15), 51 (18), 51 (14).
HRMS: Calcd for C17H25N2O5F3S2–CF3SO3: 309.163676. Found: 309.163596.
Elemental Analysis: Anal. Calcd for C16H24N2O2S · 1/2(CF3SO3H) (383.48): C, 51.68;
H, 6.44; N, 7.31. Found: C, 51.88; H, 6.40; N, 7.24.
IR (CHCl3): ν˜ = 3062 (w), 3011 (w), 2928 (s), 28.58 (m), 2804 (w), 1589 (w), 1448 (m),
1348 (w), 1236 (s), 1145 (m), 1107 (m), 1079 (m), 993 (w), 869 (w), 827 (w), 795 (w), 754
(vs), 695 (m), 665 (w), 638 (w), 600 (m), 512 (m) cm−1.
Optical Rotation: [α]D = +48.9
◦ (c = 1.0, CH2Cl2).
Melting Point: 51 ◦C.
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N-((1S,2S,3aR,7aR)-2-Hydroxyoctahydro-1H-inden-1-yl)-2-methylpropane-2-sulfonamide
(160)
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To a solution of alcohol 100 (80 mg, 0.19 mmol) in THF (5 mL) was added Raney-
Nickel (50%-slurry in H2O, 880 mg, 7.47 mmol) and the resulting mixture was stirred
at room temperature for 10 h. After filtering the reaction mixture over celite, the fil-
trate was concentrated in a rotary evaporator. Purification by column chromatography
(pentane/Et2O, 1:2) yielded the 1,2-amino alcohol 160 (47 mg, 92%) as a white solid.
Analytical data of 160
Rf: 0.48 (pentane/Et2O, 1:4).
1H NMR (400 MHz, CDCl3): δ = 1.17–1.39 (m, 2H), 1.48–1.73 (m, 6H) (CH2-CH-CH2,
CH2-CH-CH2-CH2, N-CH-CH-CH2, N-CH-CH-CH2-CH2), 1.44 (s, 9H, C(CH3)3), 1.79–
1.85 (m, 1H, N-CH-CH-CH2), 1.89–1.97 (m, 1H, CH2-CH-CH2), 2.15–2.23 (m, 2H, O-
CH-CH2), 3.40 (d, J = 1.9 Hz, 1H, OH), 3.55 (dt, J = 5.0 Hz, J = 9.9 Hz, 1H, N-CH), 4.10
(ddd, J = 1.7 Hz, J = 5.0 Hz, J = 9.2 Hz, 1H, O-CH), 4.28 (d, J = 9.9 Hz, 1H, NH).
13C NMR (100 MHz, CDCl3): δ = 21.3 (u, CH2), 24.3 (d, CH3), 24.7 (u, CH2), 24.9 (u,
CH2), 29.6 (u, CH2), 36.3 (d, CH), 37.9 (u, CH2), 44.3 (d, CH), 60.1 (u, C), 66.3 (d, CH),
80.4 (d, CH).
MS (EI, 70 eV): m/z (%) 276 [M+ + 1] (2), 155 (27), 154 (100), 138 (9), 137 (8), 136 (17),
111 (12), 110 (89), 109 (20), 95 (15), 94 (6), 93 (11), 82 (8), 81 (7), 79 (6), 72 (18), 69 (6), 67
(13), 59 (6), 58 (10), 57 (98), 56 (31), 55 (18), 54 (6), 53 (5).
HRMS: Calcd for C13H25NO3S–C4H9SO2: 154.123189. Found: 154.123076.
IR (CHCl3): ν˜ = 3501 (s), 3272 (s), 2926 (vs), 28.59 (vs), 2663 (w), 1728 (w), 1586 (w),
1453 (s), 1396 (w), 1366 (w), 1297 (s), 1216 (m), 1121 (s), 1000 (m), 917 (m), 892 (m), 833
(w), 757 (vs), 663 (s), 602 (w), 561 (m), 514 (m), cm−1.
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Optical Rotation: [α]D = –82.4
◦ (c = 1.0, CH2Cl2).
Melting Point: 121 ◦C.
Dimethyl 2-(3-(benzyloxy)benzyl)malonate (167)
O
MeO 1
2
OMe
O
O
3
Ph
167
To a solution of dimethyl malonate (166) (0.79 mL, 6.9 mmol) in DMF (5 mL) was
added sodium hydride (276 mg, 60% in mineral oil, 6.9 mmol) at 0 ◦C and the resulting
mixture was allowed to stirr for 15 min. Then a solution of 1-(benzyloxy)-3-(chloro-
methyl)benzene90 (1.07 g, 4.6 mmol) in DMF (5 mL) was added and the mixture was
stirred for 3 h at room temperature. The reaction mixture was quenched with HCl
(0.5 M) and extracted with EtOAc (3 × 100 mL). The combined organic phases were
washed with H2O, NaHCO3 and brine. The combined organic layers were dried with
MgSO4, concentrated in a rotary evaporator. Purification by column chromatography
(pentane/Et2O, 3:2) gave malonate 167 (1.10 g, 73%) as a colourless oil.
Analytical data of 167
Rf: 0.43 (pentane/Et2O, 3:2).
1H NMR (400 MHz, CDCl3): δ = 3.19 (d, J = 7.6 Hz, 2H, CO-CH-CH2), 3.67 (s, 6H,
O-CH3), 3.68 (t, J = 7.6 Hz, 1H, CO-CH-CH2), 5.01 (s, 2H, Ph-CH2-O), 6.77–6.83 (m, 3H,
Ph), 7.15–7.22 (m, 1H, Ph), 7.28–7.41 (m, 5H, Ph).
13C NMR (100 MHz, CDCl3): δ = 34.9 (u, CH2), 52.7 (d, CH3), 53.6 (d, CH), 70.0 (u,
CH2), 113.2 (d, CH), 115.4 (d, CH), 121.3 (d, CH), 127.5 (d, CH), 127.9 (d, CH), 128.6 (d,
CH), 129.6 (d, CH), 137.0 (u, C), 139.4 (u, C), 158.9 (u, C), 169.1 (u, C).
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Methyl 3-(3-(benzyloxy)phenyl)propanoate (162)
MeO
O
1
2 O
3
Ph
162
Malonate 167 (950 mg, 2.89 mmol), lithium chloride (0.2 g, 4.72 mmol) and water (0.5
mL) were dissolved in DMSO (10 mL) and the mixture was heated at reflux for 4 h.
After the mixture was cooled to room temperature water was added and the mixture
was extracted with Et2O (3 × 100 mL). The combined organic phases were washed
with water (3 × 10 mL) and brine (10 mL), dried with MgSO4 and concentrated in a
rotary evaporator. Purification by column chromatography (pentane/Et2O, 4:1) gave
the methyl ester 162 (289 mg, 37%) as a colourless oil.
Analytical data of 162
Rf: 0.68 (pentane/Et2O, 1:1).
1H NMR (400 MHz, CDCl3): δ = 2.62 (t, J = 7.8 Hz, 2H, CO-CH2), 2.92 (t, J = CO-CH2-
CH2), 3.66 (s, 3H, O-CH3), 5.03 (s, 2H, Ph-CH2-O), 6.79–6.84 (m, 3H, Ph), 7.18–7.22 (m,
1H, Ph), 7.27–7.43 (m, 5H, Ph).
13C NMR (100 MHz, CDCl3): δ = 31.1 (u, CH2), 35.7 (u, CH2), 51.8 (d, CH3), 70.0 (u,
CH2), 112.5 (d, CH), 115.0 (d, CH), 120.9 (d, CH), 127.5 (d, CH), 127.9 (d, CH), 128.6 (d,
CH), 129.5 (d, CH), 137.0 (u, C), 142.2 (u, C), 158.9 (u, C), 173.2 (u, C).
tert-Butyl 2-iodo-3-phenylpropanoate (168)
O
1 2t-BuO
3
I
Ph
168
To a solution of diisopropylamine (0.74 mL, 5.25 mmol) in THF (10 mL) at 0 ◦C was
dropwise added n-BuLi (2.54 mL of 1.6 M solution in THF, 4.04 mmol) and the result-
ing mixture was stirred for 15 min. After the mixture was cooled to –78 ◦C, it was
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cannulated into a solution of tert-butyl 3-phenylpropanoate (833 mg, 4.04 mmol) in
THF (5 mL) at –78 ◦C and the resulting mixture was stirred at this temperature for 1 h.
Then a solution of benzyl 2-iodoacetate108 (1.12 g, 4.04 mmol) in THF (5mL) was added
to the reaction mixture, which was subsequently stirred for 1 h at –78 ◦C. The mixture
was quenched with sat. NH4Cl and extracted with Et2O (4 × 100 mL). The combined
organic phases were dried with MgSO4 and concentrated under reduce pressure. Pu-
rification by flash column chromatography (increasing polarity of pentane/Et2O from
19:1 to 1:1) furnished the iodo phenylpropanoate 168 (290 mg, 22%) as a pale yellow oil.
Analytical data of 168
Rf: 0.75 (pentane/Et2O, 1:1).
1HNMR (400 MHz, CDCl3): δ = 1.39 (s, 9H, C(CH3)3), 3.20 (dd, J = 6.6 Hz, J = 14.3 Hz,
1H, P-CHH), 3.41 (dd, J = 9.3 Hz, J = 14.3 Hz, 1H, Ph-CHH), 4.41 (dd, J = 6.6 Hz, J = 9.3
Hz, 1H, I-CH), 7.18–7.21 (m, 2H, Ph), 7.23–7.31 (m, 3H, Ph).
13C NMR (100 MHz, CDCl3): δ = 23.2 (d, CH), 27.7 (d, CH3), 42.6 (u, CH2), 82.1 (u, C),
127.1 (d, CH), 128.5 (d, CH), 128.9 (d, CH), 138.7 (u, C), 169.8 (u, C).
GC / MS (CI, isobutane): m/z (%) 333 [M+ + 1] (53), 278 (9), 277 (100), 149 (38).
IR (capillary): ν˜ = 3061 (w), 3027 (w), 2977 (m), 2930 (m), 1727 (vs), 1601 (w), 1492 (m),
1454 (m), 1394 (w), 1366 (m), 1291 (m), 1234 (m), 1150 (vs), 1036 (w), 975 (w), 844 (m),
743 (m), 699 (m), 607 (w), 509 (w) cm−1.
tert-Butyl 3-(3-(benzyloxy)phenyl)propanoate (163)
O
1
2
t-BuO
3 O Ph
163
To a solution of diisopropylamine (2.0 mL, 14.3 mmol) in THF (15 mL) at 0 ◦C was
added n-BuLi (6.86 mL of 1.6 M solution in THF, 10.98 mmol) and the resulting mix-
ture was stirred for 15 min. After the mixture was cooled to –78 ◦C, tert-butyl acetate
(1.48 mL, 10.98 mmol) was added dropwise and the mixture was allowed to warm
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to –30 ◦C over 1 h and cooled back to –78 ◦C. Then a solution of 1-(benzyloxy)-3-
(bromomethyl)benzene91 (2.49 mg, 9.0 mmol) in THF (8 mL) was added and the mix-
ture was stirred for 1 h. The mixture was quenched with sat. NH4Cl and extracted
with Et2O (4 × 100 mL). The combined organic phases were dried with MgSO4 and
concentrated under reduce pressure. Purification by flash column chromatography
(increasing polarity of pentane/Et2O from 19:1 to 1:1) furnished the tert-butyl ester 163
(2.46 g, 88%) as a white solid.
Analytical data of 163
Rf: 0.53 (pentane/Et2O, 9:1).
1H NMR (400 MHz, CDCl3): δ = 1.42 (s, 9H, C(CH3)3), 2.53 (t, J = 7.9 Hz, 2H, CO-
CH2), 2.88 (t, J = 7.9 Hz, 2H, CO-CH2-CH2), 5.04 (s, 2H, Ph-CH2-O), 7.17–7.21 (m, 3H,
Ph), 7.30–7.34 (m, 1H, Ph), 7.36–7.44 (m, 5H, Ph).
13C NMR (100 MHz, CDCl3): δ = 28.1 (d, CH3), 31.1 (u, CH2), 36.9 (u, CH2), 69.8 (u,
CH2), 80.2 (u, C), 112.2 (d, CH), 114.8 (d, CH), 120.8 (d, CH), 127.3 (d, CH), 127.7 (d,
CH), 128.4 (d, CH), 129.2 (d, CH), 136.9 (u, C), 142.3 (u, C), 158.7 (u, C), 172.0 (u, C).
MS (EI, 70 eV): m/z (%) 312 [M+] (15), 256 (19), 239 (8), 196 (7), 165 (7), 123 (7), 92 (9),
91 (100), 57 (8).
IR (KBr): ν˜ = 2969 (m), 2934 (m), 2881 (m), 1724 (vs), 1608 (s), 1580 (s), 1486 (s), 1452
(s), 1371 (s), 1305 (s), 1281 (s), 1228 (m), 1149 (vs), 1026 (s), 933 (w), 905 (m), 850 (m),
786 (m), 752 (s), 694 (s), 628 (w), 518 (m) cm−1.
Elemental Analysis: Anal. Calcd for C20H24O3 (312.40): C, 76.89; H, 7.74. Found: C,
76.99; H, 7.48.
Melting Point: 47 ◦C.
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3-(3-(Benzyloxy)phenyl)propanoic acid (172)
O
1
2
HO
3 O Ph
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To a solution of the tert-butyl ester 163 (4.37 g, 14 mmol) in CH2Cl2 (90 mL) was added
trifluoroacetic acid (10.8 mL, 140 mmol) at 0 ◦C. The mixture was allowed to warm
to room temperature and stirred for 10 h. The volatiles were removed in vacuo and
the resulting residue dissolved in EtOAc (100 mL). The solution was washed with
sat. NaHCO3 and brine, dried with MgSO4 and concentrated under reduced pres-
sure. Purification by column chromatography (EtOAc/cyclohexane, 3:2) furnished the
carboxylic acid 172 (2.98 g, 83%) as a white solid.
Analytical data of 172
Rf: 0.35 (EtOAc/cyclohexane, 2:3).
1HNMR (400MHz, CDCl3): δ = 2.61 (t, J = 8.0 Hz, 2H, CO-CH2), 2.89 (t, J = 8.0 Hz, 2H,
CO-CH2-CH2), 4.98 (s, 2H, Ph-CH2-O), 6.76–6.81 (m, 3H, Ph), 7.29–7.40 (m, 6H, Ph).
13C NMR (100 MHz, CDCl3): δ = 30.9 (u, CH2), 36.1 (u, CH2), 69.8 (u, CH2), 112.3 (d,
CH), 114.8 (d, CH), 120.7 (d, CH), 127.3 (d, CH), 127.7 (d, CH), 128.3 (d, CH), 129.3 (d,
CH), 136.8 (u, C), 141.9 (u, C), 158.7 (u, C), 178.6 (u, C).
MS (EI, 70 eV): m/z (%) 256 [M+] (25), 91 (100), 65 (7).
IR (KBr): ν˜ = 3032 (w), 2973 (w), 2936 (w), 1703 (vs), 1594 (m), 1493 (w), 1444 (m), 1381
(w), 1315 (m), 1256 (s), 1165 (m), 1082 (w), 1017 (m), 915 (w), 853 (w), 793 (m), 737 (m),
695 (m), 624 (w), 492 (m) cm−1.
Elemental Analysis: Anal. Calcd for C16H16O3 (256.30): C, 74.98; H, 6.29. Found: C,
75.24; H, 5.99.
Melting Point: 74-76 ◦C.
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(S)-4-Benzyl-3-(3-(3-(benzyloxy)phenyl)propanoyl)oxazolidin-2-one (171)
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The carboxylic acid 172 (1.56 g, 6.09 mmol) was dissolved in THF (30 mL) and the
solution was cooled to –30 ◦C. Triethyl amine (2.1 ml, 15.2 mmol) and pivaloyl chlo-
ride (0.75 mL, 6.09 mmol) were added and the mixture was stirred at –30 ◦C for 2 h.
Then lithium chloride (284 mg, 6.7 mmol) and (S)-4-benzyloxazolidin-2-one (1.03 g,
5.79 mmol) were added at once and the reaction mixture was allowed to stir for 1 d
whereby the temperature of the mixture slowly rose to room temperature. Then the
mixture was diluted with Et2O (200 mL) and washed successively with sat. NH4Cl,
NaOH (1.0 M) and brine. The organic phase was dried with MgSO4 and concentrated
in a rotary evaporator. Purification by column chromatography (EtOAc/cyclohexane,
2:3) afforded oxazolidinone 171 (1.97 g, 82%) as a colourless oil.
Analytical data of 171
Rf: 0.51 (EtOAc/cyclohexane, 2:3).
1H NMR (400 MHz, CDCl3): δ = 2.73 (dd, J = 9.4 Hz, J = 13.5 Hz, 1H, O-CHH-CH),
2.93–3.04 (m, 2H, CO-CH2-CH2), 3.17–3.34 (m, 3H, O-CHH-CH, CO-CH2), 4.10 (d, J =
5.2 Hz, 2H, Ph-CH2-CH), 4.60 (m, 1H, N-CH), 5.00 (s, 2H, Ph-CH2-O), 6.79–6.92 (m, 3H,
Ph), 7.12–7.43 (m, 11H, Ph).
13C NMR (100 MHz, CDCl3): δ = 30.2 (u, CH2), 36.9 (u, CH2), 37.7 (u, CH2), 54.9 (d,
CH), 66.0 (u, CH2), 69.7 (u, CH2), 112.3 (d, CH), 115.0 (d, CH), 120.9 (d, CH), 127.0 (d,
CH), 127.3 (d, CH), 127.7 (d, CH), 128.3 (d, CH), 128.7 (d, CH), 129.2 (d, CH), 129.3 (d,
CH), 135.0 (u, C), 136.8 (u, C), 141.9 (u, C), 153.1 (u, C), 158.7 (u, C), 172.0 (u, C).
MS (EI, 70 eV): m/z (%) 416 [M+ + 1] (15), 415 (56), 324 (11), 239 (7), 238 (23), 147 (7), 92
(11), 90 (100), 65 (6).
HRMS: Calcd for C26H25NO4: 415.178358. Found: 415.178285.
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IR (CHCl3): ν˜ = 3062 (w), 3028 (w), 2920 (w), 2868 (w), 1781 (vs), 1700 (s), 1586 (m),
1490 (m), 1450 (m), 1385 (s), 1353 (m), 1256 (s), 1214 (s), 1159 (m), 1109 (m), 1077 (w),
1046 (m), 920 (w), 875 (w), 847 (w), 755 (vs), 699 (s), 668 (w), 631 (w), 593 (w), 526 (w),
505 (w), 462 (w) cm−1.
Optical Rotation: [α]D = +53.6
◦ (c = 1.0, CH2Cl2).
(R)-tert-Butyl 4-((S)-4-benzyl-2-oxooxazolidin-3-yl)-3-(3-(benzyloxy)benzyl)-4-oxobu-
tanoate (170)
O
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To a solution of oxazolidinone 171 (1.38 g, 3.33 mmol) in THF (40 mL) at –65 ◦C was
added dropwise sodium hexamethyldisilazide (3.66 mL of 1.0 M solution in THF, 3.66
mmol) within 10 min. After stirring the mixture for 45 min at –65 ◦C, tert-butyl 2-
bromoacetate (0.63 mL, 4.33 mmol) was added dropwise within 12 min and the result-
ing mixture was stirred for 3 h at –70 ◦C. The reaction mixture was quenched with sat.
NH4Cl and stirred for 12 h. The volatiles were removed under reduced pressure and
the remaining aqueous solutionwas extractedwith EtOAc (3× 250mL). The combined
organic phases were successively washed with HCl (1.0 M), sat. NaHCO3 and brine.
The organic layer was dried with MgSO4 and concentrated in a rotary evaporator. Pu-
rification by flash column chromatography (increasing polarity of EtOAc/cyclohexane
from 1:9 to 2:3) furnished the diastereomerically pure tert-butyl oxobutanoate 170 (1.26
g, 71%) as a colourless oil.
Analytical data of 170
Rf: 0.59 (EtOAc/cyclohexane, 2:3).
1H NMR (300 MHz, CDCl3): δ = 1.40 (s, 9H, C(CH3)3), 2.36 (dd, J = 4.2 Hz, J = 17.0
Hz, 1H, CO-CHH), 2.60 (dd, J = 9.2 Hz, J = 13.1 Hz, 1H, C-CHH-CH-CO), 2.73 (dd, J =
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9.9 Hz, J = 13.4 Hz, 1H, O-CHH-CH), 2.82 (dd, J = 10.9 Hz, J = 17.0 Hz, 1H, CO-CHH),
2.99 (dd, J = 6.2 Hz, J = 13.1 Hz, 1H, C-CHH-CH-CO), 3.30 (dd, J = 3.2 Hz, J = 13.4 Hz,
1H, O-CHH-CH), 3.91 (m, 1H, Ph-CHH-CH-N), 4.06 (dd, J = 2.5 Hz, J = 8.9 Hz, 1H, Ph-
CHH-CH-N), 4.42–4.56 (m, 2H, N-CH, N-CO-CH), 5.05 (s, 2H, Ph-CH2-O), 6.80–6.93
(m, 3H, Ph), 7.16–7.44 (m, 11H, Ph).
13C NMR (75 MHz, CDCl3): δ = 28.1 (d, CH3), 36.7 (u, CH2), 37.6 (u, CH2), 38.3 (u,
CH2), 41.2 (d, CH), 55.6 (d, CH), 65.9 (u, CH2), 69.9 (u, CH2), 80.8 (u, C), 113.3 (d, CH),
115.6 (d, CH), 121.9 (d, CH), 127.2 (d, CH), 127.6 (d, CH), 127.9 (d, CH), 128.5 (d, CH),
128.9 (d, CH), 129.45 (d, CH), 129.53 (d, CH), 135.7 (u, C), 137.0 (u, C), 139.6 (u, C), 153.0
(u, C), 158.8 (u, C), 171.2 (u, C), 175.3 (u, C).
MS (EI, 70 eV): m/z (%) 529 [M+] (3), 474 (10), 473 (31), 456 (8), 382 (7), 187 (6), 178 (32),
117 (9), 92 (9), 91 (100), 57 (13).
IR (CHCl3): ν˜ = 2928 (w), 1780 (vs), 1723 (s), 1700 (s), 1597 (m), 1488 (w), 1451 (m), 1389
(m), 1356 (m), 1289 (w), 1255 (m), 1217 (m), 1154 (s), 1110 (w), 1022 (m), 955 (w), 843
(w), 757 (vs), 699 (m), 667 (w), 499 (w), 471 (w) cm−1.
Elemental Analysis: Anal. Calcd for C32H35NO6 (529.62): C, 72.57; H, 6.66; N, 2.64.
Found: C, 72.80; H, 6.63; N, 2.57.
Optical Rotation: [α]D = +94.9
◦ (c = 1.0, CH2Cl2).
(R)-2-(3-(Benzyloxy)benzyl)-4-tert-butoxy-4-oxobutanoic acid (169)
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To a solution of tert-butyl oxobutanoate 170 (2.83 g, 5.34 mmol) in THF/H2O (4:1, 12.5
mL) at 0 ◦C H2O2 (1.84 mL of 35% solution in H2O, 21.4 mmol) and lithium hydroxide
(205 mg, 8.55 mmol) were added and the resulting mixture was stirred for 3 h. The
reaction mixture was diluted with H2O and the volatiles were removed under reduced
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pressure. The remaining aqueous solution was cooled to 0 ◦C and EtOAc (50 mL) was
added. The pH of the resulting mixture was adjusted to pH 4–5 upon addition of 10%
citric acid solution under intensive stirring. The organic layer was separated and the
aqueous phase was extracted with EtOAc (3 × 150 mL). The combined organic layers
were washed with brine, dried with MgSO4 and concentrated in vacuo. Purification
by column chromatography (pentane/Et2O/AcOH, 1:4:0.1) gave the oxobutanoic acid
169 (1.92 g, 97%) as a colourless oil and (S)-4-benzyloxazolidin-2-one (843 mg, 89%)
(R f : 0.15, pentane/Et2O/AcOH, 1:4:0.1) as a white solid.
Analytical data of 169
Rf: 0.76 (pentane/Et2O/AcOH, 1:4:0.1).
1H NMR (300 MHz, CDCl3): δ = 1.41 (s, 9H, C(CH3)3), 2.33 (dd, J = 4.5 Hz, J = 16.8
Hz, 1H, HOOC-CH-CHH), 2.54 (dd, J = 8.7 Hz, J = 16.8 Hz, 1H, HOOC-CH-CHH),
2.71 (dd, J = 10.5 Hz, J = 15.2 Hz, 1H, C-CHH-CH-CO), 3.03–3.13 (m, 2H, C-CHH-CH-
CO, HOOC-CH), 5.03 (s, 2H, Ph-CH2-O), 6.75–6.86 (m, 3H, Ph), 7.17–7.22 (m, 1H, Ph),
7.30–7.44 (m, 5H, Ph), 11.35 (br s, 1H, COOH).
13C NMR (75 MHz, CDCl3): δ = 28.2 (d, CH3), 36.1 (u, CH2), 37.5 (u, CH2), 43.2 (d,
CH), 70.0 (u, CH2), 81.2 (u, CH2), 113.1 (d, CH), 115.7 (d, CH), 121.7 (d, CH), 127.5 (d,
CH), 128.0 (d, CH), 128.6 (d, CH), 129.6 (d, CH), 136.9 (u, C), 139.7 (u, C), 158.9 (u, C),
170.9 (u, C), 180.6 (u, C).
MS (EI, 70 eV): m/z (%) 370 [M+] (8), 314 (29), 205.0 (11), 91 (100), 57 (11).
IR (capillary): ν˜ = 2976 (s), 2931 (m), 2874 (m), 1725 (vs), 1593 (m), 1489 (m), 1450 (m),
1371 (m), 1259 (s), 1155 (vs), 1030 (m), 951 (w), 847 (w), 781 (w), 740 (m), 697 (m), 628
(w), 568 (w), 509 (w) cm−1.
Elemental Analysis: Anal. Calcd for C22H26O5 (370.44): C, 71.33; H, 7.07. Found: C,
71.38; H, 7.08.
Optical Rotation: [α]D = +7.9
◦ (c = 1.0, CH2Cl2).
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(3R)-tert-Butyl-3-(3-(benzyloxy)benzyl)-4-((1S,2R,3R,3aS,7aR)-2-hydroxy-3-((S)-N-meth-
ylphenylsulfonimidoyl)octahydro-1H-inden-1-ylamino)-4-oxobutanoate (175)
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To a mixture of the β-amino alcohol 161 (591 mg, 1.92 mmol) and oxobutanoic acid 169
(591 mg, 1.60 mmol) in DMF (20 mL) at0 ◦C was added solid benzotriazole-1-yl-oxy-
tris(dimethylamino)-phosphonium hexafluorophosphate (BOP) (708 mg, 1.60 mmol),
followed by the addition of ethyldiisopropyl amine (0.74 mL, 4.48 mmol). The reac-
tion mixture was allowed to warm to room temperature and stirred for 5 h. Then the
reaction mixture was quenched with 10% citric acid and extracted with EtOAc (3 ×
100 mL). The combined organic phases were washed with H2O, NaHCO3 and brine,
dried with MgSO4 and concentrated in a rotary evaporator. Purification by column
chromatography (CHCl3/Et2O, 1:1) furnished amide 175 (1.0 g, 95%) as a white solid.
Analytical data of 175
Rf: 0.51 (CHCl3/Et2O, 1:1).
1H NMR (300 MHz, CDCl3): δ = 0.98–1.52 (m, 8H) (S-CH-CH-CH2, S-CH-CH-CH2-
CH2, N-CH-CH-CH2, N-CH-CH-CH2-CH2), 1.40 (s, 9H, C(CH3)3), 1.92–2.00 (m, 1H,
N-CH-CH-CH2), 2.17–2.27 (m, 1H, S-CH-CH-CH2), 2.36 (dd, J = 17.1 Hz, J = 4.0 Hz,
1H, CO-CH-CHH-CO), 2.61 (dd, J = 17.1 Hz, J = 9.9 Hz, 1H, CO-CH-CHH-CO), 2.63 (s,
3H, NCH3), 2.69 (dd, J = 13.0 Hz, J = 7.2 Hz, 1H, CO-CH2-CH-CHH), 2.77–2.87 (m, 1H,
N-CO-CH), 2.97 (dd, J = 13.0 Hz, J = 7.4 Hz, 1H, CO-CH2-CH-CHH), 3.05–3.08 (m, 1H,
S-CH), 4.11–4.19 (m, 1H, N-CH), 4.30 (s, 1H, OH), 4.35–4.40 (m, 1H, O-CH), 5.08 (s, 2H,
Ph-CH2-O), 5.79 (d, J = 6.4 Hz, 1H, NH), 6.81–6.89 (m, 3H, Ph), 7.22–7.59 (m, 9H, Ph),
7.81–7.85 (m, 2H, Ph).
13C NMR (75 MHz, CDCl3): δ = 20.7 (u, CH2), 23.6 (u, CH2), 24.8 (u, CH2), 28.0 (d,
CH3), 29.4 (d, CH3), 30.1 (u, CH2), 36.7 (d, CH), 37.3 (u, CH2), 38.1 (u, CH2), 40.1 (d,
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CH), 44.5 (d, CH), 57.9 (d, CH), 70.0 (u, CH2), 74.3 (d, CH), 77.9 (d, CH), 81.0 (u, C),
113.1 (d, CH), 115.7 (d, CH), 121.8 (d, CH), 127.6 (d, CH), 127.9 (d, CH), 128.6 (d, CH),
129.4 (d, CH), 129.7 (d, CH), 132.9 (d, CH), 137.1 (u, C), 140.5 (u, C), 159.0 (u, C), 171.7
(u, C), 175.9 (u, C).
MS (EI, 70 eV): m/z (%) 660 [M+] (4), 449 (14), 315 (15), 314 (85), 279 (10), 154 (26), 152
(18), 137 (19), 136 (98), 135 (16), 125 (38), 107 (45), 97 (10), 91 (100), 79 (16), 78 (15), 58
(24), 57 (29), 55 (18), 52 (12).
IR (KBr): ν˜ = 3331 (m), 3249 (w), 3061 (m), 2932 (vs), 2863 (m), 2343 (w), 2330 (w), 2249
(w), 1727 (vs), 1643 (m), 1588 (w), 1544 (m), 1491 (w), 1450 (m), 1369 (m), 1316 (w), 1254
(s), 1151 (s), 1083 (w), 1028 (m), 953 (w), 911 (w), 846 (w), 795 (w), 735 (s), 695 (s), 608
(m), 495 (m) cm−1.
Elemental Analysis: Anal. Calcd for C38H48N2O6S (570.74): C, 69.06; H, 7.32; N, 4.24.
Found: C, 68.96; H, 7.05; N, 4.15.
Optical Rotation: [α]D = +13.8
◦ (c = 1.01, MeOH).
Melting Point: 71 ◦C.
(2R)-N4-(Benzyloxy)-2-(3-(benzyloxy)benzyl)-N1-((1S,2R,3R,3aS,7aR)-2-hydroxy-3-((S)-
N-methylphenylsulfonimidoyl)octahydro-1H-inden-1-yl)succinamide (177)
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To a solution of amide 175 (208 mg, 0.31 mmol) in CH2Cl2 (6 mL) and H2O (0.55 mL)
was added trifluoroacetic acid (5.5 mL, 71 mmol) dropwise and the resulting mixture
was stirred at room temperature for 3 h. The reaction mixture was concentrated to
half of its original volume in a rotary evaporator. The residue was then dried by co-
evaporationwith toluene (3× 15mL). The resulting crude acid, O-benzylhydroxylamine-
HCl (99mg, 0.62mmol) andO-(benzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium tetraflu-
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oroborate (TBTU) (100 mg, 0.31 mmol) were dissolved in DMF (10 mL) and the solu-
tion was cooled to 0 ◦C followed by addition of ethyldiisopropyl amine (0.26 mL, 1.55
mmol). The reaction mixture was stirred at 0 ◦C for 15 min and then warmed to room
temperature. After the mixture was stirred for 2 h, it was poured into a mixture of
EtOAc (20 mL) and 5% citric acid (20 mL). The mixture was extracted with EtOAc (3
× 25 mL). The combined organic phases were washed with 5% citric acid, H2O, sat.
NaHCO3 and brine, dried with MgSO4 and concentrated in a rotary evaporator. Pu-
rification by HPLC (Kromasil Si 100, 30 mm, EtOAc, 254 nm + RI, 25 mL/min) afforded
the O-protected hydroxamic acid 177 (188 mg, 85%) as a white solid.
Analytical data of 177
1H NMR (400 MHz, CDCl3, 25
◦C): δ = 0.85–1.46 (m, 8H, S-CH-CH-CH2, S-CH-CH-
CH2-CH2, N-CH-CH-CH2, N-CH-CH-CH2-CH2), 1.81–1.84 (m, 1H, N-CH-CH-CH2),
2.07–2.15 (m, 2H, N-CO-CH2) 2.26–2.32 (m, 3H, S-CH-CH-CH2), 2.50 (s, 3H, NCH3),
2.63 (dd, J = 6.9 Hz, J = 13.5 Hz, 1H, N-CO-CH2-CH-CHH), 2.81–2.86 (m, 1H, N-CO-
CH2-CH-CHH), 2.93–2.98 (m, 1H, N-CO-CH), 3.01 (dd, J = 9.3 Hz, J = 6.0 Hz, 1H,
S-CH), 4.12 (dt, J = 11.0 Hz, J = 6.0 Hz, 1H, N-CH), 4.33 (t, J = 6.0 Hz, 1H, O-CH), 4.72
(s), 4.75 (s) (2H, N-O-CH2-Ph), 4.95 (s, 2H, C-O-CH2-Ph), 6.51 (brs, 1H, CH-NH), 6.70–
6.77 (m, 3H, Ph), 7.10–7.51 (m, 14H, Ph), 7.72–7.77 (m, 2H, Ph), 9.01 (brs), 9.20 (brs),
(1H, O-NH).
13C NMR (100 MHz, CDCl3, 25
◦C): δ = 21.1 (u,CH2), 23.8 (u, CH2), 24.7 (u, CH2), 29.5
(d, CH3), 29.9 (u, CH2), 33.6, 35.2 (u, CH2), 36.6 (d, CH), 38.7 (u, CH2), 40.1 (d, CH),
43.5, 45.0 (d, CH), 57.6 (d, CH), 69.9 (u, CH2), 74.0 (d, CH), 76.8 (d, CH), 78.2, 79.3 (u,
CH2), 113.1 (d, CH), 115.7 (d, CH), 121.8 (d, CH), 127.6 (d, CH), 127.8 (d, CH), 128.5 (d,
CH), 129.0 (d, CH), 129.4 (d, CH), 129.6 (d, CH), 132.9 (d, CH), 135.4 (u, C), 136.7 (u, C),
137.0 (u, C), 140.1 (u, C), 140.7 (u, C), 158.8 (u, C), 169.1 (u, C), 175.2, 175.9 (u, C).
1H NMR (400 MHz, CDCl3, 55
◦C): δ = 0.89–1.45 (m, 8H, S-CH-CH-CH2, S-CH-CH-
CH2-CH2, N-CH-CH-CH2, N-CH-CH-CH2-CH2), 1.91–1.87 (m, 1H, N-CH-CH-CH2),
2.12–2.41 (m, 3H, S-CH-CH-CH2, N-CO-CH2), 2.51 (s, 3H, NCH3), 2.65 (dd, J = 6.9 Hz,
J = 13.5 Hz, 1H, N-CO-CH2-CH-CHH), 2.83–2.88 (m, 1H, N-CO-CH2-CH-CHH), 2.93–
2.95 (m, 1H, N-CO-CH), 3.01 (dd, J = 9.3 Hz, J = 5.8 Hz, 1H, S-CH), 4.09 (dt, J = 11.0 Hz,
J = 5.8 Hz, 1H, N-CH), 4.30 (t, J = 5.8 Hz, 1H, O-CH), 4.74 (s, 2H, N-O-CH2-Ph), 4.96
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(s, 2H, C-O-CH2-Ph), 6.23 (brs, 1H, CH-NH), 6.71–6.77 (m, 3H, Ph), 7.10–7.49 (m, 14H,
Ph), 7.71–7.74 (m, 2H, Ph), 8.84 (brs, 1H, O-NH).
13C NMR (100 MHz, CDCl3, 55
◦C): δ = 21.1 (u,CH2), 23.9 (u, CH2), 24.6 (u, CH2), 29.3
(d, CH3), 29.8 (u, CH2), 35.0 (u, CH2), 36.6 (d, CH), 38.7 (u, CH2), 40.2 (d, CH), 44.9 (d,
CH), 57.9 (d, CH), 70.1 (u, CH2), 74.2 (d, CH), 76.8 (d, CH), 78.4 (u, CH2), 113.2 (d, CH),
115.9 (d, CH), 121.8 (d, CH), 127.4 (d, CH), 127.7 (d, CH), 128.4 (d, CH), 129.0 (d, CH),
129.3 (d, CH), 129.6 (d, CH), 132.7 (d, CH), 137.2 (u, C), 137.3 (u, C), 140.3 (u, C), 159.0
(u, C), 175.2 (u, C).
MS (EI, 70 eV): m/z (%) 709 [M+] (1), 156 (6), 136 (13), 125 (14), 108 (11), 107 (20), 106
(13), 105 (10), 97 (5), 91 (100), 79 (10), 78 (10), 77 (22), 65 (10), 52 (13).
MS (CI, isobutane): m/z (%) 710 [M+ + 1] (1), 309 (10), 181 (5), 156 (24), 136 (5), 125
(41), 108 (10), 107 (68), 105 (7), 93 (10), 92 (8), 91 (100), 79 (39), 77 (6).
FTMS-ESI: Calcd for C41H47N3O6S+H: 710.32583. Found: 710.32585.
High Energy Collision Dissociation of [M+H]+
Calcd for fragment Found
C34H39N2O5S: 587.25742 587.25737
C34H39N2O5: 555.28535 555.28515
C34H34NO3: 504.25322 504.25348
C27H30NO4: 432.21694 432.21670
C18H15O3: 279.10157 279.10167
C9H16NO: 154.12264 154.12247
C7H7: 91.05423 91.05399
IR (CHCl3): ν˜ = 3552 (w), 3276 (m), 3068 (w), 3012 (w), 2927 (s), 2860 (m), 2805 (w),
1652 (s), 1588 (w), 1548 (w), 1492 (w), 1448 (m), 1384 (w), 1240 (s), 1153 (m), 1108 (w),
1080 (w), 1030 (w), 908 (m), 877 (m), 755 (vs), 697 (m), 667 (w), 614 (m), 572 (w), 509
(m), 459 (w) cm−1.
Optical Rotation: [α]D = +16.4
◦ (c = 1.0, CH2Cl2).
Melting Point: 84 ◦C.
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6.1.4 Attempted deprotection of the O,O-dibenzyl protected hydroxy
hydroxamic acid 177
§ A solution of amide 177 (100 mg, 0.14 mmol) and 5% Pd/BaSO4 (60 mg) inMeOH
(70 mL) were placed in a 100 ml autoclave. After degassing the autoclave with
hydrogen three times, a pressure of 50 psi of H2 was applied. The mixture was
stirred at room temperature with a magnetic stirrer for 4 h. TLC analysis of the
mixture showed no conversion. The mixture was filtered over celite and concen-
trated in a rotary evaporator. Amide 177 was recovered (94 mg, 94%). The 1H
NMR spectra of the recovered amide 177 indicated pure compound.
§ A solution of amide 177 (100 mg, 0.14 mmol) and 5% Pd/BaSO4 (60 mg) inMeOH
(70 mL) were placed in a 100 ml autoclave. After degassing the autoclave with
hydrogen three times, a pressure of 290 psi of H2 was applied. The mixture was
stirred at room temperature with a magnetic stirrer for 4 h. TLC analysis of the
mixture showed no conversion. The mixture was filtered over celite and concen-
trated in a rotary evaporator. Amide 177 was recovered (90 mg, 90%). The 1H
NMR spectra of the recovered amide 177 indicated pure compound.
§ A solution of amide 177 (100 mg, 0.14 mmol) and 5% Pd/BaSO4 (60 mg) inMeOH
(40 mL) were placed in a 200 ml autoclave. After degassing the autoclave with
hydrogen three times, a pressure of 50 psi of H2 was applied. The mixture was
mechanically stirred at room temperature for 5 h. TLC analysis of the mixture
showed no conversion. The mixture was filtered over celite and concentrated
in a rotary evaporator. Amide 177 was recovered (89 mg, 89%). The 1H NMR
spectra of the recovered amide 177 indicated pure compound.
§ A solution of amide 177 (80 mg, 0.11 mmol) and 5% Pd/BaSO4 (48 mg) in MeOH
(20 mL) was placed in a 100-mL Erlenmeyer flask. The flask was placed on a
shaker apparatus and then connected to a balloon of H2. The head-space was
evacuated and back-filled three-times with H2. The mixture was shaken at room
temperature for 4 h under H2 atmosphere. TLC analysis of the mixture showed
no conversion. The mixture was filtered over celite and concentrated in a rotary
evaporator. Amide 177 was recovered (74 mg, 93%). The 1H NMR spectra of the
recovered amide 177 indicated pure compound.
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§ A solution of amide 177 (37 mg, 0.05 mmol) and 5% Pd/BaSO4 (111 mg) inMeOH
(20 mL) was placed in a 100-mL Erlenmeyer flask. The flask was placed on a
shaker apparatus and then connected to a balloon of H2. The head-space was
evacuated and back-filled three-times with H2. The mixture was shaken at room
temperature for 4 h under H2 atmosphere. TLC analysis of the mixture showed
no conversion. The mixture was filtered over celite and concentrated in a rotary
evaporator. Amide 177 was recovered (34 mg, 92%). The 1H NMR spectra of the
recovered amide 177 indicated pure compound.
§ A solution of amide 177 (30 mg, 0.04 mmol) and 5% Pd/C (36 mg, wet support,
Degussa type E 101 NO/W) in MeOH (30 mL) was placed in a 100-mL Erlen-
meyer flask. The flask was placed on a shaker apparatus and then connected to
a balloon of H2. The head-space was evacuated and back-filled three-times with
H2. The mixture was shaken at room temperature for 4 h under H2 atmosphere.
TLC analysis of the mixture showed no conversion. The mixture was added 5%
Pd/C (144 mg, wet support, Degussa type E 101 NO/W) and shaken at room
temperature for 6 h under H2 atmosphere. TLC analysis of the mixture showed
no conversion. The mixture was filtered over celite and concentrated in a rotary
evaporator. Amide 177 was recovered (27 mg, 90%). The 1H NMR spectra of the
recovered amide 177 indicated pure compound.
§ A solution of amide 177 (30 mg, 0.04 mmol) and trifluoroacetic acid (3.2 mL, 0.04
mmol) in MeOH (30 mL) was placed in a 100-mL Erlenmeyer flask. The flask was
placed on a shaker apparatus and shaken for 30 min at room temperature under
an argon atmosphere. 5% Pd/C (36mg, wet support, Degussa type E 101 NO/W)
was added to mixture. After shaking the mixture for 4 h at room temperature
under H2 atmosphere, TLC analysis showed no conversion. The mixture was
added 5% Pd/C (144 mg, wet support, Degussa type E 101 NO/W) and shaken
for 4 h at room temperature under H2 atmosphere. TLC analysis of the mixture
showed no conversion. The mixture was filtered over celite and concentrated in a
rotary evaporator. Purification by column chromatography (EtOAc) gave amide
177 (26 mg, 87%). The 1HNMR spectra of the recovered amide 177 indicated pure
compound.
§ A solution of amide 177 (50 mg, 0.07 mmol), formic acid (10 mL, 0.28 mmol) and
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5% Pd/C (30 mg) in MeOH (20 mL) was heated at reflux under argon for 4 h. The
mixture was cooled to room temperature. TLC analysis of the mixture showed no
conversion. Themixture was filtered over celite and the solvent was removed in a
rotary evaporator. Purification by column chromatography (EtOAc) gave amide
177 (46 mg, 92%). The 1HNMR spectra of the recovered amide 177 indicated pure
compound.
§ A suspension of 5% Pd/C (30 mg), ammonium formate (22 mg, 0.35 mmol) and
amide 177 (50 mg, 0.07 mmol) inMeOH (15mL) was heated at reflux under argon
for 5 h. Themixture was cooled to room temperature. TLC analysis of themixture
showed no conversion. The mixture was filtered over celite and concentrated in a
rotary evaporator. Purification by column chromatography (EtOAc) gave amide
177 (44 mg, 88%). The 1HNMR spectra of the recovered amide 177 indicated pure
compound.
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6.2 XRAY structure analysis
6.2.1 Xray structure ofN-((1S,2R,3R,3aS,6aR)-2-hydroxy-3-((S)-N-methyl-
phenylsulfonimidoyl)octahydropentalen-1-yl)-2-methylpropane-
2-sulfonamide (108)
Crystal Structure Report of 108:
Chemical Formula 2 · C19H30N2O4S2
Fromula Weight 829.18
Crystal System monoclinic
Space group (No.) P21(4)
Z 2
a 7.485(2) A˚
b 27.373(7) A˚
c 11.051(3) A˚
α 90.0◦
β 104.137(4)◦
γ 90.0◦
Cell volume 2195.6(10) A˚3
Density calc. 1.254g/cm3
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Radiation CuKα (1.54179 A˚)
Range for lattice parameters 8.10E < θ < 17.33◦
Absorption coefficient 2.41 mm−1
Temperature 150 K
Crystal source recrystallized from EtOAc
Crystal colour colourless
Crystal shape plate
Crystal size ca. 0.4 · 0.4 · 0.4 mm
Data Collection:
Diffractometer type Enraf-Nonius CAD4
Collection method ω/2θ scans
Absorption correction none
No. of reflections measured 8889
No. of independent reflections 4239a)
No. of observed reflections 3630a)
θmax 72.94
◦
hmin → hmax -9→ 9
kmin → kmax -33→ 31
Imin → Imax -13→ 13
Criterion for observed I > 2σ(I)
Rint 0.03(4)
Standard reflections 2 -4 -1, 2 -3 -1, 2 -5 -1
Variation 16308(450) 10066(298) 1217(48)
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Refinement:
On F
Treatment of hydrogens Calculated in idealized positions. Us fixed at
1.5 times of U of the corresponding heavy atom
prior to final refinement. No refinement of hy-
drogen parameters
R 0.078
Rw 0.096
Weighing scheme w = 1/[10σ2(F)]
No. of parameters refined 487
No. of reflections in refmnt. 3264a)
Residual electrons density -0.98/0.73e/A˚
r*111 not refined
XABS112 0.014(52)b)
Goodness to fit 0.998
Solution XTAL3.7113
Remarks a) Friedel pairs averaged
b) From separate calculation
Definitions:
Ueq = 1/3∑i ∑j Uija
∗
i a
∗
j aiaj
The anisotropic displacement factor in the structure factor expression is:
t = exp[-2pi2(∑i ∑j Uijhihja
∗
i a
∗
j )]
Atomic Positional and Isotropic Displacement Parameters:
Atom x/a y/b z/c Ueq/A˚
2
S1a 0.3568(3) 0.5752(9) 0.5005(2) * 0.053(1)
S2a 0.3001(3) 0.8114(9) 0.5290(2) * 0.060(2)
O1a 0.3827(9) 0.5758(9) 0.3739(5) * 0.073(5)
O2a 0.438(1) 0.6765(9) 0.6781(7) * 0.106(7)
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Atom x/a y/b z/c Ueq/A˚
2
O3a 0.2020(9) 0.8067(9) 0.6263(6) * 0.085(6)
O4a 0.232(1) 0.8436(9) 0.4263(7) * 0.084(6)
N1a 0.522(1) 0.5784(9) 0.6136(6) * 0.065(5)
N2a 0.319(1) 0.758(1) 0.4761(7) * 0.062(5)
C1a 0.213(1) 0.525(1) 0.5093(8) * 0.055(6)
C2a 0.181(2) 0.5121(9) 0.6237(9) * 0.069(7)
C3a 0.079(2) 0.473(1) 0.636(1) * 0.083(9)
C4a 0.009(2) 0.444(1) 0.534(1) * 0.09(1)
C5a 0.038(2) 0.456(1) 0.418(1) * 0.09(1)
C6a 0.144(2) 0.497(1) 0.406(1) * 0.074(8)
C7a 0.225(1) 0.628(1) 0.5225(9) * 0.055(6)
C8a 0.073(1) 0.640(1) 0.405(1) * 0.077(8)
C9a -0.134(2) 0.633(1) 0.423(2) * 0.19(2)
C10a -0.196(2) 0.685(1) 0.429(2) * 0.15(2)
C11a -0.105(2) 0.715(1) 0.358(2) * 0.13(1)
C12a 0.089(1) 0.694(1) 0.3869(9) * 0.063(7)
C13a 0.226(1) 0.715(1) 0.5047(8) * 0.051(6)
C14a 0.350(1) 0.672(1) 0.5489(9) * 0.062(6)
C15a 0.535(2) 0.832(1) 0.601(1) * 0.072(8)
C16a 0.618(2) 0.796(1) 0.706(1) * 0.11(1)
C17a 0.521(2) 0.882(1) 0.652(2) * 0.12(1)
C18a 0.640(2) 0.833(1) 0.498(2) * 0.11(1)
C19a 0.657(2) 0.538(1) 0.628(1) * 0.085(9)
S1b 0.3987(3) 0.7597(9) 1.0991(2) * 0.048(1)
S2b 0.2824(4) 0.5217(9) 1.0385(2) * 0.060(2)
O1b 0.3917(8) 0.7552(9) 1.2276(5) * 0.065(4)
O2b 0.5762(8) 0.6542(9) 1.0558(7) * 0.078(5)
O3b 0.183(1) 0.5261(9) 0.9109(6) * 0.077(5)
O4b 0.208(1) 0.4918(9) 1.1189(7) * 0.089(6)
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Atom x/a y/b z/c Ueq/A˚
2
N1b 0.5835(9) 0.7611(9) 1.0618(7) * 0.063(5)
N2b 0.310(1) 0.575(1) 1.0972(6) * 0.060(5)
C1b 0.259(1) 0.8103(9) 1.0389(7) * 0.047(5)
C2b 0.228(1) 0.8206(9) 0.9140(8) * 0.056(6)
C3b 0.118(2) 0.860(1) 0.8677(9) * 0.071(7)
C4b 0.038(2) 0.888(1) 0.943(1) * 0.077(8)
C5b 0.077(2) 0.879(1) 1.068(1) * 0.071(8)
C6b 0.185(1) 0.840(1) 1.1165(9) * 0.059(6)
C7b 0.297(1) 0.7074(9) 1.0169(7) * 0.043(5)
C8b 0.092(1) 0.698(1) 1.0173(8) * 0.054(6)
C9b -0.046(1) 0.714(1) 0.895(1) * 0.081(9)
C10b -0.065(1) 0.668(1) 0.815(1) * 0.10(1)
C11b -0.077(2) 0.630(1) 0.903(1) * 0.09(1)
C12b 0.071(1) 0.642(1) 1.0210(9) * 0.057(6)
C13b 0.268(1) 0.6209(9) 1.0274(7) * 0.049(6)
C14b 0.397(1) 0.662(1) 1.0803(8) * 0.054(6)
C15b 0.508(2) 0.497(1) 1.039(1) * 0.075(8)
C16b 0.595(2) 0.532(1) 0.957(1) * 0.10(1)
C17b 0.624(2) 0.497(1) 1.172(1) * 0.11(1)
C18b 0.476(2) 0.447(1) 0.984(2) * 0.12(1)
C19b 0.699(2) 0.803(1) 1.099(1) * 0.09(1)
H6b 0.2094(-) 0.8336(-) 1.2044(-) * 0.090(-)
H8b 0.0589(-) 0.7162(-) 1.0846(-) * 0.081(-)
H7b 0.3101(-) 0.7106(-) 0.9328(-) * 0.065(-)
H13a 0.1677(-) 0.7265(-) 0.5650(-) * 0.077(-)
H2a 0.2323(-) 0.5328(-) 0.6968(-) * 0.105(-)
H12b 0.0373(-) 0.6300(-) 1.0939(-) * 0.087(-)
H14b 0.4204(-) 0.6624(-) 1.1671(-) * 0.080(-)
H13b 0.2786(-) 0.6095(-) 0.9474(-) * 0.072(-)
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Atom x/a y/b z/c Ueq/A˚
2
H7a 0.1710(-) 0.6211(-) 0.5900(-) * 0.084(-)
H2b 0.2880(-) 0.8026(-) 0.8609(-) * 0.086(-)
H12a 0.1476(-) 0.7009(-) 0.3215(-) * 0.093(-)
H6a 0.1710(-) 0.5033(-) 0.3267(-) * 0.110(-)
H5a -0.0140(-) 0.4343(-) 0.3512(-) * 0.132(-)
H3b 0.0994(-) 0.8670(-) 0.7814(-) * 0.105(-)
H5b 0.0304(-) 0.8986(-) 1.1264(-) * 0.106(-)
H14a 0.4442(-) 0.6705(-) 0.5044(-) * 0.093(-)
H3a 0.0554(-) 0.4651(-) 0.7158(-) * 0.123(-)
H4b -0.0512(-) 0.9137(-) 0.9018(-) * 0.114(-)
H8a 0.0836(-) 0.6171(-) 0.3372(-) * 0.111(-)
H9ba -0.1597(-) 0.7244(-) 0.9083(-) * 0.120(-)
H9bb 0.0068(-) 0.7405(-) 0.8574(-) * 0.120(-)
H11ba -0.0463(-) 0.5985(-) 0.8668(-) * 0.132(-)
H11bb -0.1948(-) 0.6268(-) 0.9150(-) * 0.132(-)
H18aa 0.5803(-) 0.8539(-) 0.4322(-) * 0.165(-)
H18ab 0.7629(-) 0.8388(-) 0.5251(-) * 0.165(-)
H18ac 0.6279(-) 0.7990(-) 0.4568(-) * 0.165(-)
H19ba 0.8126(-) 0.8016(-) 1.0720(-) * 0.140(-)
H19bb 0.6363(-) 0.8329(-) 1.0600(-) * 0.140(-)
H19bc 0.7302(-) 0.8088(-) 1.1866(-) * 0.140(-)
H4a -0.0593(-) 0.4172(-) 0.5503(-) * 0.136(-)
H10ba -0.1736(-) 0.6704(-) 0.7498(-) * 0.144(-)
H10bb 0.0391(-) 0.6649(-) 0.7809(-) * 0.144(-)
H16aa 0.5460(-) 0.7972(-) 0.7707(-) * 0.165(-)
H16ab 0.6048(-) 0.7625(-) 0.6765(-) * 0.165(-)
H16ac 0.7398(-) 0.8023(-) 0.7449(-) * 0.165(-)
H16ba 0.5280(-) 0.5316(-) 0.8733(-) * 0.150(-)
H16bb 0.6049(-) 0.5635(-) 0.9904(-) * 0.150(-)
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Atom x/a y/b z/c Ueq/A˚
2
H16bc 0.7201(-) 0.5202(-) 0.9599(-) * 0.150(-)
H17ba 0.5683(-) 0.4751(-) 1.2227(-) * 0.175(-)
H17bb 0.7437(-) 0.4851(-) 1.1754(-) * 0.175(-)
H17bc 0.6284(-) 0.5284(-) 1.2059(-) * 0.175(-)
H11aa -0.1058(-) 0.7464(-) 0.3776(-) * 0.195(-)
H11ab -0.1609(-) 0.7095(-) 0.2682(-) * 0.195(-)
H18ba 0.4156(-) 0.4267(-) 1.0374(-) * 0.165(-)
H18bb 0.3912(-) 0.4478(-) 0.9040(-) * 0.165(-)
H18bc 0.5846(-) 0.4315(-) 0.9803(-) * 0.165(-)
H10ab -0.2848(-) 0.6952(-) 0.4699(-) * 0.240(-)
H9aa -0.2176(-) 0.6176(-) 0.3602(-) * 0.300(-)
H9ab -0.1348(-) 0.6198(-) 0.5032(-) * 0.300(-)
H17aa 0.4573(-) 0.8812(-) 0.7234(-) * 0.180(-)
H17ab 0.6381(-) 0.8970(-) 0.6894(-) * 0.180(-)
H17ac 0.4501(-) 0.9040(-) 0.5938(-) * 0.180(-)
H19aa 0.6070(-) 0.5082(-) 0.6532(-) * 0.127(-)
H19ab 0.7000(-) 0.5322(-) 0.5571(-) * 0.127(-)
H19ac 0.7644(-) 0.5458(-) 0.6973(-) * 0.127(-)
H2bN 0.3224(-) 0.5806(-) 1.1841(-) * 0.090(-)
H2aN 0.3550(-) 0.7623(-) 0.4051(-) * 0.090(-)
H2aO 0.4645(-) 0.6455(-) 0.7250(-) * 0.157(-)
H2bO 0.5996(-) 0.6909(-) 1.0639(-) * 0.115(-)
H10aa -0.3280(-) 0.6809(-) 0.3875(-) * 0.240(-)
Atomic Displacement Parameters
Atom U11 U22 U33 U12 U13 U23
S1a 0.049(1) 0.073(2) 0.040(1) -0.003(1) 0.0140(8) 0.003(1)
S2a 0.057(1) 0.079(2) 0.042(1) 0.010(1) 0.0079(9) -0.015(1)
S2a 0.057(1) 0.079(2) 0.042(1) 0.010(1) 0.0079(9) -0.015(1)
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Atom U11 U22 U33 U12 U13 U23
O1a 0.077(4) 0.109(6) 0.039(3) -0.005(5) 0.023(3) 0.011(4)
O2a 0.097(6) 0.099(7) 0.086(5) -0.014(5) -0.044(4) 0.008(5)
O3a 0.065(4) 0.139(8) 0.055(4) 0.008(5) 0.022(3) -0.034(5)
O4a 0.091(5) 0.092(6) 0.065(4) 0.021(5) 0.012(4) -0.004(4)
N1a 0.047(4) 0.099(7) 0.046(4) -0.002(5) 0.004(3) 0.005(5)
N2a 0.056(4) 0.093(7) 0.041(4) -0.004(5) 0.016(3) -0.005(4)
C1a 0.049(5) 0.070(7) 0.044(4) 0.004(5) 0.010(4) 0.003(5)
C2a 0.074(7) 0.086(9) 0.048(5) -0.009(6) 0.014(5) 0.012(5)
C3a 0.079(8) 0.10(1) 0.073(7) -0.012(7) 0.021(6) 0.021(7)
C4a 0.080(8) 0.09(1) 0.10(1) -0.014(8) 0.014(7) 0.016(8)
C5a 0.088(9) 0.10(1) 0.066(7) -0.013(8) 0.001(6) -0.024(7)
C6a 0.079(7) 0.088(9) 0.054(6) -0.005(7) 0.014(5) -0.017(6)
C7a 0.040(4) 0.068(7) 0.055(5) -0.004(5) 0.005(4) -0.005(5)
C8a 0.047(5) 0.10(1) 0.068(6) -0.008(6) -0.009(5) 0.007(6)
C9a 0.049(7) 0.23(3) 0.26(3) -0.05(1) -0.04(1) 0.15(2)
C10a 0.057(8) 0.28(3) 0.14(1) 0.04(1) 0.052(9) 0.07(2)
C11a 0.061(8) 0.14(2) 0.16(2) 0.029(9) -0.015(9) -0.02(1)
C12a 0.049(5) 0.089(9) 0.049(5) 0.000(5) 0.010(4) 0.013(5)
C13a 0.048(5) 0.067(7) 0.042(4) 0.009(5) 0.016(4) -0.003(4)
C14a 0.042(5) 0.073(8) 0.067(6) -0.008(5) 0.004(4) 0.003(6)
C15a 0.063(6) 0.081(9) 0.069(6) -0.007(6) 0.009(5) -0.013(6)
C16a 0.070(8) 0.14(2) 0.10(1) -0.011(9) -0.023(7) 0.01(1)
C17a 0.10(1) 0.13(1) 0.13(1) -0.02(1) 0.034(9) -0.06(1)
C18a 0.067(7) 0.14(1) 0.13(1) -0.014(9) 0.037(8) -0.01(1)
C19a 0.065(7) 0.10(1) 0.088(8) 0.017(7) 0.016(6) 0.015(7)
S1b 0.045(1) 0.064(1) 0.0366(9) -0.000(1) 0.0102(8) 0.004(1)
S2b 0.076(2) 0.065(2) 0.041(1) -0.008(1) 0.020(1) -0.004(1)
O1b 0.068(4) 0.096(5) 0.028(2) 0.007(4) 0.006(2) 0.004(3)
O2b 0.041(3) 0.090(6) 0.104(5) 0.011(4) 0.020(4) -0.002(5)
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Atom U11 U22 U33 U12 U13 U23
O3b 0.077(5) 0.101(6) 0.050(3) 0.017(5) 0.009(3) -0.019(4)
O4b 0.127(7) 0.072(6) 0.075(5) -0.038(5) 0.041(5) -0.009(4)
N1b 0.035(4) 0.078(6) 0.082(5) -0.003(4) 0.024(4) 0.011(5)
N2b 0.080(5) 0.070(5) 0.034(3) -0.006(5) 0.020(3) 0.001(4)
C1b 0.044(4) 0.053(6) 0.044(4) -0.005(4) 0.009(3) 0.004(4)
C2b 0.059(5) 0.065(7) 0.048(5) 0.006(5) 0.017(4) 0.007(5)
C3b 0.081(7) 0.067(8) 0.060(6) -0.001(6) 0.009(5) 0.015(5)
C4b 0.067(7) 0.067(8) 0.096(8) 0.017(6) 0.015(6) 0.013(7)
C5b 0.062(6) 0.068(8) 0.090(8) 0.013(6) 0.034(6) -0.005(6)
C6b 0.056(5) 0.074(7) 0.051(5) -0.002(5) 0.021(4) -0.008(5)
C7b 0.037(4) 0.061(6) 0.034(4) -0.005(4) 0.015(3) -0.000(4)
C8b 0.037(4) 0.071(7) 0.056(5) -0.002(4) 0.019(4) -0.000(5)
C9b 0.045(5) 0.12(1) 0.070(6) 0.004(7) -0.001(5) 0.017(7)
C10b 0.047(6) 0.17(1) 0.063(6) 0.002(8) -0.004(5) -0.014(9)
C11b 0.054(6) 0.11(1) 0.095(9) -0.014(7) 0.012(6) -0.031(9)
C12b 0.048(5) 0.071(7) 0.059(5) -0.004(5) 0.023(4) -0.002(5)
C13b 0.053(5) 0.061(6) 0.036(4) -0.004(5) 0.017(4) -0.000(4)
C14b 0.046(5) 0.070(7) 0.046(4) 0.001(5) 0.012(4) 0.004(5)
C15b 0.083(8) 0.073(8) 0.065(6) 0.019(7) 0.010(6) -0.004(6)
C16b 0.078(8) 0.13(1) 0.104(9) 0.025(9) 0.042(7) 0.01(1)
C17b 0.11(1) 0.13(1) 0.077(8) 0.01(1) -0.013(7) 0.007(9)
C18b 0.12(1) 0.10(1) 0.12(1) 0.04(1) 0.005(9) -0.026(9)
C19b 0.055(6) 0.11(1) 0.12(1) -0.009(7) 0.026(6) 0.008(9)
H6b 0.090(-) 0.090(-) 0.090(-) 0.000(-) 0.022(-) 0.000(-)
H8b 0.081(-) 0.081(-) 0.081(-) 0.000(-) 0.020(-) 0.000(-)
H7b 0.065(-) 0.065(-) 0.065(-) 0.000(-) 0.016(-) 0.000(-)
H13a 0.077(-) 0.077(-) 0.077(-) 0.000(-) 0.019(-) 0.000(-)
H2a 0.105(-) 0.105(-) 0.105(-) 0.000(-) 0.026(-) 0.000(-)
H12b 0.087(-) 0.087(-) 0.087(-) 0.000(-) 0.021(-) 0.000(-)
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Atom U11 U22 U33 U12 U13 U23
H14b 0.080(-) 0.080(-) 0.080(-) 0.000(-) 0.020(-) 0.000(-)
H13b 0.072(-) 0.072(-) 0.072(-) 0.000(-) 0.018(-) 0.000(-)
H7a 0.084(-) 0.084(-) 0.084(-) 0.000(-) 0.021(-) 0.000(-)
H2b 0.086(-) 0.086(-) 0.086(-) 0.000(-) 0.021(-) 0.000(-)
H12a 0.093(-) 0.093(-) 0.093(-) 0.000(-) 0.023(-) 0.000(-)
H6a 0.110(-) 0.110(-) 0.110(-) 0.000(-) 0.027(-) 0.000(-)
H5a 0.132(-) 0.132(-) 0.132(-) 0.000(-) 0.032(-) 0.000(-)
H3b 0.105(-) 0.105(-) 0.105(-) 0.000(-) 0.026(-) 0.000(-)
H5b 0.106(-) 0.106(-) 0.106(-) 0.000(-) 0.026(-) 0.000(-)
H14a 0.093(-) 0.093(-) 0.093(-) 0.000(-) 0.023(-) 0.000(-)
H3a 0.123(-) 0.123(-) 0.123(-) 0.000(-) 0.030(-) 0.000(-)
H4b 0.114(-) 0.114(-) 0.114(-) 0.000(-) 0.028(-) 0.000(-)
H8a 0.111(-) 0.111(-) 0.111(-) 0.000(-) 0.027(-) 0.000(-)
H9ba 0.120(-) 0.120(-) 0.120(-) 0.000(-) 0.029(-) 0.000(-)
H9bb 0.120(-) 0.120(-) 0.120(-) 0.000(-) 0.029(-) 0.000(-)
H11ba 0.132(-) 0.132(-) 0.132(-) 0.000(-) 0.032(-) 0.000(-)
H11bb 0.132(-) 0.132(-) 0.132(-) 0.000(-) 0.032(-) 0.000(-)
H18aa 0.165(-) 0.165(-) 0.165(-) 0.000(-) 0.040(-) 0.000(-)
H18ab 0.165(-) 0.165(-) 0.165(-) 0.000(-) 0.040(-) 0.000(-)
H18ac 0.165(-) 0.165(-) 0.165(-) 0.000(-) 0.040(-) 0.000(-)
H19ba 0.140(-) 0.140(-) 0.140(-) 0.000(-) 0.034(-) 0.000(-)
H19bb 0.140(-) 0.140(-) 0.140(-) 0.000(-) 0.034(-) 0.000(-)
H19bc 0.140(-) 0.140(-) 0.140(-) 0.000(-) 0.034(-) 0.000(-)
H4a 0.136(-) 0.136(-) 0.136(-) 0.000(-) 0.033(-) 0.000(-)
H10ba 0.144(-) 0.144(-) 0.144(-) 0.000(-) 0.035(-) 0.000(-)
H10bb 0.144(-) 0.144(-) 0.144(-) 0.000(-) 0.035(-) 0.000(-)
H16aa 0.165(-) 0.165(-) 0.165(-) 0.000(-) 0.040(-) 0.000(-)
H16ab 0.165(-) 0.165(-) 0.165(-) 0.000(-) 0.040(-) 0.000(-)
H16ac 0.165(-) 0.165(-) 0.165(-) 0.000(-) 0.040(-) 0.000(-)
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Atom U11 U22 U33 U12 U13 U23
H16ba 0.150(-) 0.150(-) 0.150(-) 0.000(-) 0.037(-) 0.000(-)
H16bb 0.150(-) 0.150(-) 0.150(-) 0.000(-) 0.037(-) 0.000(-)
H16bc 0.150(-) 0.150(-) 0.150(-) 0.000(-) 0.037(-) 0.000(-)
H17ba 0.175(-) 0.175(-) 0.175(-) 0.000(-) 0.043(-) 0.000(-)
H17bb 0.175(-) 0.175(-) 0.175(-) 0.000(-) 0.043(-) 0.000(-)
H17bc 0.175(-) 0.175(-) 0.175(-) 0.000(-) 0.043(-) 0.000(-)
H11aa 0.195(-) 0.195(-) 0.195(-) 0.000(-) 0.048(-) 0.000(-)
H11ab 0.195(-) 0.195(-) 0.195(-) 0.000(-) 0.048(-) 0.000(-)
H18ba 0.165(-) 0.165(-) 0.165(-) 0.000(-) 0.040(-) 0.000(-)
H18bb 0.165(-) 0.165(-) 0.165(-) 0.000(-) 0.040(-) 0.000(-)
H18bc 0.165(-) 0.165(-) 0.165(-) 0.000(-) 0.040(-) 0.000(-)
H10ab 0.240(-) 0.240(-) 0.240(-) 0.000(-) 0.059(-) 0.000(-)
H9aa 0.300(-) 0.300(-) 0.300(-) 0.000(-) 0.073(-) 0.000(-)
H9ab 0.300(-) 0.300(-) 0.300(-) 0.000(-) 0.073(-) 0.000(-)
H17aa 0.180(-) 0.180(-) 0.180(-) 0.000(-) 0.044(-) 0.000(-)
H17ab 0.180(-) 0.180(-) 0.180(-) 0.000(-) 0.044(-) 0.000(-)
H17ac 0.180(-) 0.180(-) 0.180(-) 0.000(-) 0.044(-) 0.000(-)
H19aa 0.127(-) 0.127(-) 0.127(-) 0.000(-) 0.031(-) 0.000(-)
H19ab 0.127(-) 0.127(-) 0.127(-) 0.000(-) 0.031(-) 0.000(-)
H19ac 0.127(-) 0.127(-) 0.127(-) 0.000(-) 0.031(-) 0.000(-)
H2bN 0.090(-) 0.090(-) 0.090(-) 0.000(-) 0.022(-) 0.000(-)
H2aN 0.090(-) 0.090(-) 0.090(-) 0.000(-) 0.022(-) 0.000(-)
H2aO 0.157(-) 0.157(-) 0.157(-) 0.000(-) 0.038(-) 0.000(-)
H2bO 0.115(-) 0.115(-) 0.115(-) 0.000(-) 0.028(-) 0.000(-)
H10aa 0.240(-) 0.240(-) 0.240(-) 0.000(-) 0.059(-) 0.000(-)
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6.2.2 Xray structure ofN-((1S,2R,3R,3aS,7aR)-2-hydroxy-3-((S)-N-methyl-
phenylsulfonimidoyl)octahydro-1H-inden-1-yl)-2-methylpropane-
2-sulfonamide (100)
Crystal Structure Report of 100:
Chemical Formula 2 · C20H32N2O4S2
Fromula Weight 857.24
Crystal System monoclinic
Space group (No.) P21(4)
Z 2
a 8.042(3) A˚
b 26.666(5) A˚
c 10.848(7) A˚
α 90.0◦
β 105.34(2)◦
γ 90.0◦
Cell volume 2243.5(17) A˚3
Density calc. 1.269g/cm3
Radiation CuKα (1.54179 A˚)
Range for lattice parameters ◦ < θ < ◦
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Absorption coefficient 2.375 mm−1
Temperature 150 K
Crystal source recrystallized from EtOAc
Crystal colour colourless
Crystal shape irregular
Crystal size ca. 0.4 · 0.4 · 0.4 mm
Data Collection:
Diffractometer type Enraf-Nonius CAD4
Collection method ω/2θ scans
Absorption correction none
No. of reflections measured 9109
No. of independent reflections 8454a)
No. of observed reflections 8167a)
θmax 74.19
◦
hmin → hmax -9→ 9
kmin → kmax -26→ 33
Imin → Imax -12→ 13
Criterion for observed I > 2σ(I)
Rint 0.03(3)
Standard reflections 4 2 2, -4 2 -2, 4 -2 2
Variation 1234(99) 1178(99) 1131(92)
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Refinement:
On F
Treatment of hydrogens Calculated in idealized positions. Us fixed at
1.5 times of U of the corresponding heavy atom
prior to final refinement. No refinement of hy-
drogen parameters
R 0.080
Rw 0.106
Weighing scheme w = 1/[20σ2(F)]
No. of parameters refined 505
No. of reflections in refmnt. 8156
Residual electrons density -1.69/1.13e/A˚3
r*111 not refined
XABS112 0.014(52)b)
Goodness to fit 1.419
Solution XTAL3.7113
Definitions:
Ueq = 1/3∑i ∑j Uija
∗
i a
∗
j aiaj
The anisotropic displacement factor in the structure factor expression is:
t = exp[-2pi2(∑i ∑j Uijhihja
∗
i a
∗
j )]
Atomic Positional and Isotropic Displacement Parameters:
Atom x/a y/b z/c Ueq/A˚
2
S1a 0.4068(2) 0.3806(5) 1.1248(1) * 0.0184(7)
S2a 0.3227(2) 0.1382(5) 1.0330(1) * 0.0216(8)
O1a 0.3857(6) 0.3707(5) 1.2538(4) * 0.027(2)
O2a 0.5890(5) 0.2764(5) 1.0413(5) * 0.028(3)
O3a 0.2279(6) 0.1457(5) 0.9024(4) * 0.031(3)
O4a 0.2494(7) 0.1060(5) 1.1111(5) * 0.039(3)
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Atom x/a y/b z/c Ueq/A˚
2
N1a 0.5853(6) 0.3873(5) 1.1036(5) * 0.026(3)
N2a 0.3617(6) 0.1927(5) 1.1014(5) * 0.021(3)
C1a 0.2630(7) 0.4312(5) 1.0644(6) * 0.020(3)
C2a 0.2228(8) 0.4406(5) 0.9321(6) * 0.026(3)
C3a 0.1061(9) 0.4781(6) 0.8836(7) * 0.032(4)
C4a 0.0337(9) 0.5068(6) 0.9618(8) * 0.036(4)
C5a 0.078(1) 0.4970(6) 1.0929(7) * 0.037(4)
C6a 0.1914(9) 0.4583(6) 1.1455(7) * 0.030(4)
C7a 0.6858(9) 0.4312(6) 1.1605(8) * 0.042(5)
C8a 0.3292(7) 0.3294(5) 1.0248(5) * 0.017(3)
C9a 0.4350(7) 0.2816(5) 1.0811(6) * 0.019(3)
C10a 0.3059(7) 0.2401(5) 1.0337(6) * 0.019(3)
C11a 0.1415(7) 0.2619(5) 1.0584(6) * 0.020(3)
C12a 0.1362(7) 0.3157(5) 1.0050(6) * 0.019(3)
C13a 0.0416(7) 0.3187(5) 0.8600(6) * 0.025(3)
C14a -0.1313(8) 0.2917(6) 0.8303(6) * 0.029(4)
C15a -0.1050(8) 0.2368(6) 0.8650(7) * 0.030(4)
C16a -0.0248(7) 0.2312(5) 1.0100(6) * 0.025(3)
C17a 0.5300(9) 0.1135(5) 1.0321(7) * 0.029(4)
C18a 0.6139(9) 0.1476(6) 0.9537(8) * 0.036(4)
C19a 0.498(1) 0.0607(6) 0.9757(8) * 0.041(5)
C20a 0.642(1) 0.1114(6) 1.1714(8) * 0.049(5)
S1b 0.3868(2) 0.1842(5) 0.5123(1) * 0.0214(7)
S2b 0.3125(2) 0.4227(5) 0.5609(1) * 0.0260(8)
O1b 0.3962(6) 0.1936(5) 0.3801(4) * 0.030(3)
O2b 0.4239(6) 0.2885(5) 0.7332(4) * 0.036(3)
O3b 0.2414(7) 0.4558(5) 0.4544(5) * 0.039(3)
O4b 0.2177(6) 0.4172(5) 0.6562(5) * 0.035(3)
N2b 0.3416(7) 0.3667(5) 0.5098(5) * 0.025(3)
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Atom x/a y/b z/c Ueq/A˚
2
N1b 0.5497(6) 0.1812(5) 0.6245(5) * 0.028(3)
C1b 0.2502(8) 0.1312(5) 0.5044(6) * 0.026(3)
C2b 0.225(1) 0.1128(6) 0.6187(7) * 0.038(4)
C3b 0.117(1) 0.0725(6) 0.6147(9) * 0.052(6)
C4b 0.036(1) 0.0495(6) 0.499(1) * 0.053(6)
C5b 0.065(1) 0.0683(6) 0.3861(8) * 0.047(5)
C6b 0.172(1) 0.1089(5) 0.3881(7) * 0.034(4)
C7b 0.6678(9) 0.1392(6) 0.6171(8) * 0.039(4)
C8b 0.2666(7) 0.2317(5) 0.5618(6) * 0.021(3)
C9b 0.3712(7) 0.2808(5) 0.5970(6) * 0.022(3)
C10b 0.2494(7) 0.3237(5) 0.5338(6) * 0.021(3)
C11b 0.1436(7) 0.2982(5) 0.4117(6) * 0.024(3)
C12b 0.1021(7) 0.2457(6) 0.4538(6) * 0.025(3)
C13b -0.0582(9) 0.2440(6) 0.5078(8) * 0.043(5)
C14b -0.2108(8) 0.2711(6) 0.4140(8) * 0.045(5)
C15b -0.1665(9) 0.3251(6) 0.3978(7) * 0.039(4)
C16b -0.0145(8) 0.3276(6) 0.3367(6) * 0.032(4)
C17b 0.530(1) 0.4453(6) 0.6376(8) * 0.037(4)
C18b 0.611(1) 0.4100(6) 0.7506(9) * 0.053(5)
C19b 0.632(1) 0.4458(6) 0.5386(9) * 0.052(6)
C20b 0.506(1) 0.4981(6) 0.6848(9) * 0.054(6)
H2a 0.2789(-) 0.4203(-) 0.8784(-) * 0.045(-)
H8b 0.2359(-) 0.2189(-) 0.6345(-) * 0.035(-)
H12a 0.0764(-) 0.3370(-) 1.0510(-) * 0.033(-)
H8a 0.3415(-) 0.3375(-) 0.9411(-) * 0.030(-)
H11a 0.1463(-) 0.2599(-) 1.1498(-) * 0.035(-)
H6a 0.2218(-) 0.4501(-) 1.2376(-) * 0.051(-)
H18ba 0.5415(-) 0.4102(-) 0.8130(-) * 0.084(-)
H18bb 0.7234(-) 0.4190(-) 0.7931(-) * 0.084(-)
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Atom x/a y/b z/c Ueq/A˚
2
H18bc 0.6080(-) 0.3761(-) 0.7204(-) * 0.084(-)
H6b 0.1950(-) 0.1203(-) 0.3102(-) * 0.056(-)
H9b 0.4701(-) 0.2786(-) 0.5662(-) * 0.038(-)
H12b 0.0750(-) 0.2225(-) 0.3818(-) * 0.042(-)
H4a -0.0492(-) 0.5321(-) 0.9233(-) * 0.060(-)
H19aa 0.4332(-) 0.0629(-) 0.8885(-) * 0.066(-)
H19ab 0.4358(-) 0.0416(-) 1.0221(-) * 0.066(-)
H19ac 0.6052(-) 0.0445(-) 0.9797(-) * 0.066(-)
H15aa -0.2135(-) 0.2186(-) 0.8414(-) * 0.050(-)
H15ab -0.0304(-) 0.2210(-) 0.8200(-) * 0.050(-)
H9a 0.4783(-) 0.2815(-) 1.1728(-) * 0.033(-)
H20aa 0.6578(-) 0.1436(-) 1.2087(-) * 0.077(-)
H20ab 0.7468(-) 0.0948(-) 1.1814(-) * 0.077(-)
H20ac 0.5774(-) 0.0919(-) 1.2238(-) * 0.077(-)
H13aa 0.1115(-) 0.3031(-) 0.8113(-) * 0.041(-)
H13ab 0.0228(-) 0.3526(-) 0.8339(-) * 0.041(-)
H10b 0.1826(-) 0.3367(-) 0.5894(-) * 0.036(-)
H11b 0.2101(-) 0.2965(-) 0.3494(-) * 0.039(-)
H16aa -0.1079(-) 0.2411(-) 1.0527(-) * 0.042(-)
H16ab 0.0009(-) 0.1958(-) 1.0287(-) * 0.042(-)
H4b -0.0363(-) 0.0204(-) 0.4983(-) * 0.084(-)
H3a 0.0781(-) 0.4849(-) 0.7938(-) * 0.051(-)
H7ba 0.7649(-) 0.1398(-) 0.6914(-) * 0.063(-)
H7bb 0.7054(-) 0.1409(-) 0.5432(-) * 0.063(-)
H7bc 0.6088(-) 0.1076(-) 0.6190(-) * 0.063(-)
H2b 0.2823(-) 0.1290(-) 0.6983(-) * 0.063(-)
H5b 0.0040(-) 0.0525(-) 0.3089(-) * 0.075(-)
H16ba -0.0530(-) 0.3128(-) 0.2497(-) * 0.051(-)
H16bb 0.0150(-) 0.3610(-) 0.3267(-) * 0.051(-)
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Atom x/a y/b z/c Ueq/A˚
2
H15ba -0.2659(-) 0.3414(-) 0.3459(-) * 0.063(-)
H15bb -0.1347(-) 0.3396(-) 0.4795(-) * 0.063(-)
H14aa -0.1999(-) 0.3062(-) 0.8805(-) * 0.048(-)
H14ab -0.1887(-) 0.2947(-) 0.7427(-) * 0.048(-)
H10a 0.2910(-) 0.2321(-) 0.9452(-) * 0.033(-)
H18aa 0.6315(-) 0.1788(-) 0.9896(-) * 0.060(-)
H18ab 0.5379(-) 0.1493(-) 0.8678(-) * 0.060(-)
H18ac 0.7197(-) 0.1327(-) 0.9468(-) * 0.060(-)
H14ba -0.2330(-) 0.2544(-) 0.3294(-) * 0.075(-)
H14bb -0.3114(-) 0.2681(-) 0.4412(-) * 0.075(-)
H13ba -0.0318(-) 0.2603(-) 0.5866(-) * 0.066(-)
H13bb -0.0874(-) 0.2097(-) 0.5177(-) * 0.066(-)
H3b 0.0935(-) 0.0599(-) 0.6911(-) * 0.082(-)
H5a 0.0266(-) 0.5170(-) 1.1466(-) * 0.060(-)
H19ba 0.5851(-) 0.4679(-) 0.4714(-) * 0.083(-)
H19bb 0.6365(-) 0.4124(-) 0.5041(-) * 0.083(-)
H19bc 0.7519(-) 0.4553(-) 0.5768(-) * 0.083(-)
H20ba 0.4530(-) 0.5187(-) 0.6172(-) * 0.087(-)
H20bb 0.6076(-) 0.5114(-) 0.7365(-) * 0.087(-)
H20bc 0.4235(-) 0.4958(-) 0.7411(-) * 0.087(-)
H2bb 0.3166(-) 0.3686(-) 0.4215(-) * 0.045(-)
H2aa 0.3108(-) 0.1911(-) 1.1689(-) * 0.038(-)
H O2a 0.5973(-) 0.3104(-) 1.0411(-) * 0.048(-)
H O2b 0.4179(-) 0.2500(-) 0.7312(-) * 0.059(-)
H7aa 0.6148(-) 0.4534(-) 1.1913(-) * 0.068(-)
H7ab 0.7324(-) 0.4468(-) 1.0998(-) * 0.068(-)
H7ac 0.7788(-) 0.4202(-) 1.2317(-) * 0.068(-)
Atomic Displacement Parameters
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Atom U11 U22 U33 U12 U13 U23
S1a 0.0202(6) 0.0144(6) 0.0205(7) -0.0015(5) 0.0049(5) 0.0005(5)
S2a 0.0254(7) 0.0158(7) 0.0250(7) -0.0038(5) 0.0090(6) -0.0037(5)
O1a 0.033(2) 0.028(2) 0.020(2) -0.001(2) 0.007(2) 0.003(2)
O2a 0.015(2) 0.025(2) 0.047(3) 0.002(2) 0.012(2) -0.000(2)
O3a 0.028(2) 0.037(3) 0.022(2) 0.003(2) -0.002(2) -0.006(2)
O4a 0.055(3) 0.029(3) 0.039(3) -0.023(2) 0.022(3) -0.011(2)
N1a 0.018(2) 0.026(3) 0.033(3) -0.004(2) 0.004(2) 0.005(2)
N2a 0.028(2) 0.013(2) 0.024(3) 0.001(2) 0.010(2) -0.005(2)
C1a 0.021(3) 0.014(3) 0.022(3) -0.002(2) 0.001(2) 0.002(2)
C2a 0.032(3) 0.016(3) 0.028(3) 0.001(2) 0.004(3) 0.002(2)
C3a 0.036(4) 0.023(3) 0.031(4) 0.005(3) 0.000(3) 0.010(3)
C4a 0.034(4) 0.025(4) 0.048(5) 0.007(3) 0.008(3) 0.008(3)
C5a 0.042(4) 0.032(4) 0.042(4) 0.015(3) 0.019(3) 0.003(3)
C6a 0.034(3) 0.024(3) 0.034(4) 0.003(3) 0.011(3) -0.000(3)
C7a 0.030(3) 0.032(4) 0.061(5) -0.010(3) 0.006(3) 0.008(3)
C8a 0.013(2) 0.017(3) 0.021(3) 0.002(2) 0.004(2) 0.005(2)
C9a 0.016(2) 0.014(3) 0.027(3) -0.003(2) 0.006(2) -0.003(2)
C10a 0.013(2) 0.020(3) 0.022(3) 0.003(2) 0.002(2) 0.003(2)
C11a 0.014(2) 0.022(3) 0.024(3) -0.002(2) 0.005(2) 0.002(2)
C12a 0.013(2) 0.019(3) 0.026(3) 0.001(2) 0.005(2) -0.001(2)
C13a 0.019(3) 0.026(3) 0.025(3) -0.001(2) -0.000(2) 0.003(2)
C14a 0.021(3) 0.042(4) 0.022(3) -0.003(3) -0.000(2) 0.001(3)
C15a 0.020(3) 0.033(4) 0.035(4) -0.006(2) 0.005(3) -0.009(3)
C16a 0.017(3) 0.025(3) 0.032(3) -0.005(2) 0.005(2) 0.002(3)
C17a 0.029(3) 0.019(3) 0.035(4) 0.005(2) 0.003(3) 0.001(3)
C18a 0.031(3) 0.031(4) 0.050(5) 0.000(3) 0.017(3) -0.002(3)
C19a 0.047(4) 0.021(4) 0.054(5) 0.010(3) 0.012(4) -0.004(3)
C20a 0.044(4) 0.039(5) 0.049(5) 0.010(4) -0.012(4) -0.001(4)
S1b 0.0240(6) 0.0202(7) 0.0208(7) -0.0036(6) 0.0072(5) 0.0000(6)
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Atom U11 U22 U33 U12 U13 U23
S2b 0.0341(8) 0.0204(7) 0.0239(7) 0.0052(6) 0.0086(6) -0.0035(6)
O1b 0.034(2) 0.038(3) 0.020(2) -0.003(2) 0.013(2) 0.007(2)
O2b 0.040(3) 0.029(3) 0.026(2) -0.007(2) -0.011(2) -0.002(2)
O3b 0.060(3) 0.030(3) 0.022(2) 0.017(2) 0.003(2) 0.004(2)
O4b 0.035(3) 0.040(3) 0.032(3) 0.005(2) 0.014(2) -0.010(2)
N1b 0.023(2) 0.030(3) 0.028(3) 0.002(2) 0.002(2) -0.006(2)
N2b 0.029(3) 0.017(3) 0.029(3) 0.006(2) 0.008(2) -0.002(2)
C1b 0.028(3) 0.020(3) 0.027(3) -0.007(2) 0.003(2) -0.007(2)
C2b 0.051(4) 0.035(4) 0.029(4) -0.012(3) 0.012(3) 0.002(3)
C3b 0.061(5) 0.052(5) 0.044(5) -0.025(4) 0.018(4) 0.008(4)
C4b 0.044(5) 0.030(4) 0.079(7) -0.015(3) 0.006(5) -0.005(4)
C5b 0.049(5) 0.032(4) 0.049(5) -0.009(4) -0.005(4) -0.010(4)
C6b 0.045(4) 0.027(4) 0.027(4) -0.001(3) 0.006(3) -0.006(3)
C7b 0.031(3) 0.033(4) 0.047(4) 0.008(3) 0.002(3) -0.004(3)
C8b 0.018(3) 0.023(3) 0.021(3) -0.007(2) 0.007(2) -0.003(2)
C9b 0.020(3) 0.019(3) 0.028(3) -0.003(2) 0.004(2) -0.003(2)
C10b 0.015(2) 0.027(3) 0.020(3) -0.001(2) 0.002(2) -0.002(2)
C11b 0.019(3) 0.027(3) 0.020(3) -0.000(2) -0.002(2) -0.002(2)
C12b 0.017(3) 0.030(3) 0.028(3) -0.002(2) 0.004(2) -0.003(3)
C13b 0.021(3) 0.059(5) 0.048(5) -0.002(3) 0.009(3) 0.015(4)
C14b 0.015(3) 0.074(6) 0.048(5) 0.003(3) 0.009(3) 0.017(4)
C15b 0.030(3) 0.051(5) 0.033(4) 0.009(3) 0.002(3) -0.002(3)
C16b 0.026(3) 0.037(4) 0.027(3) 0.005(3) -0.002(3) 0.003(3)
C17b 0.038(4) 0.022(3) 0.052(5) -0.004(3) 0.013(3) -0.009(3)
C18b 0.043(4) 0.048(5) 0.053(5) -0.001(4) -0.013(4) 0.001(4)
C19b 0.055(5) 0.058(6) 0.044(5) -0.013(4) 0.017(4) -0.013(4)
C20b 0.067(6) 0.033(5) 0.063(6) -0.010(4) 0.017(5) -0.022(4)
H2a 0.045(-) 0.045(-) 0.045(-) 0.000(-) 0.012(-) 0.000(-)
H8b 0.035(-) 0.035(-) 0.035(-) 0.000(-) 0.009(-) 0.000(-)
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Atom U11 U22 U33 U12 U13 U23
H12a 0.033(-) 0.033(-) 0.033(-) 0.000(-) 0.009(-) 0.000(-)
H8a 0.030(-) 0.030(-) 0.030(-) 0.000(-) 0.008(-) 0.000(-)
H11a 0.035(-) 0.035(-) 0.035(-) 0.000(-) 0.009(-) 0.000(-)
H6a 0.051(-) 0.051(-) 0.051(-) 0.000(-) 0.013(-) 0.000(-)
H18ba 0.084(-) 0.084(-) 0.084(-) 0.000(-) 0.022(-) 0.000(-)
H18bb 0.084(-) 0.084(-) 0.084(-) 0.000(-) 0.022(-) 0.000(-)
H18bc 0.084(-) 0.084(-) 0.084(-) 0.000(-) 0.022(-) 0.000(-)
H6b 0.056(-) 0.056(-) 0.056(-) 0.000(-) 0.015(-) 0.000(-)
H9b 0.038(-) 0.038(-) 0.038(-) 0.000(-) 0.010(-) 0.000(-)
H12b 0.042(-) 0.042(-) 0.042(-) 0.000(-) 0.011(-) 0.000(-)
H4a 0.060(-) 0.060(-) 0.060(-) 0.000(-) 0.016(-) 0.000(-)
H19aa 0.066(-) 0.066(-) 0.066(-) 0.000(-) 0.017(-) 0.000(-)
H19ab 0.066(-) 0.066(-) 0.066(-) 0.000(-) 0.017(-) 0.000(-)
H19ac 0.066(-) 0.066(-) 0.066(-) 0.000(-) 0.017(-) 0.000(-)
H15aa 0.050(-) 0.050(-) 0.050(-) 0.000(-) 0.013(-) 0.000(-)
H15ab 0.050(-) 0.050(-) 0.050(-) 0.000(-) 0.013(-) 0.000(-)
H9a 0.033(-) 0.033(-) 0.033(-) 0.000(-) 0.009(-) 0.000(-)
H20aa 0.077(-) 0.077(-) 0.077(-) 0.000(-) 0.020(-) 0.000(-)
H20ab 0.077(-) 0.077(-) 0.077(-) 0.000(-) 0.020(-) 0.000(-)
H20ac 0.077(-) 0.077(-) 0.077(-) 0.000(-) 0.020(-) 0.000(-)
H13aa 0.041(-) 0.041(-) 0.041(-) 0.000(-) 0.011(-) 0.000(-)
H13ab 0.041(-) 0.041(-) 0.041(-) 0.000(-) 0.011(-) 0.000(-)
H10b 0.036(-) 0.036(-) 0.036(-) 0.000(-) 0.010(-) 0.000(-)
H11b 0.039(-) 0.039(-) 0.039(-) 0.000(-) 0.010(-) 0.000(-)
H16aa 0.042(-) 0.042(-) 0.042(-) 0.000(-) 0.011(-) 0.000(-)
H16ab 0.042(-) 0.042(-) 0.042(-) 0.000(-) 0.011(-) 0.000(-)
H4b 0.084(-) 0.084(-) 0.084(-) 0.000(-) 0.022(-) 0.000(-)
H3a 0.051(-) 0.051(-) 0.051(-) 0.000(-) 0.013(-) 0.000(-)
H7ba 0.063(-) 0.063(-) 0.063(-) 0.000(-) 0.017(-) 0.000(-)
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Atom U11 U22 U33 U12 U13 U23
H7bb 0.063(-) 0.063(-) 0.063(-) 0.000(-) 0.017(-) 0.000(-)
H7bc 0.063(-) 0.063(-) 0.063(-) 0.000(-) 0.017(-) 0.000(-)
H2b 0.063(-) 0.063(-) 0.063(-) 0.000(-) 0.017(-) 0.000(-)
H5b 0.075(-) 0.075(-) 0.075(-) 0.000(-) 0.020(-) 0.000(-)
H16ba 0.051(-) 0.051(-) 0.051(-) 0.000(-) 0.013(-) 0.000(-)
H16bb 0.051(-) 0.051(-) 0.051(-) 0.000(-) 0.013(-) 0.000(-)
H15ba 0.063(-) 0.063(-) 0.063(-) 0.000(-) 0.017(-) 0.000(-)
H15bb 0.063(-) 0.063(-) 0.063(-) 0.000(-) 0.017(-) 0.000(-)
H14aa 0.048(-) 0.048(-) 0.048(-) 0.000(-) 0.013(-) 0.000(-)
H14ab 0.048(-) 0.048(-) 0.048(-) 0.000(-) 0.013(-) 0.000(-)
H10a 0.033(-) 0.033(-) 0.033(-) 0.000(-) 0.009(-) 0.000(-)
H18aa 0.060(-) 0.060(-) 0.060(-) 0.000(-) 0.016(-) 0.000(-)
H18ab 0.060(-) 0.060(-) 0.060(-) 0.000(-) 0.016(-) 0.000(-)
H18ac 0.060(-) 0.060(-) 0.060(-) 0.000(-) 0.016(-) 0.000(-)
H14ba 0.075(-) 0.075(-) 0.075(-) 0.000(-) 0.020(-) 0.000(-)
H14bb 0.075(-) 0.075(-) 0.075(-) 0.000(-) 0.020(-) 0.000(-)
H13ba 0.066(-) 0.066(-) 0.066(-) 0.000(-) 0.017(-) 0.000(-)
H13bb 0.066(-) 0.066(-) 0.066(-) 0.000(-) 0.017(-) 0.000(-)
H3b 0.082(-) 0.082(-) 0.082(-) 0.000(-) 0.022(-) 0.000(-)
H5a 0.060(-) 0.060(-) 0.060(-) 0.000(-) 0.016(-) 0.000(-)
H19ba 0.083(-) 0.083(-) 0.083(-) 0.000(-) 0.022(-) 0.000(-)
H19bb 0.083(-) 0.083(-) 0.083(-) 0.000(-) 0.022(-) 0.000(-)
H19bc 0.083(-) 0.083(-) 0.083(-) 0.000(-) 0.022(-) 0.000(-)
H20ba 0.087(-) 0.087(-) 0.087(-) 0.000(-) 0.023(-) 0.000(-)
H20bb 0.087(-) 0.087(-) 0.087(-) 0.000(-) 0.023(-) 0.000(-)
H20bc 0.087(-) 0.087(-) 0.087(-) 0.000(-) 0.023(-) 0.000(-)
H2bb 0.045(-) 0.045(-) 0.045(-) 0.000(-) 0.012(-) 0.000(-)
H2aa 0.038(-) 0.038(-) 0.038(-) 0.000(-) 0.010(-) 0.000(-)
H O2a 0.048(-) 0.048(-) 0.048(-) 0.000(-) 0.013(-) 0.000(-)
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Atom U11 U22 U33 U12 U13 U23
H O2b 0.059(-) 0.059(-) 0.059(-) 0.000(-) 0.016(-) 0.000(-)
H7aa 0.068(-) 0.068(-) 0.068(-) 0.000(-) 0.018(-) 0.000(-)
H7ab 0.068(-) 0.068(-) 0.068(-) 0.000(-) 0.018(-) 0.000(-)
H7ac 0.068(-) 0.068(-) 0.068(-) 0.000(-) 0.018(-) 0.000(-)
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